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Public Health Significance: Idiopathic pulmonary fibrosis (IPF) is a devastating lung 
disease affecting over 100,000 people every year in the U.S. There is no prevention, cure, or 
effective treatment for the disease, and the life expectancy after diagnosis is about 3 years. The 
disease is characterized by progressive and irreversible deposition of fibrotic proteins in the lung. 
The etiology of the disease is poorly understood, but there is abundant evidence the pro-fibrotic 
cytokine transforming growth factor beta (TGFβ) plays a major role in the disease process. 
TGFβ acts principally through the DNA-binding transcription factor SMAD3. The research 
presented here may lead directly to new pharmacological interventions for IPF, thereby 
substantially decreasing morbidity and mortality rates for the disease. 
To gain new insights into how the TGFβ/SMAD3 transcriptional regulatory pathway 
might promote pulmonary fibrosis, I combined high-throughput molecular biology 
measurements with systems biology computational tools to study transcriptional regulation of the 
TGFβ/SMAD3 pathway in A549 alveolar epithelial cells. The first tier of measurement consisted 
of chromatin immunoprecipitation combined with whole-genome promoter microarrays (ChIP-
on-chip). This technique globally identifies the promoter regions of genes bound by the SMAD3 
transcription factor. A second tier of systems-wide information consisted of whole-genome gene 
expression microarrays, which measures levels of mRNA activated by the TGFβ/SMAD3 
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 v 
pathway. These two tiers of transcription information were integrated and analyzed using 
systems biology computational tools. The analysis yielded three novel findings. The first is that 
the TGFβ/SMAD3 pathway transcriptionally regulates transgelin, a protein that signifies the 
TGFβ-induced transition of epithelial cells into collagen-secreting myofibroblasts. The second is 
that the TGFβ/SMAD3 pathway also regulates the transcription factor FOXA2, which plays a 
major role in lung development and surfactant production. The third is possible TGFβ/SMAD3 
transcriptional regulation of PINX1, which is a potent suppressor of telomere reverse 
transcriptase (hTERT). All three of these proteins are mechanistically linked to genes or 
processes that are already suspected of being involved in the pathophysiology of IPF. Thus, a 
systems-level approach to studying transcriptional regulatory networks is a valuable tool for 
discovering new biological pathways or new connections between known biological pathways. 
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1 INTRODUCTION 
1.1 PUBLIC HEALTH SIGNIFICANCE 
Idiopathic pulmonary fibrosis (IPF) is a chronic and fatal interstitial lung disease 
affecting over 100,000 people every year in the United States alone [1, 2]. It is characterized by 
the progressive and irreversible replacement of healthy, flexible lung tissue with stiff, fibrous 
proteins. It is a severely debilitating disease for which there is currently no prevention, cure, or 
effective therapy [2-8]. The life expectancy of IPF patients from time of diagnosis is three to four 
years, and about 50% of patients will die within 2 to 3 years after diagnosis [2, 9-11]. The 
etiology of IPF is poorly understood, but it appears some complex combination of genetic and 
environmental factors play a role. The central issue in understanding the etiology and 
pathophysiology of IPF is elucidating specific genomic and molecular mechanism(s) responsible 
for the abnormal cellular behavior that results in pulmonary fibrosis. Further, the research 
presented here may lead directly to new pharmacological interventions for IPF, thereby 
substantially decreasing morbidity and mortality rates for the disease. 
New technologies—particularly sophisticated computational tools and massively parallel 
(high-throughput) biological measurements—allow for simultaneous global discovery of 
interconnections and functional pathways between thousands of genes and the proteins they 
encode. This holistic, top-level approach to biological investigation is known as systems biology. 
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It promises to provide biological insights not readily discernable using traditional single gene, 
single protein experimentation. 
In this study, a systems-level approach was applied to a cell culture model system to 
better understand the etiology and molecular pathophysiology of IPF. One conclusion from this 
exercise is that a systems-level approach is a valuable tool for gaining new insights into the 
molecular basis for complex diseases, and therefore is well-suited for studying IPF and other 
complex diseases of great public health significance. 
1.2 OVERVIEW OF THE APPROACH USED IN THIS STUDY 
Multiple environmental, aging, and genetic factors likely play causal roles in the etiology 
of IPF. However, in the pathophysiology of IPF, one of the most robust findings is the 
involvement of transforming growth factor beta (TGFβ). TGFβ is a major anti-inflammatory 
cytokine that is well-established as inducing epithelial cells to convert to fibroblasts, and then 
inducing fibroblasts to secrete fibrotic proteins [12-16]. This is the case both in the context of 
normal wound repair and in abnormal fibrotic organ diseases. TGFβ regulates transcription of 
particular genes principally through the DNA-binding transcription factor SMAD3. Although 
much is known about the TGFβ/SMAD3 signal transduction proteins on the cell surface and in 
the cytoplasm, little is still known about what and how genes are transcriptionally regulated in 
the nucleus [17-24]. Therefore, it is clear TGFβ plays a major role in IPF, and the transcription 
factor SMAD3 is a major mediator of TGFβ signaling to the nucleus. But exactly what genes 
SMAD3 activates and how that pathway might be responsible for abnormally depositing fibrotic 
proteins in the lung is still unclear. 
 3 
By employing a systems biology approach to studying transcriptional regulation in 
pulmonary epithelial cells at the global level, the hope is to gain new insights into what the 
TGFβ/SMAD3 pathway might be doing to promote fibrotic deposition. The first such systems-
level approach used in this work is a high-throughput measurement technique that combines 
chromatin immunoprecipitation with promoter microarrays (ChIP-on-chip). The principle behind 
ChIP is that a specific transcription factor (in this case SMAD3) can be isolated from the nucleus 
along with a portion of each of the promoter regions in the DNA to which it is bound. By 
amplifying these short stretches of promoter-region DNA, labeling them with a fluorescent dye, 
and then hybridizing them to a promoter microarray, we can tell what gene promoter regions had 
been originally bound by SMAD3. By identifying what gene promoter regions had been bound 
by SMAD3, we then know which gene coding regions are potentially regulated by the SMAD3 
transcription factor. Therefore, ChIP-on-chip gives us a method for identifying from among the 
entire cell genome which subset of genes might be transcriptionally regulated specifically 
through the TGFβ/SMAD3 pathway. 
A second systems-level approach used in the present work is the gene expression 
microarray. Gene expression microarrays are firmly established in all areas of life science 
research as a method for globally identifying up- and down-regulated mRNA levels from cells 
[25-30]. In this case, gene expression microarrays provides a second tier of information to 
complement that from ChIP-on-chip. While ChIP-on-chip provides information on which gene 
promoters are bound by SMAD3, gene expression microarrays tell us what actually happens to 
transcript levels of each gene—whether gene transcription is activated, repressed, or whether 
there is no actual change in mRNA transcription level at all. 
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Finally, these high-throughput technologies would be of little use unless we can evaluate 
the information in a proper biological context. The third element of the systems-level approach I 
applied in this work is therefore the use of a number of sophisticated computational methods, 
including gene functional network discovery tools [31-33]. We first use computational biology 
tools to process the raw information from promoter and gene expression microarrays. The array 
images must be converted to computational data structures containing the biologically-relevant 
measurement data. Since all measurements in any scientific context necessarily contain both 
systematic and random error, the microarray data must then be evaluated statistically to identify 
significantly bound, up-regulated, and down-regulated genes. Since potentially hundreds or 
thousands of genes are likely to be identified, this information must be further evaluated with the 
assistance of computational tools. First, genes can be grouped in terms of their similar behaviors 
(up- or down-regulation) and/or their known functions by statistical algorithms that cluster them 
according to their degree of behavior or functional similarity [34]. Using massive databases that 
contain curated information about already-known transcriptional networks, signaling pathways, 
and molecular functions of genes and gene products, our identified gene lists can be further 
mapped according to their participation in these known pathways [32, 33]. This allows us to (1) 
verify that our data agree with what functions they are known to participate in—this serves to 
give us confidence in the quality of our experimental techniques, and (2) discover connections of 
our identified gene groups with previously unknown functions or pathways. Thus, a systems-
level approach to studying transcriptional regulatory networks promises to discover new 
biological pathways or connections between biological pathways not previously known. 
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1.3 OVERVIEW OF FINDINGS 
Using the approaches described above yielded three specific findings. One is the 
identification of TGFβ/SMAD3 regulation of a gene called transgelin, whose protein participates 
in the transformation of pulmonary epithelial cells into fibrotic-protein-secreting myofibroblasts 
[35]. The second is the identification of a connection between the TGFβ/SMAD3 pathway and 
the forkhead winged helix transcription factor FOXA2. FOXA2 is an important transcriptional 
regulator necessary for both proper lung development during embryogenesis and for proper lung 
function in maturity [36-40]. A key function of FOXA2 is the transcriptional regulation of 
surfactant proteins, which play a major role in lung health and whose dysregulation can result in 
pulmonary fibrosis [41-45]. Finally, this study identified a novel connection between the 
TGFβ/SMAD3 pathway and the PinX1 gene, whose protein product is a potent inhibitor of 
telomerase (hTERT) [46-49]. PinX1-mediated inhibition of hTERT can induce apoptosis in cells 
as well as limit their ability to appropriately proliferate in response to tissue damage [46, 48, 49]. 
Further, loss-of-function mutations in hTERT have been reported in familial forms of pulmonary 
fibrosis, which strongly implicates the involvement of hTERT in IPF [50, 51]. All three of these 
findings, the result of a systems-level experimental approach, link specific targets of the 
TGFβ/SMAD3 transcriptional regulatory pathway with the pathogenesis of IPF. 
Additionally, at the global level, this study demonstrated the functional pathways 
involved in the TGFβ−induced transition of A549 alveolar epithelial cells toward cells that have 
the molecular characteristics of myofibroblasts. While the observation that TGFβ induces A549 
cells to undergo epithelial-mesenchymal transition was published in 2007 [13], this is the first 
study to globally show the functional groups and networks of genes involved in the process. 
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1.4 DOCUMENT ORGANIZATION 
The study described here is the result of the integration of diverse technologies and 
approaches. There is also a large amount of background material to discuss to be able to put the 
study in its proper biological context. Therefore this document necessarily spans a number of 
varied topics. The following (second) chapter is an overview of what IPF is, how it is diagnosed 
and characterized, and some of the suspected environmental or genetic contributions to the 
disease process. The third chapter discusses in more detail what is known about the cytokine 
TGFβ itself, the SMAD3 protein, and how the TGFβ/SMAD3 signal transduction cascade 
operates. The fourth chapter takes a short detour from biology to discuss some of the 
methodological and (lightly) philosophical issues surrounding the systems biology approach to 
biological research. The fifth and sixth chapters discuss in relative detail the technologies used—
the specific principles and limitations of ChIP-on-chip and gene expression microarrays, 
respectively. Chapter seven formally describes the methods used in the study. Chapter eight 
exhibits and discusses the specific findings. And finally, chapter nine discusses the importance 
and relevance of the findings in the context of IPF, as well as suggesting future avenues for 
research. 
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2 IDIOPATHIC PULMONARY FIBROSIS 
Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease characterized by excessive 
fibrotic protein deposition in the lungs. This abnormal fibrotic tissue significantly reduces the 
normal flexibility of the lung and interferes with exchange of O2 and CO2 in the alveolar spaces. 
IPF is a progressively debilitating disease for which there is currently no prevention, cure, or 
effective therapy [1, 2]. Moreover, the underlying cause(s) and cellular mechanisms responsible 
for the disease are poorly understood [2-8]. 
 
 
Figure 2-1. Severe end-stage pulmonary fibrosis in a lung taken from an autopsy performed in 
the 1980s [52]. 
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IPF is a subset of a much larger group of lung disorders known as diffuse parenchymal 
lung diseases (DPLDs). These diseases broadly affect the interstitium, or tissues between and 
surrounding the alveolar spaces in the lung. Among the many different diseases that make up the 
category of DPLDs, many lung diseases involve the development of pulmonary fibrosis as a 
secondary outcome of the disease process. Some of these lung diseases stem from chronic 
occupational dust exposures, such as from asbestos, metallic particles, and silica dust [10, 53, 
54]. Pulmonary fibrosis can also be a serious side effect of some pharmaceuticals such as the 
antiarrhythmic agents amiodarone and propanolol and the antibiotic nitrofurantoin [55, 56]. 
Similarly, some antineoplastic cytotoxic agents used in chemotherapy as well as oncological 
radiotherapy may induce pulmonary fibrosis [12, 57, 58]. Sarcoidosis, an inflammatory disease 
characterized by accumulation of granulomas in tissues, can also result in pulmonary fibrosis 
[10, 55]. Some autoimmune or connective tissue diseases, such as rheumatoid arthritis and 
systemic sclerosis may induce pulmonary fibrosis as well [10, 53, 55]. In all of these cases, 
pulmonary fibrosis is a secondary effect of some other disease process. In IPF, fibrosis is the 
primary effect of the disease. 
IPF is the most severe of all of the DPLDs. The life expectancy of IPF patients from the 
time of diagnosis is three to four years, and about 50% of patients will die within 2 to 3 years 
after diagnosis [2, 9-11]. Although a number of drug treatments are commonly prescribed for IPF 
patients, none have been proven to be particularly effective against the disease [2, 7, 56]. The 
most effective measure is a single or double lobe lung transplantation for suitable recipients, 
which obviously has severe practical limitations and is certainly not preferable as a first-line 
medical treatment [3]. At best, some of the disease symptoms can be managed, such as 
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delivering oxygen to help alleviate the dyspsnea and chronic hypoxia that are common in late 
stages of the disease [2]. 
 
 
 
Figure 2-2. Relationship of IPF to other types of Diffuse Parenchymal Lung Diseases. 
 
There are a number of potential risk factors for IPF, however, none of them have been 
clearly identified as unequivocal causes of IPF. Current or former cigarette smoking has the 
strongest association with IPF, with an estimated odds ratio of between 1.6 and 2.9 [2, 56, 59, 
60]. Exposure to infectious viruses such as Epstein-Barr virus, cytomegalovirus, influenza, and 
hepatitis C is also suggested as a potential risk factor, however exposure to most of these viruses 
in the population is very common while only a tiny minority of those exposed will ever develop 
 10 
IPF [2, 56]. In one study, 87% of IPF patients had gastroesophageal reflux disease (GERD), and 
it was postulated that chronic aspiration of stomach acid aerosol might play a role in the 
development of IPF [2, 53, 55, 61]. As in the case of exposure to common viruses, GERD is an 
extremely widespread diagnosis especially in those 40 years or older; the vast majority of those 
with GERD will never develop IPF. As of yet there have been no robust genetic associations 
with IPF (see Genetic Association with IPF section below) as well as no clear race, ethnicity, or 
geographic distribution [2, 57]. The strongest demographic associations continue to be with age 
(>40 years) and gender, with an approximately 60%-40% split in favor of males [2, 57]. IPF 
appears to be a complex disease involving numerous partial ultimate causes that might include 
pathogenic exposures, polygenic factors, environmental exposures, age, and others not yet 
identified. 
 
 
Figure 2-3. Multiple possible causes of disease making for complex interactions. 
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2.1 SYMPTOMS AND DIAGNOSIS 
The most common initial symptom of pulmonary fibrosis is shortness of breath, 
especially upon exertion. This symptom can be associated with a great many other medical 
conditions, however, and is often ignored by the patient until it has progressed to a significant 
degree. Other symptoms include a dry cough or the presentation of “crackles” audible to a 
physician upon chest auscultation [2]. Some patients develop “clubbing” of the fingertips as a 
result of chronic oxygen deprivation [2]. Pulmonary fibrosis is often differentially diagnosed 
through a combination of non-invasive and invasive diagnostic tests. One of the least invasive 
diagnostic test procedures is spirometry, or pulmonary function testing, where such variables as 
lung capacity, mechanical compliance, and maximal air flow are measured [10, 62]. Chest x-rays 
and high-resolution CT scans are commonly used to look for observable, macroscopic changes in 
the structure of the lung [2, 56, 62]. Bronchoscopy and bronchoalveolar lavage (BAL; washing 
and sampling of lung spaces with saline) may be used to rule out other diagnoses, such as 
infections [10]. Finally, a lung biopsy can be used to provide a definitive diagnosis when other 
potential causes are ruled out [2, 10, 62]. 
At the histopathology level, idiopathic pulmonary fibrosis is characterized by the 
appearance of small foci of fibroblasts which deposit fibrotic proteins such as collagens in the 
interstitium. This fibrotic deposition progresses outwardly from these foci and cause portions of 
the lung to take on a characteristic “honeycomb” appearance that can be identified through lung 
X-ray or CT scan [10, 62]. The progressive replacement of healthy, flexible alveolar tissue with 
stiff fibrotic lesions begins to inhibit proper respiratory movement as well as severely interfere 
with gas exchange in the lung. Therefore, IPF patients will understandably experience dyspnea 
as a result of increasingly diminished lung function [56]. In situations in which pulmonary 
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fibrosis occurs and all known proximal causes (i.e., other DLPDs) are ruled out, the disease is 
then diagnosed as “idiopathic” pulmonary fibrosis. 
The time course of IPF is extremely variable. Some patients have a stable period of 
disease progression interspersed with periods of acute exacerbations. Others experience a rapid 
deterioration after diagnosis [4, 63]. A sizable proportion of IPF patients develop pulmonary 
hypertension and eventually die of cardiovascular events or congestive heart failure; others will 
die of acute respiratory distress or other IPF-related complications [4, 10, 63, 64]. 
 
Figure 2-4. Patient CT scans showing progression of IPF after nine months 
(right)(courtesy Kevin Gibson, M.D.). 
  
Figure 2-5. Histology, normal lung (left) versus IPF lung (right) showing fibrotic deposits 
(courtesy Naftali Kaminski, MD). 
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2.2 GENETIC ASSOCIATIONS WITH IPF 
DPLDs in general, and IPF in particular, are relatively rare diseases and therefore 
difficult to study in the population. The vast majority of cases of IPF occur sporadically, i.e., 
they rarely cluster in families. IPF appears to be a complex polygenic disease likely involving 
multiple environmental interactions as well. Further, the relative contribution of many individual 
genes to the disease may each be small—it is the combinatory effect that may be most important 
[65]. Elucidating the genetic causes or predispositions for the disease is also complicated by the 
fact that until recently, there has been no consensus on a precise definition of the IPF phenotype. 
Despite these difficulties, a number of studies have shown possible genetic factors 
involved in the pathogenesis of IPF. First, histologically identical cases of pulmonary fibrosis 
have been reported in monozygotic twins reared separately [66-68]. Pulmonary fibrosis has also 
been seen in the same generation of a single family as well as vertical transmission between 
generations [69-72] 
Also, pulmonary fibrosis is associated with a number of well-defined genetic disorders, 
including Hermansky-Pudlack Syndrome, Gaucher Disease, Nieman-Pick Disease, and Familial 
Hypocalciuric Hypercalcemia [73-80]. This indicates some mode of inheritance of genes 
responsible for the development of pulmonary fibrosis. 
In 2005 Steele et. al., identified 111 families with 309 people affected and 360 people 
unaffected by idiopathic interstitial pneumonias (IIPs). They showed a statistically significant 
association for disease risk among sibling pairs (p<0.001). Twenty pedigrees also showed 
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vertical transmission of the disease, including three families with male-to-male transmission. 
These results are consistent with an autosomal dominant with incomplete penetrance inheritance 
model [81].  
In addition to familial aggregation, several IIP studies point to specific gene mutations. 
One such gene, surfactant protein C (Sp-C; SFTPC), codes for a hydrophobic membrane protein 
produced by alveolar type II epithelial cells. It works with other surfactant proteins (A,B,D) to 
reduce surface tension in the aqueous alveolar space, allowing the alveoli to expand properly for 
gas exchange. Surfactants are required for proper lung function. In one case study, a c.460 G → 
A mutation in SFTPC and consequent defective Sp-C protein was detected in both a mother and 
daughter with IIPs [41, 42]. Similarly, Thomas et. al., identified an SFTPC mutation  (Exon 5 + 
128 A → T) in a familial cluster of IPF cases [44]. 
 
 
Figure 2-6. Pedigree and associated restriction analysis of SFTPC variants. 
(A) pedigree showing affected and non-affected individuals. (B) Electrophoretic gel 
showing Bsr1 restriction digest gene fragment containing Exon 5 of the Sp-C gene. Note 
non-affecteds uniformly show a single band, whereas affected have three. (C) Diagram 
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showing restriction site in mutation but not normal Exon 5 SFTPC sequence (reproduced 
from Thomas, et. al. 2002) [44]. 
 
Telomere reverse transcriptase (hTERT) is another gene which has an association with 
IPF. Telomeres contain multiple repeats of the TTAGGG sequence at the ends of chromosomes. 
Some of these repeat sequences are lost with each cell division. The telomerase enzyme encoded 
by hTERT, along with the RNA component of telomerase (hTERC), mediates addition of 
TTAGGG to replace those lost during cell division. Without the proper telomerase activity, 
telomeres will shorten to the point that cells will fail to divide [82].  Tsakiri et al., performed 
linkage analysis of 46 families with two or more individuals affected with IIPs. They identified 
hTERT as a candidate gene. Mutation analysis revealed a missense mutation and a frameshift 
mutation in hTERT that co-segregated with IIP in two families. Sequence comparisons of hTERT 
between 44 sporadic IPF cases and probands from 44 unrelated families revealed five other 
mutations. One family had a mutation in TERC as well. Those individuals with heterozygous 
mutations in hTERT or hTERC had shorter telomere lengths compared to controls [50, 51]. Thus, 
telomerase is another gene with a distinct association with IPF, and may also provide a clue to 
the overall profoundly increased risk of IPF with age.  
Other genetic associations with IPF have been found with ELMO domain-containing 
protein 2 (ELMOD2) [83], variants of the surfactant proteins Sp-A and Sp-B (SP-A, Sp-B) [84-
86], complement receptor 1 (CR1)[87], and interleukin-1 receptor antagonist (IL-1ra) and tumor 
necrosis factor α (TNFα) [88]. Each of these linkages and association with genetic mutations 
have been found in some studies but not others. In most cases of sporadic IPF, no genetic 
association has yet been found [43, 65, 88]. This suggests that of many possible genes involved 
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in the disease, few if any are both necessary and sufficient causes. However, the coincidence of 
multiple genetic, pathogenic, and environmental causes may constitute sufficiency. 
2.3 EXTRACELLULAR MATRIX 
In pulmonary fibrosis, the most visible evidence of the disease process takes place in the 
pulmonary interstitium, or the extracellular material in between and surrounding the alveolar sac. 
The study of how this abnormal, progressive fibrotic deposition occurs therefore centers largely 
around how the extracellular matrix, or ECM, is produced, maintained, remodeled, and degraded. 
In multicellular animals, extracellular matrix (ECM) refers to material between cells that 
provides anchorage and mechanical support, as well as serving as mediators of intercellular 
communication [89, 90]. ECM is primarily made of fibrous structural proteins predominated by 
collagens, along with various polysaccharides and proteoglycans. Among the 28 different types 
of characterized collagens are fibrillar (Type I, II, III, V, XI), facit (Type IX, XII, XIV), short 
chain (Type VIII, X), basement membrane (Type IV) and others (Type VI, VII, XIII) [89, 90]. 
Other major structural proteins include fibronectin, elastin, and laminins [89, 90]. Among the 
proteoglycan components of ECM are heparin sulfate, keratin sulfates, and condroitin sulfates 
[90]. 
The ECM also includes a myriad of cell signaling molecules such as cytokines, cell 
adhesion molecules, proteases, growth factors and other molecules that interact with the cell 
surface receptors on the adjoining cell surfaces [90]. In cartilage, production and maintenance of 
ECM is performed by chondrocytes [90]. Similarly, in bone, osteoblasts are responsible for 
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matrix deposition and bone formation [90]. In the majority of tissue types including lung, 
fibroblasts predominantly produce and maintain ECM structural proteins [14, 91]. 
Far from being a passive structure, the ECM is a dynamic community of bioactive 
molecules, its ever-changing architecture the result of continuous protein deposition and active 
protein remodeling. Chief among these remodeling agents are proteolytic enzymes known as 
matrix metalloproteinases (MMPs). MMPs are zinc-dependent endopeptidases that catalyze the 
cleavage and/or degradation of various proteins found in the ECM [92-95]. Since the ECM 
consists of numerous fibrous structural proteins interwoven with various cytokines, receptors, 
and growth factors, catalytic cleavage of these bioactive molecules can in some circumstances 
inactive, or active, them. MMPs are therefore active regulators of both structural architecture and 
inter-cellular signaling. Among the 23 types of human MMPs characterized, each exhibits 
specific activity against particular substrates, e.g., collagenases, gelatinases, stromelysins, and 
membrane-type MMPs (MT-MMPs) [89, 90, 92, 93]. MMPs types also differ in their biological 
functions: some may cleave cell surface receptors and cell adhesion molecules, some release 
apoptotic ligands (such as the FAS ligand), and others activate or inactivate chemokines [92, 93]. 
MMPs therefore play a critical role in mediating cell behavior, such as cell proliferation, cell 
adhesion and migration, differentiation, angiogenesis, apoptosis and host defense [92, 93]. 
MMPs are themselves regulated by endogenous tissue inhibitors of metalloproteinases (TIMPs), 
consisting of a family of four protease inhibitors: TIMP-1, TIMP-2, TIMP-3 and TIMP-4 [92, 
93]. 
Elucidating the complex dynamics of ECM structure and function is therefore extremely 
important in understanding a great variety of normal biological processes as well as pathological 
conditions. The interplay of structural and bioactive molecules in the ECM, and particularly 
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those of MMPs and TIMPs, are of particular interest in understanding the molecular 
pathophysiology of IPF [89, 96, 97]. In addition to being important in pulmonary fibrosis, these 
processes are also crucial to wound healing, host defense, embryogenesis and development, and 
angiogenesis, and tumor metastasis, migration, and metastatic anchorage [14, 92, 93, 95]. 
2.4 WOUND REPAIR, EPITHELIAL-MESENCHYMAL TRANSITION, AND 
FIBROTIC DEPOSITION 
In mechanical wounding of the epidermis, the first immediate activity is coagulation of 
blood mediated by a complex cascade of blood clotting factors. The result of this clotting is a 
temporary mechanical stabilization of the wound by a hemostatic plug of a dense, strong, fibrous 
protein known as fibrin [90, 91]. Concurrently, an immediate localized inflammatory reaction 
occurs and produces chemoattractants that recruit monocytes and neutrophils to the area. This 
acute inflammatory reaction is later followed by the start of a repair phase in which acute 
inflammation is suppressed and fibrinolytic substances begin partially dissolving clotted fibrin. 
This allows epithelial cells and fibroblasts to migrate toward the area to begin the process of re-
epithelialization [98-100]. 
In response to pro-repair cytokines and growth signals—most notably TGFβ1 secreted by 
activated macrophages—the cytoskeletal structure of fibroblasts begins to change. Fibroblasts 
begin expressing proteins which give them some of the contractile properties of muscle cells 
(e.g., alpha smooth muscle actin), and are hence known as myofibroblasts [12, 91, 101]. 
Similarly in response to TGFβ1, some epithelial cells proliferate, dissociate from their basement 
membranes via MMP activity, transform into myofibroblasts, and migrate toward the wound 
 19 
area. This cell type transformation is known as epithelial-mesenchymal transition, or EMT [12, 
14, 98-103]. A third potential source of fibroblasts that may migrate to the injured area via the 
bloodstream is bone-marrow derived mesenchymal stem cells known as fibrocytes [12, 102, 
104]. 
Being both motile and contractile, the myofibroblasts infiltrate the wounded area and 
anchor themselves. They then begin “pulling” the edges of the wound together [90, 91]. 
Myofibroblasts also actively deposit large quantities of collagens and other structural proteins 
that build up the ECM in and around the wounded area, resulting in a more long-term structural 
stabilization of the damaged epidermis. MMPs and TIMPs are also secreted which continually 
remodel and sculpt the fibrous ECM architecture [91, 100]. Normally, after sufficient ECM has 
been deposited to protect and stabilize a wound, the myofibroblasts are no longer needed and 
begin to undergo programmed cell death, or apoptosis [91]. Some of the ECM proteins continue 
to be degraded by MMPs and are resorbed, allowing epithelial cells to migrate into the area, 
proliferate, and re-epithelialize the previously damaged areas [98-100]. However, when there is 
excessive deposition of fibrotic material, or the material is not properly degraded and removed, 
the result is a prominent residual “patch” of fibrous structural proteins we commonly refer to as 
scar tissue. TGFβ1 is a major mediator of all of these repair activities, most notably fibroblast 
and myofibroblast recruitment, EMT, secretion of collagens, and upregulation and secretion of 
various MMPs and TIMPs [12, 89-91, 105]. 
In idiopathic pulmonary fibrosis, no such mechanical wounding is evident that would 
account for either an acute inflammatory phase or a repair phase. The major feature of idiopathic 
pulmonary fibrosis is uncontrolled, aberrant “wound repair” in the lung where no such repair is 
apparently necessary. As in the case of mechanical wound healing of epidermis, however, 
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fibroblasts and myofibroblasts proliferate and migrate to the area. Similarly, epithelial cells 
undergo EMT, and migrate to the area as myofibroblasts as well. Deposition of collagens and 
other fibrotic proteins, which in other tissues would serve to mechanically stabilize and repair a 
wound, proves to be a serious problem in the interstitium around alveolar spaces. Again, TGFβ1 
is a known major mediator of these events and as discussed earlier is present in active form in 
high concentrations in active IPF foci [13, 91, 106, 107]. 
For many years the prevailing hypothesis was that IPF must result from some form of 
chronic inflammation in the lung [8, 10, 99, 100, 108]. However, there is abundant evidence that 
the etiology of IPF is not quite so simple and that chronic inflammation is unlikely to be its 
primary cause. First, in histopathological examination of tissue samples taken from IPF patients, 
there is typically little evidence of inflammation [8, 10, 100, 107]. Similarly, markers of chronic 
inflammation in IPF patients do not correlate with severity of IPF progression or with deaths. 
Conversely, in cases of known interstitial lung diseases involving chronic inflammation, the 
cases do not often progress toward fibrosis [8]. Finally, although anti-inflammatory and immune-
suppressing drugs have been traditionally given to IPF patients for many years, these drugs have 
been shown to have no effect on improving disease outcomes or reducing deaths [1, 8, 108]. 
More recently, the prevailing ideas about the etiology of IPF surround some as-yet 
unknown mechanism that induces alveolar epithelial cell damage, followed by pro-fibrotic 
mechanisms [56]. Based on transgenic animal models and microarray studies, a number of 
cytokine signaling pathways and cellular functions have been proposed as being involved in the 
pathogenesis of IPF. Among these are transforming growth factor beta-1 (TGFβ1), tumor 
necrosis factor (TNFα), angiogenesis and cell recruitment, coagulation cascades, apoptosis, lipid 
metabolism, and expression of multiple regulatory molecules in the alveolar epithelial cells 
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[109]. Of these possible key mediators of fibrosis, a significant amount of evidence points 
toward a major role of the cytokine TGFβ1. The evidence and potential role of this prominent 
signaling molecule is discussed in the following chapter. 
2.5 EXPERIMENTAL METHODS COMMON IN IPF RESEARCH 
There are several general approaches and models common in IPF research. Like most 
biomedical research, experiments are often conducted using cell culture models, animal models, 
and human (clinical and post-mortem) studies. 
Cell cultures of lung epithelial cells and fibroblasts are often used to study cell signaling 
and transcriptional regulation of key factors hypothesized to be involved in IPF pathogenesis. 
While primary human lung fibroblasts are relatively easy to grow in culture, primary human 
epithelial cells, and in particular Type II alveolar epithelial cells, are very difficult if not 
impossible to culture and expand in the laboratory. A less desirable but more practical alternative 
is using transformed or epithelial cancer cell lines, since they are much easier to maintain and 
grow up in quantities necessary for most molecular biology techniques. Single genes or 
transcription factors of interest can be knocked out using small interfering RNA (siRNA) or 
specific molecular pathway inhibitors. 
Animal models—most commonly mice, rats, and hamsters—are also often used in IPF 
research [110]. Transgenic animals, particularly those with homozygous deletions for key genes 
of interest, are commonly used to study the effect of single gene knockouts [111]. Adenoviral-
mediated gene transfer is also used to over-express certain gene products [112]. 
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The most common animal model of IPF in particular is bleomycin-induced pulmonary 
fibrosis. Bleomycin is a cytotoxic glycopeptide antibiotic most commonly used as an 
antineoplastic agent in the treatment of lymphomas, squamous cell carcinomas, and testicular 
cancer. A serious side effect of bleomycin treatment in humans is induction of pulmonary 
fibrosis. Approximately 10% of treated patients develop side effects associated with pulmonary 
toxicity, with 1% progressing to full pulmonary fibrosis [113]. 
In the animal model of bleomycin-induced pulmonary fibrosis, mice or rats are 
anesthetized and intratracheally administered high doses of bleomycin. In the first several days, 
an acute pulmonary inflammatory reaction takes place, followed by activation of fibroblasts and 
subsequent fibrotic deposition. Frank pulmonary fibrosis usually develops within days of dosing. 
The key disadvantage of the bleomycin rodent model is that the chemically-induced pulmonary 
fibrosis in rodents does not completely mimic naturally-occurring human idiopathic fibrosis, 
especially in regards to the initial acute inflammatory phase. More significantly, bleomycin-
induced fibrosis in rats and mice will often resolve over a period of time, while IPF in humans 
progressively worsens [110, 114, 115]. 
 
 
Figure 2-7. Molecular structure of bleomycin. 
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One method of assessing the severity of a fibrotic response in vivo is by measuring 
collagen content and the relative rates of collagen synthesis and degradation in the lungs. This is 
accomplished by measuring a major constituent of collagen, hydroxyproline. When collagen is 
synthesized, the amino acid proline is hydroxylated to form hydroxyproline. This hydroxylated 
amino acid allows the collagen helical structure to bend tightly, serving as a strong molecular 
“hinge” or “spring.” The only other protein that has significant amounts of hydroxyproline is 
elastin, which is another highly elastic structural protein found in fibrotic deposits [116]. By 
administering radio-labeled proline, and then measuring the absolute and relative amounts of 
proline to hydroxyproline, one can calculate rates of collagen synthesis, degradation, and 
absolute quantities of the protein in tissue [117]. 
 
 
 
 
Figure 2-8. Hydroxyproline structure (left) and the collagen triple helix (right). 
 
In humans, clinical studies on IPF include clinically-observable endpoints. Examples of 
these are imaging (X-rays, CT-scan), immunohistochemical and/or molecular characterization of 
biopsies, bronchoalevolar lavage [118, 119], and measurements of blood markers. Lung 
transplants and explants are also sources of biopsies that can be studied through molecular 
biology techniques or immunohistochemistry. Finally, post-mortem examinations of lung tissue, 
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especially if done quickly after death before autolysis has set in, provides insight into end-stage 
IPF disease [63]. 
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3 TRANSFORMING GROWTH FACTOR β1 AND SMAD3 
3.1 TRANSFORMING GROWTH FACTOR β1 
Transforming Growth Factor β1 (TGFβ1) is a key anti-inflammatory cytokine involved in 
numerous cell signaling and cellular processes. These including cell proliferation, differentiation, 
cell adhesion and migration, extracellular matrix deposition, apoptosis, embryonic development, 
and immune response [17, 18, 106, 120-123]. Dysregulated or aberrant TGFβ1 signaling is 
implicated in numerous pathological conditions including cancer, pulmonary hypertension, and a 
wide variety of organ-specific fibrotic diseases including idiopathic pulmonary fibrosis (IPF). 
[123-125].  
In humans, the TGFβ superfamily of homologous proteins consists of about 42 members 
that include three isoforms of TGFβ itself (TGFβ1, 2, and 3), nodals, activins, inhibitins, bone 
morphogenic proteins (BMPs), myostatin, and anti-Müllerian hormone (AMH) [19, 20, 22].The 
TGFβ family of proteins is also highly conserved across mammalian species [22, 121]. 
Nearly all cell types both produce and have receptors for TGFβ, although the effects on 
each type of cell are varied and specific to a particular cell type [17, 18, 20, 126, 127]. The 
isoform TGFβ1 is of particular interest in understanding IPF because it is found abundantly in 
platelets and plays the major role in wound healing as well as both normal and aberrant fibrotic 
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deposition [122, 128, 129]. More importantly, of the three isoforms, TGFβ1 is found in the 
alveolar epithelial cells and macrophages of pulmonary fibrosis patients [130]. 
(a) (b) 
 
(c) 
 
Figure 3-1. TGFβ1 Structure. 
(a) Linear structure of TGFβ1 precursor peptide; (b) three-dimensional structure of active 
TGFβ1 homodimer; (c) Processing of TGFβ1 peptide: TGFβ1 is secreted as a pro-peptide 
precursor; proteolytically cleaved, dimerized, and non-covalently associated with latency 
associated peptide (LAP); bound to ECM proteins in inactive form with latent TGF 
binding peptide (LTBP); and released/activated through proteolytic cleavage [131-134]. 
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TGFβ1 is transcribed in an inactive precursor polypeptide consisting of 390 amino acids. 
At the N-terminus lies a signal sequence consisting of 29 amino acids. The active TGFβ1 peptide 
lies at the C-terminus of the amino acid chain and is 112 amino acids long. The sequence 
upstream of the TGFβ1 sequence is known as latency-associated peptide (LAP). [133-136]. 
Upon cleavage through proteolytic hydrolysis, the LAP/TGFβ1 peptide is released and 
homodimerizes through disulfide linkages at the cysteine residues [17, 18, 133, 135]. The 
precursor molecule is also non-covalently linked to a latent TGF binding peptide (LTBP). 
Inactive TGFβ1-LAP precursor complexes are commonly secreted and stored in high 
concentrations in the ECM surrounding epithelial cells. Upon perturbation by mechanical injury 
or epithelial cell migration, proteases such as plasmin, metalloproteinase 9, elastase, cathepsins 
or the cell surface protein integrin αvβ6, cleave the TGFβ1-LAP complex to release activated 
TGFβ1 homodimer [121, 133, 135, 137-139]. TGFβ1 is an immediate-early response 
autoendocrine cytokine, and as such is ubiquitously sequestered around cells in an inactive state, 
poised to be released and activated quickly upon demand. 
3.2 SMADS 
TGFβ1 exerts its principal effects on epithelial cells and fibroblasts through the 
TGFβ1/SMAD3 signal transduction pathway operating between cell surface receptors for TGFβ1 
and the gene regulatory machinery in the nucleus [140, 141]. In humans, there are eight members 
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of the SMAD family of transcription factors.1 Of these, five are receptor-regulated SMADs, or 
R-SMAS: SMAD1, SMAD2, SMAD3, SMAD5 and SMAD9. SMAD4 is referred to as a 
common-mediator SMAD, or co-SMAD. SMAD6 and SMAD7 are antagonistic or inhibitory 
SMADs and are therefore referred to as I-SMADs [20]. 
SMAD proteins have two MAD-homology domains, an N-terminal one called MH-1 and 
a C-terminal one called MH-2. The MH-1 domain has DNA-binding activity and is necessary for 
nuclear translocation. The MH-2 domain bind proteins and transactivates other proteins SMADs 
also have a C-terminal SXS motif containing serines which are targets of activation through 
phosphorylation [20].  
 
Table 3-1. List of human SMAD proteins 
Receptor SMADs R-SMADs SMAD1, SMAD2, SMAD3, SMAD5, SMAD9 
Common-mediator 
SMADs 
co-SMAD SMAD4 
Inhibitory SMADs I-SMADs SMAD6, SMAD7 
 
 
 
 
                                                 
1 Human SMAD proteins are homologs of two proteins found in lower species. One is a Drosophila protein that 
represses an embryonic development gene called decapentaplegic. The discoverers called the “mothers against 
decapentaplegic” or “MAD”. The other protein shares homology with the C. elegans protein SMA (contracted from 
“small/male/abnormal”). The name “SMAD” therefore refers to a contraction of the two protein names, “SMA” and 
“MAD.” 
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Figure 3-2.  Linear structure of SMAD proteins. 
 
Two kinds of TGFβ1-responsive receptors are found on the cell surface: TGFβ receptor 
type I (TβRI) and TGFβ receptor type II (TβRII). Each is present as a homodimer on the cell 
surface. Both receptor types are transmembrane serine/threonine kinases [142]. Both receptor 
types are also very similar in sequence and structure, but the type I receptor has a conserved 
glycine/serine-rich sequence (GS-sequence) immediately upstream of its kinase domain. TβRI 
and TβRII receptors are general names for receptors activated by different members of the TGFβ 
family of ligands. Each pair of receptor types are also known more specifically as species of 
activin-receptor-like kinases (ALKs). Type I receptors may consist of one of seven separate ALK 
species. The type I receptor specific for TGFβ1 in particular is known as TβRI/ALK5 [20, 143]. 
The signal transduction cascade begins when a ligand, in this case the active homodimer 
form of TGFβ1, binds to and activates the TβRII receptor pair. The activated type II receptor pair 
recruits the type I receptor pair into the complex through an auxiliary protein known as Smad 
Anchor for Receptor Activation (SARA). This complex phosphorylates the GS-sequence in the 
type I receptor pair. The phosphorylated, activated type I receptor pair in turn phosphorylates the 
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cytoplasmic transcription factors SMAD2 and SMAD3. This heterodimer undergoes a 
conformational change that releases it from the receptor complex. The SMAD2/3 heterodimer 
subsequently complexes with a third co-transcription factor, SMAD4. The entire activated 
heterotrimer complex, consisting of SMAD2/3/4, then translocates into the nucleus to effect 
transcriptional regulation [17, 18, 20, 140, 144]. Prior to TGFβ1 activation, the R-SMADs are 
primarily distributed in the cytoplasm, whereas SMAD4 is distributed in both the cytoplasm and 
nucleus. The activated SMAD2/3/4 complex translocates to the nucleus through a nuclear 
localization sequence (NLS) in the MH1 domain of the R-SMADs [143].  
 
Figure 3-3. Schematic diagram of the TGFβ1/SMAD3 signaling pathway [32]. 
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The SMAD2/3/4 complex has relatively weak DNA binding affinity as well as less 
stringent DNA sequence specificity. Greater binding affinity and specificity is afforded by 
complexing with co-transcriptional activators such as CBP (cAMP-responsive element-binding 
protein binding protein) and p300. CBP/p300 also has chromatin structure-modifying histone 
acetyltransferase (HAT) activity [20]. 
Of the R-SMADs activated through the TGFβ1 pathway, only SMAD3 and SMAD 4 
have significant ability to bind DNA directly.  In terms of optimal nucleic acid sequence, 
SMAD3 and SMAD4 can bind to the sequence 5’ – CTCTAGAC – 3’. SMAD3 binds 
specifically through its MH1 domain to the sequence 5’ – GTCT – 3’ and its reverse complement 
5’ – AGAC – 3’, the later of which is commonly known as a SMAD binding element (SBE). 
SMAD3 has also been shown to bind to the sequence 5’ – GGCGGG – 3’ in the c-Myc promoter 
[20].  
The TGFβ1/SMAD3 signal transduction/gene regulation pathway also includes a negative 
feedback loop that quickly terminates pathway activation in the absence of TGFβ1 stimulation. 
The two inhibitory SMADs, SMAD6 and SMAD7, are distributed in the cell cytoplasm and are 
upregulated by the TGFβ1/SMAD3 signal transduction pathway. These I-SMADs terminate 
SMAD3 signal transduction by competing with SMAD2/3 for binding to the TβRI receptor. 
These SMADs interact with the TβRI receptor directly through their MH2 domains [20, 140, 
143, 145-147].  
Additionally, SMAD6 and SMAD7 interact directly with proteins called SMAD 
ubiquitination regulatory factor (SMURFs), of which there are two varieties, SMURF1 and 
SMURF2. These proteins in turn interact with phosphorylated SMAD2 and SMAD3 through E3 
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ubiquitin ligases to target SMAD2 and SMAD3 for degradation in the proteosome, further 
suppressing TGFβ1/SMAD3 pathway activity [20, 140, 145, 148-150]. 
Finally, in the nucleus, the R-SMADs are continually dephosphorylated and thus, 
dissociate from their complexes. They subsequently expose a nuclear export sequence (NES) and 
are shuttled back into the cytoplasm [143, 151]. 
Aside from negative regulation of the TGFβ1/SMAD3 pathway by SMAD6, SMAD7, 
and SMURFs, the pathway has numerous co-repressors of transcriptional activity. Among the 
most notable of these are the c-SKI and SNO-N proteins. They are proto-oncogene protein 
products that are found in high levels in many types of human cancer cells. They bind to the 
MH2 domains of SMAD2 and SMAD3, thereby interfering with binding with transcriptional co-
factors and with DNA [152]. They can additionally block the TGFβ1/SMAD3 pathway by 
binding to SMAD3 and sequestering it in the cytoplasm [153]. Similarly, c-MYC can inhibit 
SMAD2 and SMAD3 activity, but only from among a small subset of SMAD3 binding targets 
such as p15Ink4B and p21Cip1 [153]. 
3.3 INTERACTION OF TGFβ1/SMAD3 WITH OTHER GENE REGULATORY/ 
SIGNALING PATHWAYS 
Like other cellular and transcriptional factor pathways, the TGFβ1/SMAD3 pathway does 
not work in isolation. It is known to interact with numerous other signaling and transcription 
factor pathways through various mechanisms. One such interaction is through the inhibitory 
SMAD7. The JAK/STAT signal transduction pathway, which is activated by Interferon-γ, 
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induces SMAD7. Likewise, TNFα, IL-1, and lipopolysaccharides are well-known activators of 
NFκB, which in turn also induces SMAD7. In both these cases, we see one mechanism by which 
pro-inflammatory cytokines or stimulus can suppress activity of the TGFβ1 pathway [20]. 
Another interaction between TGFβ1 and a major signaling pathway involved in cell cycle 
progression is with mitogen-associated kinase/ MAPK/Erk [144]. MAPK and cyclin-dependent 
kinases (CDKs) can phosphorylate R-SMADs. Similarly, MAPK kinase 1 (MEKK-1) activates 
JNK and also phosphorylates SMAD2. JNK in turn phosphorylates SMAD3. Conversely, TGFβ 
is known to activate MAPK as well [20]. 
R-SMADs also interact directly with DNA-binding proteins. The phosphorylated R-
SMAD complex interacts with the forkhead box transcription factors, FOXO and FOXH1. R-
SMADs also interact with zinc-finger DNA-binding proteins such as GATA3,4,5,6 and ZNF198. 
Finally, the TGFβ/SMAD3 pathway interacts with other signaling and transcriptional activation 
pathways such as β-catenin and HIF-1A. 
3.4 EPITHELIAL-MESENCHYMAL TRANSITION 
In most cell types, TGFβ1 inhibits cell proliferation [154]. TGFβ1 stimulation of 
epithelial cells, however, either (a) inhibits cell proliferation, (b) causes cells to undergo 
apoptosis, or (c) causes them to dissociate from their basement membrane, proliferate, and 
migrate, taking on many characteristics of certain types of mesenchymal cells [16]. The latter (c) 
process is called epithelial-mesenchymal transition or EMT [12-14]. Mesenchymal cells include 
progenitor cells of muscle cells, adipocytes, osteoblasts, chondrocytes, and fibroblasts. The 
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mesenchymal cells that result from EMT closely resemble fibroblasts in morphology and 
behavior, sometimes with additional motile and contractile abilities characteristic of muscle 
cells. These resultant fibroblasts with motile/contractile characteristics are known as 
myofibroblasts. [98, 99, 154]. 
Epithelial cells normally lie in a polarized, sheet-like structure attached to a basement 
membrane. TGFβ1 stimulation of epithelial cells downregulates E-cadherin, causing the cells to 
lose tight attachment to each other and their basement membrane. The loss of E-cadherin also 
results in upregulation of c-MYC, cyclin D1, and MMP7, inducing cell proliferation and 
enhancing cell motility [125]. As the EMT process progresses, cytoskeletal rearrangement takes 
place, causing the cells to adopt a spindle-like structure characteristic of fibroblasts. The cells 
also begin expressing mesenchymal markers such as vimentin, N-cadherin, and fibronectin [125, 
155]. 
Prolonged TGFβ1 stimulation induces the mesenchymal cells to secrete collagens such as 
COL7A1, decrease protease production, and increase the secretion of protease inhibitors such as 
TIMPs and plasminogen activator inhibitor 1 (PAI-1) [19, 107, 121, 122]. Eventually the cells 
may begin expressing alpha smooth muscle actin (αSMA) and transition into motile 
myofibroblasts that aggressively infiltrate and deposit ECM proteins, particularly collagens [12-
14, 97-99, 105-107, 125]. What started as an orderly membrane-bound sheet of polarized 
epithelial cells transforms into a disorganized collection of motile mesenchymal cells that 
aggressively infiltrate other tissues, secreting fibrous proteins. While EMT is expected to occur 
during certain phases of normal embryonic development, in adults it is characteristic of fibrotic 
diseases as well as neoplastic invasion and metastasis [98, 99, 125]. 
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The TGFβ1/SMAD3 pathway in particular is implicated as being necessary, although not 
sufficient itself, in inducing EMT in epithelial cells. Cultured epithelial cells from SMAD3-
deficient mice could not be induced to undergo EMT by TGFβ1 treatment, whereas the same cell 
type cultured from wild-type mice exhibited EMT [15, 156]. 
3.5 THE TGFβ1/SMAD3 PATHWAY AND ITS IMPLICATION IN IPF 
Numerous human and animal studies implicate TGFβ1 in the pathogenesis of IPF. First, 
strongly increased TGFβ1 mRNA expression and protein secretion have been found in areas of 
active extracellular matrix deposition in fibrotic foci of IPF patient lung biopsies [130, 157-161]. 
Alveolar macrophages secrete TGFβ1 in both humans and bleomycin-induced mouse model of 
fibrosis [130, 162]. 
Further, adenoviral-vector mediated gene transfer of TGFβ1 into rats induced distorted 
alveolar and parenchymal structure, increased extracellular matrix deposition, and induced a 
characteristic “honeycombing” feature in lung architecture that are all hallmarks of pulmonary 
fibrosis [112, 139]. SMAD3 knockout mice (but not SMAD2) were protected against bleomycin-
induced pulmonary fibrosis [141, 163, 164]. Similarly, administration of the TGFβ1 inhibitor 
halofuginone in mice markedly reduced ionizing radiation-induced fibrosis [165]. When 
exogenous SMAD7, which is antagonistic against the TGFβ1/SMAD3 pathway, was introduced 
into mice through an adenoviral vector, it protected them against bleomycin-induced pulmonary 
fibrosis [166].  Also, administration of exogenous TGFβ1 induced EMT in rat alveolar Type II 
cells, and this effect was significantly blocked by adenoviral-induced SMAD7 [155]. Finally, in 
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bleomycin-induced pulmonary fibrosis in rats, SMAD3 clearly decreased in the cytoplasm and 
increased in the nucleus of lung tissue cells, indicating activation of the TGFβ1/SMAD3 pathway 
and nuclear translocation of SMAD3 [167]. Thus, there is ample experimental evidence in 
animals and humans, both directly and indirectly, that the TGFβ1/SMAD3 pathway plays a 
significant role in the pathogenesis of pulmonary fibrosis [122]. 
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4 METHODOLOGICAL ISSUES 
4.1 WHAT IS SYSTEMS BIOLOGY? 
4.1.1 REDUCTIONISM VERSUS SYSTEMS THINKING 
There are two ways to approach investigating any complex system such as a cell or 
organism. One is the reductionist approach, where the complex system is divided into component 
parts and those individual parts are studied in isolation. The other approach is holistic, where a 
global view of the interactions between the parts, as well as the characteristics of the system on 
the whole, are the objects of study. 
The idea of breaking complex systems down into their component parts as a way of 
understanding the system is both intuitive and reasonable. This is especially true during most of 
the past two and half millennia, during which natural philosophers were struggling to understand 
the mysterious workings of nature with very few tools or starting background knowledge. When 
first approaching a poorly understood system or phenomenon, it is only natural to want to open it 
up, dissect it, examine its parts, and then try to discern “what makes it tick.” As such, the 
reductionist approach has been enormously successful throughout the history of science, 
especially in such disciplines as physics and human anatomy. 
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The systems-level approach has enjoyed far less visibility until more recently. Being 
inherently complicated by definition, complex systems have generally been difficult to study 
until the appropriate mathematical, and until recently, computational tools have become 
available. Some familiar more early disciplines that have evolved a systems-level approach prior 
to the introduction of computational tools are ecology and physiology.  
One of the main questions concerning the relationship between reductionism and holism 
is whether the properties of one logically entail the other. More specifically, the question is 
whether a system on the whole has properties that could not have been predicted from a sole 
understanding of the individual parts. We call this emergent properties of the system. A simple 
example of emergence is that a detailed characterization of an individual bird’s flying behavior 
would not necessarily entail the phenomenon of a group of birds flying coherently in a flock. 
Therefore, one of the key rationales for studying organisms or populations at a systems level is to 
be able to observe and study emergent behaviors that would not lend themselves to study through 
reductionist means. 
As a more specific instance of emergent properties in biology, biological systems often 
include feeback loops that are difficult to identify or study solely using reductionist techniques. 
The very act of isolating components of a feedback loop destroys the very functional 
relationships responsible for its behavior. Negative feedback loops in particular give biological 
systems a degree of resistance to change from external pertubations, or a certain stability or 
robustness [109]. Conversely, positive feedback loops give a system unstability, or a rapid 
response to external pertubations. In some instances a positive feedback loop makes a 
subsystem’s behavior so rapidly acting toward only one of two extreme states that it can be 
considered a bistable subsystem, acting like a switch with only two states, “on” or “off.” 
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Therefore, a systems-level understanding of a biological system can provide an insight into its 
behavior not readily discerned using reductionist techniques. 
4.1.2 DIFFERENT MEANINGS OF “SYSTEMS BIOLOGY” 
Unfortunately there is no one definition of systems biology. Systems biology as a formal 
discipline is the result of a convergence of several different scientific and engineering traditions 
and methodological philosophies [109, 168-170]. 
One interpretation of systems biology is as a comprehensive explanation, description, or 
model of a complex system. In other words, we can use a systems approach to describe in detail 
a system’s properties and function at the global level. One such description is of a system’s 
structure, where the positions and inter-relationships between the component parts are identified 
and mapped. Another approach is functional, where the interactions between the component 
parts, as well as inputs and outputs, are described. A more thorough functional approach 
quantifies the dynamics of the system, particularly using series of differential equations to 
describe the system’s component’s behavior with respect to time. 
A crucial element for systems biology is the choice of representation of the system. Just 
as in mathematics, rigorous rules and definitions of terms, notations, and syntax allow for clearer 
thinking about the system. One common approach to systems biology is to use tools borrowed 
from electrical engineering. Here, a biological system is represented by notation inspired by 
electrical circuit schematics and described and analyzed using similar mathematical tools [168, 
171, 172]. 
Another interpretation of systems biology is as a methodology. The aim of systems 
biology as a methodological approach is to experimentally characterize the system by combining 
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and interpreting many individual measurements from throughout the system. In this regard, one 
can take a top-down approach, where numerous simultaneous measurements are taken 
throughout the system to produce a “snapshot” of the system’s state at one point in time. 
Dynamic behavior of the system can be captured by taking a series of such snapshots over a time 
course. Conversely, a bottom-up approach would be to combine accumulated knowledge of 
individual parts to build up towards a comprehensive model of the entire system. 
Similarly, in the systems methodological approach, a suitable representation of 
measurements and their interpretation is crucial. Systems biology information typically consists 
of large amounts of data, and often of various types. It must therefore be managed, analyzed, and 
displayed using computational tools. Most notably, systems biologists require ways to represent 
and summarize large numbers of variable magnitudes as well as denote the inter-relationships 
between variables. Some examples of common representations in systems biology are networks 
[173, 174], heat maps[34], clusters [34], and functional modules (see Figure 4-1) [175-179]. 
Additionally, to help visually manage large amounts of data, systems biology is often aided by 
interactive graphs, charts, tables that are linked to databases whose properties and functions can 
be automated [32, 33]. 
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Figure 4-1. Visual representations commonly used in systems biology approaches [180, 
181]. “Heat map” visually representing microarray expression intensity levels for individual 
genes (above left). Interconnected network of genes and/or gene products (above right) [32]. 
Sea urchin Endo16 transcriptional regulatory network represented as a pseudo-electrical 
diagram (from Yuh, et. al.) (below) [181]. 
 
The descriptive and methodological interpretations of systems biology are not mutually 
exclusive. Ideally, each informs the other to iteratively increase the overall comprehensive 
understanding of biological entities. Therefore, systems biology can be thought of as an iterative 
process, in which experimental information informs consequent biological models, and those 
biological models guide the design of experiments. This approach to biology research is 
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sometimes referred to as integrative biology, and is held by some as synonymous with systems 
biology [174, 182]. 
4.1.3 WHY SYSTEMS BIOLOGY NOW? 
In the last few years, systems biology has become a “buzz word” of sorts even though the 
systems-level approach has been around for millennia. What accounts for this robust resurgence 
of interest in a systems approach to biology? It is the result of the confluence of a number of 
technological and organizational advancements. 
First, it cannot be discounted that the systems approach is much more valuable as a tool 
when trying to solve difficult and complex problems. In other words, one reason systems biology 
has become popular recently is that most of the “easy” problems in biology and medicine have 
already been solved. Single-cause diseases and simpler biological processes were the first to be 
satisfactorily investigated, analyzed, and understood using reductionist approaches during the 
last centuries. Many of the remaining problems, such as understanding the etiology and 
progression degenerative diseases at the molecular and genetic level, for instance, seem to be the 
result of complex interactions between numerous genes and/or environmental factors. These 
problems have been frustratingly recalcitrant when addressed through reductionist means. 
Consequently, problems involving numerous variables and complex inter-relations are 
just too difficult to solve by “traditional” scientific approaches of the last century. Until as 
recently as the 1970s and 80s, scientists commonly logged their measurements by pen and paper 
and performed their own data analyses by hand. Today, using computational tools for data 
acquisition, management, analysis, and display is not only more convenient, it is increasingly 
becoming indispensable simply due to the massive amounts of data involved. 
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Great advancements in systems biology have not just come from increases in sheer 
computing power, but also in sophistication of software engineering and the impact of computer 
technology on the culture of science. The relatively low cost of computing and subsequent 
introduction of personal computers have fostered an enormous amount of communication and 
collaboration between biologists, both informally and formally. Large interactive databases are 
accessible to everyone in the scientific community. This has produced informal but enormous 
world-wide scientific collaboration. Not only has computer technology promoted collaboration 
among biologists, but amongst and between numerous other disciplines as well, including 
computer scientists, engineers, physicists, mathematicians, statisticians, and clinicians, to name 
but a few [109, 182-184]. 
In addition to the enormous contribution of computer technology to biology, rapid 
advancements in high-throughput measurements have also been important to the growth of 
systems biology. Two notable technologies, automated sequencing and microarray technology in 
particular have revolutionized the biological sciences [27, 185]. Increasingly, ever more 
sophisticated imaging sciences, robotics, and nanotechnology are also increasing the efficiency, 
reliability, accuracy, and through-put capacity of biological measurements [186-192]. 
Finally, it should be recognized that the formal policies and initiatives of educational 
institutions, corporations, and governments have been enormously important in promoting the 
growth of systems biology. Enormous research initiatives such as the Human Genome Project 
have not only produced massive amounts of biological information in and of itself, but has 
greatly advanced the development of research technologies and computational tools [193-197]. 
This could not have been possible without policies that have directed the massive resources of 
large institutions and governments towards advancing systems biology. 
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4.2 SYSTEMS BIOLOGY IN THE PRESENT STUDY 
As mentioned previously, the etiology of idiopathic pulmonary fibrosis (IPF) is poorly 
understood. It appears to be an extremely complex, multifactorial disease involving multiple 
molecular pathways, genetic factors, and most likely environmental and/or pathogenic 
exposures. As such, it has not lent itself to being studied purely by reductionist approaches. The 
present study is an application of systems-level techniques to try to elucidate information not 
easily discerned solely through reductionist techniques. 
Two high-throughput methods were used in the study described here: ChIP-on-chip and 
whole genome gene expression microarrays. The purpose of using these methods was to provide 
a “snapshot” of the transcriptional state of human alveolar cells during specific activation of the 
TGFβ1/SMAD3 pathway in hopes of providing insights not available in a gene-by-gene 
interrogation. 
Like most systems-level experiments, this study uses a combination of reductionist and 
systems approaches. For one thing, a cell culture model was used, which has a number of 
drawbacks. Being a single cell type in isolation in a culture dish, it should not be expected to 
have the same characteristics as that of an alveolar epithelial cell within its natural cellular 
ecology inside the lung of a human subject. Further, the cell line used was derived from an 
adenocarcinoma, and is therefore not completely representative of a normal, healthy alveolar 
epithelial cell.2 Second, in the series of experiments presented here, the cell systems were 
stimulated with a single substance, exogenous TGFβ1. Again, this is a reductionist approach 
because it aims to measure the effects of a single cytokine in isolation. 
                                                 
2 Due to practical considerations: human alveolar epithelial cells are nearly impossible to culture to produce the 
quantities necessary for the types of experiments used here, which is why A549 adenocarcinoma cells were used. 
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Another reductionist approach in the present study was the confirming of results of the 
systems level experiments on a gene-by-gene basis. Additionally, I followed up on particular 
findings with reductionist techniques, isolating single transcription factors and genes for further 
study (e.g., FOXA2, PINX1). 
Despite the reductionist elements of this study, the key systems-level methods used in the 
present study were: 
• Genome-wide transcription factor location analysis (ChIP-on-chip) 
• High throughput gene expression analysis (Gene expression microarrays) 
• Application of computational tools and databases to analyze data and interpret and 
display results (Ingenuity Pathways Analysis, Metacore GeneGo) [32, 33] 
• An integrative approach to using genome-wide data: comparing, combining, and 
interpreting a combination of ChIP-on-chip and gene expression data. 
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5 CHIP-ON-CHIP 
5.1 HISTORY, RATIONALE, AND BACKGROUND 
The completion of mapping of the human genome through the Human Genome Project 
(HGP) was a monumentally important scientific achievement, but it resulted in a static map of 
nucleotide sequences that said nothing about the function of, and interaction between, genes and 
gene products [193, 194, 197, 198]. An analogy would be that the HGP gave us a phone book 
with addresses of individual genes, but gave us no information about how the each individual in 
the society of genes behaves and interacts with others. To understand truly how cells function in 
both normal and disease states, it is important to understand how these genes interact, 
particularly how gene transcription is controlled. This field of study in the “post-genomics” era is 
known as functional genomics. 
The human genome consists of an estimated 25,000 genes [199-201]. In any particular 
cell type, however, only a subset of these genes are ever expressed at any one time [199, 202, 
203]. How it is determined that certain genes will be expressed in a cell, or in other words the 
logic of transcriptional regulation, is one the major frontiers left to be explored in genomics. 
The canonical model of eukaryotic gene transcription cis-regulation states that particular 
transcription factor proteins bind to specific short nucleotide sequences that reside inside or 
upstream of a gene coding region. These short nucleotide sequences are known as regulatory 
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elements. Most commonly, these regulatory elements, or motifs, are found within a couple 
thousand base pairs of the transcriptional start site of the gene sequence. This area upstream of 
the transcriptional start site of a gene is known as its promoter region [203-205]. 
 
Transcriptional Start Site (TSS)
5’ UTR Exon Exon Exon 3’ UTRIntronIntron
Poly A Signal
Promoter Region
Transcription Factor
Binding Sites
Upstream
Enhancer
5’ 3’
 
Figure 5-1. Basic anatomy of a gene promoter and coding sequence [204]. 
 
When a gene sequence is to be transcribed to mRNA (and ultimately, translated to an 
amino acid sequence and folded into a protein), a series of events occurs involving both specific 
and general transcription factor proteins. Certain transcription factors recognize specific DNA 
sequences and attach. to them. These sequence-specific transcription factors recognize these 
nucleotide sequences because they have molecular structures that allow them to recognize and fit 
snuggly within the three-dimensional structure of a particular nucleotide sequence of a DNA 
double-strand helix [204-206]. Examples of transcription factor motifs that recognize specific 
DNA sequences are described as helix-turn-helix (HTH), helix-loop-helix (HLX), zinc fingers, 
and leucine zippers [205]. These motifs recognize and fit snuggly within the major groove of the 
helical DNA structure (Figure 5-2, Figure 5-3). 
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Figure 5-2. Examples of specific transcription factor DNA-binding motifs 
(www.lbl.gov). 
 
 
 
Figure 5-3. Illustration of a specific DNA-binding protein molecular structure binding 
within the major groove of the helical DNA structure (www.lbl.gov). 
 
Upon attachment of one or more specific transcription factors, other transcriptional 
machinery elements are likewise recruited to attach to the protein/DNA complex. These are 
known as general transcription factors and co-factors. They contribute to the formation of an 
aggregation of functional proteins known as the preinitiation complex (PIC). The preinitiation 
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complex contains six general transcription factor proteins, TFIIA, TFIIB, TFIID, TFIIE, TFIIF, 
and TFIIH. Once the requisite members of the pre-initiation complex are assembled, they recruit 
RNA polymerase II (Pol II) which begins the process of transcription. The preinitiation complex 
and PolII holoenzyme begins sliding down the DNA strand, transcribing the nucleotide sequence 
of DNA to a single strand of messenger RNA (mRNA). It is this mRNA that will be further 
processed and serve as a template for translation into an amino acid sequence that will be folded 
into a protein [204, 206]. 
 
 
Figure 5-4. Basic anatomy of assembly of a preinitiation complex of specific and general 
transcription factors. 
 
A great amount of knowledge has been gained about transcriptional machinery in general 
by studying the process in viral replication, E. coli, yeast, and metazoans [205]. However, a 
major step in understanding the functions of, and functional relationships between different 
genes in an organism, is enumerating lists of target genes of specific transcription factors. We 
can attempt to predict where specific transcription factors should bind theoretically to specific 
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nucleotide sequences, or transcription factor binding elements, within the promoter elements of 
gene coding sequences using statistical and computational models [203, 207-209]. However, 
computational models of transcription factor binding do not agree completely with empirical data 
[210]. Thus, computational models may provide a heuristic guide for generating hypotheses as 
well as an important tool for understanding phylogenetic relationships between species, but they 
are not a substitute for true empirical information on transcription factor target genes. Gathering 
actual experimental data on which genes’ promoter regions are targets for specific transcription 
factors is a crucial step in learning about the functional and regulatory relationships between 
genes. As an example of a practical application of understanding transcriptional regulatory 
targets, such information may lead to identification of specific gene products as targets for 
rational drug design to block gene products that are involved in disease processes.  
5.2 CHROMATIN IMMUNOPRECIPITATION 
One standard experimental method for exploring transcription factor/DNA binding in 
vivo is chromatin immunoprecipitation (ChIP). The concept behind this method is that 
transcription factor/bound DNA complexes formed in vivo during a particular transcriptional 
state can be preserved by lightly fixing cells in that state with a cross-linking agent. Then the 
transcription factor/bound DNA complexes can be isolated using an antibody specific to the 
transcription factor. After transcription factor/bound DNA complexes are isolated and purified, 
the DNA sequences can be released from the bound protein complex and then identified. Thus, 
once identified, the DNA sequences can be matched to known gene promoter elements, in turn 
identifying the genes that had been a target for the specific transcription factor protein when the 
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original cells were in a particular transcriptional state. ChIP experiments can be performed to 
provide a snapshot of transcriptional state of cells in particular metabolic, differentiation, 
pathological, or signaling molecule-induced states. ChIP experiments are not confined to specific 
transcription factors, but can be performed using antibodies against general transcription 
machinery such as Pol II or against acetylated or deacetylated histones [211]. 
In a typical ChIP assay, cultured cells are treated with a low concentration of 
formaldehyde which lightly fixes them and consequently binds the transcriptional regulatory 
proteins to the promoter regions of their respective target genes. Cells are collected, lysed, and 
sonicated to shear chromatin into a distribution of fragment sizes ranging from around ~200bp to 
~2000 bp. An antibody against the specific transcription factor protein of interest is then used to 
isolate transcription factor/promoter fragment complexes. Usually a control pulldown is also 
performed in parallel with the antibody pulldown that serves as a background reference—this 
can be whole genome chromatin fragments, a “no-antibody” control, or a “mock” IP using an 
antibody not expected to have any affinity for the transcription factor of interest. After antibody 
capture (along with its parallel reference control), the “precipitation” step consists of 
antibody/transcription factor complexes being immobilized to Protein A or Protein G conjugated 
to agarose or magnetic beads. Once immobilized, any non-antibody-bound chromatin is washed 
away in a series of stringency wash steps. The transcription factor/promoter fragment cross-links 
are subsequently reversed, and the released promoter fragments are then analyzed.  
The DNA sequences isolated from ChIP experiments, or ChIP pulldown sequences, can 
be analyzed and identified in a number of ways. The two main categories of DNA fragment 
analysis and identification are sequence-based methods and hybridization-based methods [212-
217]. 
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The most common sequence-based analysis method is ChIP-PET (Paired End diTags) 
[216].  PET is a cloning, ditag (see below) concatenation, and sequencing-based method loosely 
based on the methods of Serial Analysis of Gene Expression (SAGE) [218]. In ChIP-PET, DNA 
fragments from ChIP pulldown are cloned into a plasmid and transfected into E. coli, producing 
a plasmid library. Plasmid DNA is extracted, purified, and digested with an MmeI restriction 
endonuclease, producing 24-mer tags from each the 5’ and 3’ ends of the sequence. The tags are 
self-ligated into ditags, concatenated, and amplified again through cloning. The amplified 
concatemers are extracted, purified, and sequenced. The individual ditag sequences are aligned 
to known sequences in the human genome. The redundancy of using both the 5’ and 3’ ends of 
the sequence provides added confidence against false positives due to experimental or 
sequencing errors [212, 216]. The main drawbacks of sequencing methods such as ChIP-PET are 
that they are extremely labor-intensive, expensive, and require specialized laboratory facilities 
and techniques. 
 
Figure 5-5. Mme1 digestion product showing length of individual sequence incorporated 
into PET ditags [219]. 
 
The hybridization-based method for analyzing ChIP pulldown sequences uses 
microarrays specifically designed to contain sequences for the promoter regions of genes, i.e., 
promoter microarrays. ChIP combined with promoter microarrays is known as ChIP-chip or 
ChIP-on-chip. In ChIP-chip, the promoter DNA fragments resulting from the ChIP antibody 
pulldown are amplified and labeled with a fluorophore such as Cy-3. A reference control 
consisting of a no-antibody or mock antibody pulldown is also labeled with a different 
fluorophore, such as Cy-5. The two labeled materials are then mixed together and hybridized to a 
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promoter microarray. After hybridization, the arrays are washed in stringency buffers and image 
analyzed on a laser scanner. The spot intensity ratios between pulldown (IP) and reference 
(mock) are indicative of the relative amount of promoter fragment sequences originating from 
the promoter sequences of the transcription factor target genes [211]. 
The first published report of ChIP-on-chip for identifying target genes of transcription 
factors was in 2002 by Lee and Young [220]. Lee and Young tagged regulatory proteins in 
Saccharomyces cerevisiae with a c-myc epitope and used an antibody against c-myc to isolate 
those regulators and identify the DNA sequences bound to them. Subsequently, researchers 
began using ChIP on mammalian cells using antibodies against native transcription factor 
proteins [221, 222]. ChIP-on-chip is now a well-established method for globally identifying gene 
promoters that are bound in a cell’s nucleus in a particular transcriptional state [211, 220, 221, 
223]. My study used the ChIP-on-chip approach, as opposed to a sequence-based method. 
Therefore, the remainder of this discussion will focus specifically on methodological issues 
surrounding the ChIP-on-chip technique. 
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Figure 5-6. Schematic overview of the ChIP procedure. 
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5.3 CHIP-ON-CHIP METHODOLOGICAL DETAILS AND LIMITATIONS 
5.3.1 FIXATION PARAMETERS 
Cross-linking agents such as formaldehyde and glutaraldehyde are commonly used in 
histology and histochemistry to preserve cellular architecture during staining and imaging. 
Cross-linking agents stabilize the positions of macromolecules by forming bridges between 
them, giving the cell “stiffness” that resists mechanical deformation and chemical degradation—
important features when histology sections are subjected to numerous chemical and mechanical 
steps. Formaldehyde in particular forms cross-links in cells by reacting with the amino group of 
the N-terminal amino acid residue and the side-chains of arginine, cysteine, histidine, and lysine 
residues [224-226]. As such, cross-linking agents such as formaldehyde alter protein 
conformation. This many not pose as much of a problem for histology studies since cells are 
imaged at the cellular structure level. However, slight alterations in protein conformation can 
significantly alter a protein’s epitope geometry and biochemical properties [225, 226]. 
In a ChIP assay, the purpose of cross-linking is to stabilize the structural relation between 
the pre-initiation complex (containing a transcription factor of interest) and its cognate nucleic 
acid sequence in chromatin. An insufficient degree of cross-linking does not stabilize the 
structure enough, while excessive cross-linking causes three problems. First, excessive cross-
linking risks changing the transcription factor protein epitope geometry, making its antibody 
recognition difficult in the subsequent pulldown step. Antibodies are typically made against the 
native protein species, not formaldehyde cross-linked proteins. Second, excessive cross-linking 
“overstabilizes” cellular cytoskeletal structure which makes it difficult to separate cellular 
material from chromatin complexes through cell lysis and ultrasonic disruption. Finally, 
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excessive cross-linking can make it difficult to expose an epitope or epitopes of the protein of 
interest so that it can be accessed by antibodies in the subsequent antibody pulldown steps (i.e., 
“epitope masking”) [225, 226]. 
Consequently, the optimal window for degree of cross-linking may be very narrow and 
must usually be determined empirically through pilot experiments for particular cell types and 
particular transcription factors under study. The major parameters to be tested in such pilot 
studies are formaldehyde concentration, cross-linking time, and cross-linking temperature. Pilot 
experiments usually are performed at a fixed temperature (e.g., room temperature), and a fixed 
low formaldehyde concentration (e.g., 1%), while cross-linking time is usually the manipulated 
experimental variable [211, 214, 221, 222, 227].  
5.3.2 SONICATION  PARAMETERS 
To perform chromatin immunoprecipitation, some method must be used to shear the 
chromatin into a manageable size distribution as well as separate the chromatin from other 
cellular components. Through empirical determination of numerous laboratories performing 
ChIP, the optimal chromatin fragment size distribution is about 200 to 2000 base pairs. There are 
two major methods of accomplishing this, restriction endonuclease digestion and ultrasonic 
disruption. Restriction endonuclease digestion effectively shears double-stranded DNA into 
fragments, but does not separate chromatin from other cellular components. When enzymatic 
methods are used, they are often used in addition to ultrasonic disruption [211]. 
Ultrasonic cellular disruption, or sonication, is performed by inserting an ultrasonic 
transducer probe into the suspension of collected cells that have been treated with formaldehyde. 
The transducer vibrates at ultrasonic frequencies (~40,000 Hz) and produces cellular disruption 
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by inducing localized cavitation. Cavitation occurs when a localized increase of enthalpy 
(thermodynamic measure of internal energy and pressure) causes liquid water to flash to vapor, 
producing tiny bubbles. When the bubbles move to adjacent areas of lower enthalpy, they 
collapse asymmetrically at supersonic speeds causing shock waves. The resultant shock waves 
are violent and energetic enough to break covalent bonds of cellular macromolecules in the 
vicinity [228]. 
 
 
 
 
Figure 5-7. Ultrasonic cell disrupter, or sonicator (left). Illustration of sonicator probe immersed 
in ChIP lysate (right). 
 
As such, sonication produces significant amounts of heat. Therefore in ChIP experiments, 
sonication is usually done in ten-to-twenty second intervals and placed in an ice bath to cool for 
perhaps sixty seconds in between [222, 229]. Nonetheless, brief periods of micro-localized 
heating is enough to fracture or denature proteins, and importantly, this includes the transcription 
factor(s) of interest. While under-sonication will not produce sufficiently lower fragment size 
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distribution, over-sonication can seriously degrade the transcription factor(s) of interest as well 
shift the chromatin fragment size distribution towards too low a size. As in the case of cross-
linking, sonication parameters also must usually be determined empirically for a particular 
experimental system [222].  
I have found that a number of sonication parameters play a key role in determining the 
fragment size distribution, and ultimately, the success of a ChIP experiment: 
• Power setting 
• Sonication make, model, and probe type 
• Volume of lysate 
• Geometry of microcentifuge or centrifuge tube 
• Depth of probe tip 
 
Figure 5-8. Agarose gel showing size fragment distributions after sonication. 
MW: molecular weight marker; Lane 1: no sonication; Lane 2: 2x10 seconds; Lane 3: 
3x10 seconds; Lane 4: 4x10 seconds. 
 59 
5.3.3 ANTIBODY 
Another potential source of variation in ChIP is the antibody used for the chromatin 
pulldown step. Ideally, the antibody should recognize and bind the appropriate epitopes on the 
transcription factor of interest. However, as mentioned previously, antibodies are typically made 
against native proteins [230]. Cross-linking of the transcription factor protein during 
formaldehyde treatment can alter the protein’s conformation, reducing or eliminating antibody 
recognition of the cognate epitope(s). Just as important, the epitopes of the transcription factor of 
interest must be presented on an outer surface so that the antibody has physical access to it. A 
transcription factor buried deep inside a large complex of transcriptional machinery proteins may 
not be physically available for antibody recognition. Therefore, there is no guarantee that even if 
an antibody is available for some particular transcription factor of interest, that it will work 
successfully for ChIP [214, 223, 225, 226]. 
Even if an appropriate ChIP antibody is found, the sensitivity and specificity of 
antibodies can vary between manufacturers and even between batches from a single 
manufacturer. The choice of antibody is limited to what is available. Again, the choice of 
antibody from among available antibodies should be determined empirically by their ability to 
bring down the intended transcription factor with minimal background. Both polyclonal and 
monoclonal antibodies have been successfully used for ChIP [211, 222].  
5.3.4 STRINGENCY WASHES 
Once the chromatin fragments in the sonicated cell lysate are bound by an antibody 
specific to the transcription factor(s) of interest, the antibody/TF complex must be separated 
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from non-specific background chromatin and cellular debris. Protein A and/or Protein G are most 
commonly used to bind antibodies.  
Protein A and Protein G are surface proteins found in the cell wall of bacteria. Protein A 
is found in Staphylococcus aureus, while Protein G is found in Strepotococcal bacteria. Each has 
a very high affinity for the Fc heavy chain of IgG1 and IgG2 in humans as well as most common 
animal sources of antibodies [231, 232]. Since their binding affinities can be manipulated by 
altering salt concentration and pH, both are commonly used in Sepharose columns to select and 
purify antibodies. In ChIP protocols, Protein A and/or Protein G conjugated to agarose or 
magnetic beads are most commonly used to bind chromatin/Ab complexes.3 
After Protein A/G binding, non-specific chromatin and cellular debris must be removed 
by a series of washes. Because Protein A/G as well as the agarose or magnetic beads themselves 
can bind some proteins and nucleic acids non-specifically, ChIP protocols typically recommend 
somewhere between four and eleven washes [233, 234]. Sometimes these washes start with 
lower stringency, low-salt washes and progress to high-salt, higher-stringency washes [234]. The 
last wash nearly always consists of a standard Tris-EDTA buffer (TE) to remove traces of 
previous wash buffers whose constituents may interfere with subsequent steps. There is no clear 
cutoff for the number of washes—more washes improve specificity but reduce overall signal. 
Therefore, for a particular ChIP/antibody experiment system, the number of bead washes must 
be determined empirically from pilot experiments [233, 235]. Non-specific binding as well as 
                                                 
3 The term “immunoprecipitation” in “ChIP” is a historical misnomer held over from traditional protein isolation 
experiments. These experiments used ionic conditions to truly chemically precipitate Ab-protein complexes, which 
were subsequently isolated into a pellet by centrifugation. In ChIP, Ab-protein complexes are not actually 
precipitated at all, but rather “captured.” The title “Chromatin Immunocapture” or “ChIC,” despite being a more 
accurate title, has not gained popularity. 
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over-washing-induced signal reduction can add to the variability and lack of consistency in ChIP 
results between separate experiments. 
5.3.5 CROSSLINK REVERSAL 
After antibody pulldown, the next step in the ChIP procedure is to reverse the 
formaldehyde-induced cross-links by applying a combination of heat (60ºC) and high salt 
concentration. Published protocols vary, but experience shows that when samples are heated 
more than 8-12 hours the signal intensity of subsequent microarrays is reduced [229, 233, 235].  
5.3.6 FRAGMENT AMPLIFICATION 
Potentially the greatest source of bias and variability in the ChIP-on-chip procedure is 
introduced during ligation-mediated PCR [223]. One of the drawbacks of ChIP is that it results in 
a very small amount of material. Promoter microarrays, on the other hand, require a large 
quantity of starting DNA, usually on the order of micrograms. The amount of amplification 
necessary is in the range of one thousand to a million fold. Since the sequences of the ChIP 
nucleic acid fragments are unknown, the most common solution is to amplify them through 
ligation-mediated PCR [236, 237]. 
Before ligation-mediated PCR can be done, ChIP nucleic acid fragments must be blunt-
ended using a DNA polymerase. This is necessary when the chromatin has been sheared by 
sonication because the DNA phosphate backbone will be broken randomly in any number of 
places. This results in the double-stranded DNA fragments having 5’ or 3’ overhangs of varying 
lengths. After the fragments are blunt-ended, blunt-end oligonucleotide linkers or adapters of 
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known sequence are ligated onto each end of the ChIP fragments. The resultant ligation product 
is then amplified using PCR with primers complementary to the linker sequence.  
There are some drawbacks to ligating linkers onto DNA fragments resulting from ChIP. 
First, ligation efficiency and specificity is severely limited because the fragments must be blunt-
ended. Blunt-end ligation does not provide the same yield as ligation performed on 
complementary sequences of overhangs (i.e., “sticky ends”) [237]. Second, the desired ligation 
product is the target DNA fragment flanked on each side by linkers. However, linker ligation 
also produces such unwanted products as linker-linker multimers, linkage between target 
fragments, and linker ligated to only one side of the target sequence (see figure 5-9). 
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Figure 5-9. Schematic overview of ligation-mediated PCR (LM-PCR) process (left). 
Examples of unwanted ligation products that reduce sensitivity, specificity, and yield of 
ChIP-chip when performed using LM-PCR amplification (right). 
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Figure 5-10. Test of ligation reaction conditions using self-ligation of a 25 base-pair 
blunt-end dsDNA linker oligonucleotide. 25 bp molecular weight marker flanks lanes; 
3% agarose gel. Lane 1: No ligase negative control, room temperature 10 minutes; Lane 
2: 2000 units T4 ligase, room temperature 10 minutes; Lane 3: No ligase control, 16°C 30 
minutes; Lane 4: 500 units T4 ligase, 16°C 30 minutes; Lane 5: 1000 units T4 ligase, 
16°C 30 minutes; Lane 6: 2000 units T4 ligase, 16°C 30 minutes. 
 
Figure 5-11. Test of ligation reaction conditions using 118 bp β-actin test sequence. 
MW: molecular weight marker; Lane 1: 24bp linker + 118 bp template, no ligase; Lane 2: 
24bp linker + 118 bp template, 500 units T4 ligase; Lane 3: 24bp linker + 118 bp 
template, no ligase; Lane 4: 24bp linker + 118 bp template, 1000 units T4 ligase. 
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Figure 5-12. Test of ligation-mediated PCR using 24 bp linkers ligated to118 bp β-actin 
test sequence. MW: 25 bp molecular weight marker. Lane 1: 100 ng template; Lane 2: 10 
ng template; Lane 3: 1 ng template; Lane 4: 100 pg template; Lane 5: 10 pg template; 
Lane 6: 1 pg template; Lane 7: 100 fg template. 
 
 
Figure 5-13. Agarose gel evaluation of ligation-mediated PCR of actual ChIP pulldown 
procedure. Lane 1: SMAD3 IP from TGFβ-stimulated A549 cells; Lane 2: SMAD3 IP 
from non-stimulated control A549 cells; Lane 3: Mock IP from non-stimulated control 
A549 cells. 
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LM-PCR is also known to introduce bias based on sequence and input fragment size 
[203]. Ligation efficiency is skewed toward shorter DNA fragments, and subsequent PCR 
amplification exponentially increases this bias [238]. Additionally, Taq polymerase commonly 
used in PCR amplification misincorporates nucleotides on the order of 10-4 errors per nucleotide, 
and additionally lack proofreading ability [239]. Alternative, higher-fidelity heat-resistant DNA 
polymerases derived from sources such as Pfu and Vent have lower error rates and therefore 
might be preferable to traditional Taq polymerase [240-242].  
There are some alternatives to LM-PCR as a DNA amplification technique. Most are 
whole genome amplification methods developed and used for such applications as SNP detection 
or comparative genome hybridization (CGH) [243]. One non-PCR-based whole genome 
amplification technique used successfully to amplify very low quantities of genomic DNA is 
called multiple displacement amplification (MDA) [244-246]. In this method, random hexamer 
primers are annealed to denatured, ssDNA fragments. Phi29 DNA polymerase is used to fill in 
the complementary DNA strand, subsequently displacing the adjacent hexamer primer and 
complementary strands. It has been used to amplify genomic DNA up to 1000-fold without 
introducing sequence bias  However, despite these attractive attributes, my pilot experiments 
have shown that Phi29-based MDA does not work well for amplifying short DNA fragments 
such as in the case of ChIP. 
 
Figure 5-14. Multiple strand displacement amplification (MDA) process 
 67 
Finally, T7-based linear amplification of DNA (TLAD) uses Alu I restriction 
endonuclease digestion and a terminal transferase to add a polyT tail on the 3’ end [247]. 
A primer containing a 3’polyA tract and 5’ T7 promoter is annealed to the polyT tail. Taq 
polymerase is used to synthesize the second strand. The dsDNA is then placed into an in 
vitro transcription reaction followed by reverse transcription, producing numerous cDNA 
copies of the original sequence. While this technique has the advantage that it does not 
introduce sequence and length-dependent biases, it is not commonly used due to the time-
consuming, cumbersome protocol [248]. 
5.3.7 FLUOROPHORE LABELING 
Once DNA fragments are amplified, they must be labeled with a fluorophore for 
microarray analysis. The three most common DNA fluorophore labeling methods are direct 
labeling, indirect labeling, and dendrimer labeling (Genisphere, Inc., Hatfield, PA) [249, 250]. 
The direct and indirect methods involve denaturing of the input DNA into single strands. The 
ssDNA is either reverse transcribed into complementary RNA (cRNA) or used as a template for 
synthesizing complementary DNA (cDNA). The direct labeling method incorporates Cy3-dUTP 
or Cy5-dUTP fluorophore directly into either the newly-synthesized cRNA or DNA. This is 
often done by end-labeling or random-primed, Klenow-based extension [233]. In the Klenow-
based extension, an equimolar mix of dATP, dCTP, and dGTP is added along with a reduced 
molarity of dTTP. The deficit of dTTP is made up with either Cy5- or Cy3-dUTP, which will be 
incorporated into the new strand by the Klenow fragment DNA polymerase. 
The indirect labeling method incorporates a modified (amino-allyl) dUTP during reverse 
transcription or 2nd strand cDNA synthesis. The fluorophore is then subsequently covalently 
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bonded to the (amino-allyl) dUTP in the resultant cRNA or cDNA. Dendrimer labeling uses a 
multi-armed molecular (dendritic structure) whose arms contain fluorophores. In dendrimer 
labeling, the reverse transcriptase or cDNA synthesis reaction is primed with an oligonucleotide 
containing a dendrimer “capture” sequence. The cDNAs containing the “capture” sequences are 
hybridized to the dendrimers whose arms contain multiple (~200) fluorophore molecules. The 
cDNA/dendrimer/fluorophore complex is then hybridized to the microrarray [250]. 
 
Figure 5-15. Dendrimer (Genisphere, Inc.) 
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A.1.3 
 
 
Figure 5-16. Cy-3 and Cy-5 normalized excitation and emission spectra (left) and 
Cy3/Cy5 molecular structures (right). 
 
There are several limitations of using fluorophores, in this case Cy-3 and Cy-5 in 
particular. First, since their emission spectra overlap, there is a small amount of signal 
confounding between probe/target complexes using the different dyes. Also, Cy-3 and Cy-5 are 
different sized molecules (see Figure 5-11) and may incorporate into newly synthesized DNA at 
slightly different rates during the labeling reaction step. Therefore the labeling efficiency 
between the two dyes can introduce dye bias. In addition, in direct and indirect labeling of DNA, 
dye incorporate is sequence-dependent, i.e., fluorophores are incorporated in some but not all of 
the T nucleotide positions. More significantly, both dyes, but especially Cy-5, are subject to 
degradation by airborne ozone. Thus, the signal intensity of Cy-5 probe/target complexes on 
microarrays can diminish significantly in a matter of minutes. Since microarrays are laser-
scanned one at a time, Cy-5 signal can vary significantly from one scanned array to the next. 
Even worse, the Cy-5 signal can fade from one side or corner of a slide to the other. To help 
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combat this problem, microarray manufactures often offer anti-oxidant treatments for their arrays 
(e.g., Agilent’s proprietary Stabilization and Drying Solution), which appears to be somewhat 
but not completely effective. 
5.3.8 PROMOTER MICROARRAY DESIGN, ANALYSIS, AND LIMITATIONS 
There are a number of microarray platforms, although most are gene expression arrays. 
ChIP-chip by definition requires microarrays that cover significant portions of the promoter 
regions of the human genome. Currently, two manufacturers dominate the ChIP-chip promoter 
microarray market. 
Agilent whole genome human promoter arrays contain an average four to six separate 
probes 60-mer oligonucleotide probes spaced at approximately 100 to 300 base pair intervals. 
The probes cover ~2000 base pair upstream to ~800 base pair downstream of the transcriptional 
start site for 18,002 transcriptional start sites representing 17,917 RefSeq genes. The probe 
sequences have been designed specifically to limit cross-hybridization and other artifacts. First, 
the probes are designed to avoid areas of repetitive nucleotide sequences. Also, the predicted 
melting temperature of the probes are optimized to be as close as possible for all probes [251]. 
The arrays also contain approximately 2000 positive and negative control probes. Of these 663 
probes are includes that have sequences unique to Arabidopsis thaliana genes. They serve as 
negative controls for non-specific hybridization. The arrays also contain 616 “gene desert” 
negative controls identified from intergenic regions 1 Mb or greater which are assumed to not be 
bound by promoter-binding transcriptional regulators [252]. 
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NimbleGen human promoter arrays contain 50-75-mer probes with approximately 100bp 
spacing between probes. They have several designs based on RefSeq sequences that cover ~3000 
to ~5000 base pair promoter regions from among ~11,000 to ~18,000 separate genes [253]. 
5.3.9 PROMOTER MICROARRAY ANALYSIS ISSUES 
The ultimate purpose of any microarray measurement is to gain biological knowledge. 
Ideally then, the fluorescence intensity measurements of target/probe complexes on promoter 
microarrays will reflect actual biological information from the input sample. However, this 
information is often embedded into and obscured by numerous sources of random and systematic 
errors. These errors are unavoidable and generated by experimental procedures and measurement 
techniques. Ideally, the purpose of any data manipulation steps on raw microarray data is to 
systematically minimize these errors so that the information best reflecting true biological reality 
shines through. In essence, microarray data is a collection of numbers that must be “calibrated” 
to the biology. 
Two general issues arise with microarray data: one is calibrating the data within a 
microarray to minimize the effects of biases or errors; the other is calibrating differences 
between microarrays. This calibration is known broadly as normalization. For within array 
normalization, the goal is to remove systematic bias. For between array normalization, the goal is 
to make the between-array data comparable by standardizing their ranges. Within-array and 
between-array bias can come from a number of known and unknown sources. These include: 
Total fluorescence intensities differ between arrays, both due to features of the arrays themselves 
and due to the laser scanner used. Also, in dual-dye systems, one dye may be stronger than the 
other across-the-board, or be stronger than the other as a function of total fluorescent intensity. 
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This may vary within an array and also between separate arrays. Finally, there will always be at 
least a small amount of background or residual fluorescence on arrays, and this background can 
be different depending on area within the same area, and between separate arrays. 
For instance, consider two arrays. Array one’s intensity values of one array range from 
100 to 1000 and array two’s intensity values range from 0 to 10,000. The number 1000 on the 
first or 10,000 on the second are somewhat arbitrary and therefore meaningless without 
comparison to a biological standard. Therefore, the array values are normalized to each other so 
that the ranges can be made comparable. 
In the absence of a true biological standard, there are several conventional choices for 
normalization methods for microarray data. One normalization method is simply to scale the 
array data globally by some constant factor so that they each have same mean or median. 
Another method is to adjust the intensity values of array data by some non-linear function so that 
their ranges agree. Examples of this are quantile normalization or lowess (“Robust Locally 
Weighted Regression and Smoothing Scatterplots”) [254]. In quantile normalization, each data 
set is ranked in order of intensity values and then divided into quantiles. The quantiles are then 
individually adjusted to the average for that quantile. Quantile normalization forces each 
individual array dataset to have the same intensity distribution. Lowess normalization, on the 
other hand, is similar in concept except that it adjusts each data point individually instead of by 
quantile. Lowess forces the data at every intensity value to have an equal mean. 
To assess arrays for dye bias on dual-dye arrays, we usually make an MA plot, where M 
= log(R/G) and A = log ( GR ⋅ ). If the relative intensity of each dye does not change as a 
function of overall spot intensity, then the scatterplot should generally follow a horizontal line. If 
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the plot shows a trend toward turning up or down, this indicates a need to use a normalization 
technique that ideally flattens and rotates the trend toward horizontal. 
 
Figure 5-17. MA plot of microarray data, un-normalized data (left) and after lowess 
normalization (right). 
 
The conventional approach to processing raw microarray data is discussed in more detail 
in the following chapter Gene Expression Microarray Technology and Methods. However, the 
following major steps apply to both gene expression microarrays and ChIP promoter 
microarrays: 
 
• Microarray image quality assessment and filtering 
• Feature (spot) identification and background subtraction 
• Log2 transform 
• Normalization 
• Analysis 
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Traditional normalization techniques were developed for gene expression microarrays, 
not promoter microarrays. One major assumption in gene expression microarrays is that there 
will be an approximately equal number of down-regulated and up-regulated genes. With 
promoter microarrays used in ChIP-chip, there is either promoter binding or no binding. 
Therefore, in a scatter plot of intensity values one would expect to see an asymmetric bulge or 
hump of data points corresponding to binding events. Finally, ChIP-chip usually uses dual-dye 
arrays, where the 2nd dye is a reference such as mock IP, no-antibody IP, or whole cell extract. 
Additionally, tiled promoter microarrays use information from adjacent probes. Clusters 
of probe binding events within the same gene promoter region are more informative than single 
probe binding, as in the case of gene expression arrays. 
With respect to mock IP/no-antibody IP/wce reference, the common approach is to 
subtract the reference from the IP signal. This, however, can introduce noise 
As mentioned previously, promoter array probes are usually spaced ~100 to ~300 bp 
apart. Since promoter array target sequences typically range from ~300 to ~2000 base pairs, their 
positions can be expected to overlap a number of probes. True TF binding events, therefore, 
should be indicated by target hybridization to several adjacent promoter array probes. Promoter 
array analysis usually makes use of this fact that clusters of probe binding, especially those that 
center around a single point, normally indicates a true TF binding event. Most promoter 
microarray analysis techniques therefore plot probe intensities (y-axis) versus genomic position 
(x-axis), and use a “sliding window” to detect the presence of clusters of probe binding, and 
especially clusters of intensity values that loosely follow a characteristic “peaked” shape. This is 
illustrated in Figure 5-18 below. 
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Figure 5-18. Promoter microarray design and interpretation. 
Top: 60-mer probes are designed from sequences spaced at ~100 to ~300 bp intervals 
spanning the proximal promoter region and immediately downstream of the 
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transcriptional start site (TSS). Microarray Construction: Microarrays are spotted with 
60-mer probes designed as described. Microarray Hybridization: ChIP is performed, 
yielding nucleic acid fragments labeled with Cy5 (IP; red) and Cy3 (Mock IP reference; 
green). These fragments are hybridized to probes on the arrays. Signal Intensities: The 
relative signal intensities reflect the amount of bound target to each probe, and can be 
plotted as a function of chromosomal position. Curve Fit: Non-specific target binding 
should be randomly distributed, whereas true promoter fragment target binding should 
roughly correspond to a peaked distribution surrounding the actual binding site. A curve 
fit to this model of promoter target binding is used to distinguish true binding events from 
non-specific signal (noise). 
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6 GENE EXPRESSION MICROARRAY TECHNOLOGY AND METHODS 
6.1 CONCEPTUAL ORIGIN AND EVOLUTION OF THE MICROARRAY 
As is well known, protein production in cells is mediated through translation of 
messenger RNA. Quantifying levels of each type of mRNA provides two kinds of information: 
indirect information about the protein-mediated molecular activities within cells, and direct 
information about transcriptional regulation per se. Both kinds of information are extremely 
important to life science and medical researchers. Traditional molecular biology approaches 
toward mRNA quantification, such as northern blotting, measure no more than dozens of mRNA 
species at one time. In northern blotting, RNA is first separated by size by gel electrophoresis, 
transferred and immobilized to a porous membrane, denatured, and detected by hybridization 
with a complementary nucleic acid probe conjugated to a molecular indicator. The molecular 
indicator is usually radioactive (e.g., end-labeling by P32), colorimetric, or 
phosphorescence/fluorescence. When hybridization is complete, non-specific and excess 
indicator is washed away and the blot is imaged. The resultant band(s) location on the blot 
provides information about the size of the mRNA species, while band intensity serves as a 
measure of the original mRNA species quantity [255-258]. 
While northern blotting is a very specific measurement due to analysis by both nucleic 
size and sequence specificity, the process is laborious, cumbersome, and expensive. A less 
 78 
laborious approach is to omit the electrophoresis step and simply perform hybridization, 
indicator development, and imaging. This type of nucleic acid detection and quantification is 
known as a “dot blot.” 
 
Figure 6-1. Example of a “dot blot.” 
 
From the mid-1980s through the mid-1990s, new technologies for measuring large 
numbers of mRNA sample levels grew out of the dot blot concept [259-265]. What restricts the 
number of samples that can be run at one time on northern blotting is the requirement for 
electrophoresis, which takes up a great deal of space on a two-dimensional membrane. When this 
requirement is removed (e.g., dot blot), the number of samples that can be run at one time is 
limited by the size of each individual dot. Thus, one can easily analyze dozens or hundreds of 
mRNA samples on a suitable dot blot using suitably small dots arrayed into an efficient 
geometric arrangement. 
Since cells from E. coli through humans contain many thousands of mRNA transcripts4, 
it is even more attractive to researchers to be able to run mRNA from an entire transcriptome at 
once, i.e., thousands of mRNA transcripts. This massively parallel, “whole transcriptome” 
approach provides a comprehensive snapshot of the transcriptional activity of cells at one point 
                                                 
4 At the time of this writing, the number of known human RNA transcripts is 48,400 [199]. 
 79 
in time. One limitation of the dot blot array, even in miniaturized form, is that the biological 
samples must be spotted individually, and the array is probed by the probe(s). By reversing the 
target/probe relationship, the microarray was born. 
The nucleic acid microarray was pioneered by Mark Schena and Pat Brown at Stanford 
[27, 266, 267]. The concept of the microarray is to immobilize hundreds or thousands of 
sequence-specific probes on a substrate, and then allow the nucleic acid target (i.e., the biological 
sample) to hybridize to the stationary probes. The target, not the probe, is labeled with an 
indicator (typically fluorescence). By miniaturizing the size of the probe footprint (dot) to the 
order of microns, and immobilizing thousands of probe dots in an efficient spatial geometry on 
the substrate, one can simultaneously measure thousands of mRNA transcript levels. Also, since 
DNA is more chemically stable than RNA, DNA probes are usually used on the arrays. Thus, 
this massively parallel mRNA measurement technology became known as DNA microarrays. 
There are a number of general technological variations of the DNA microarray. The first 
microarrays used full-length cDNA probes (variable length, and up to100s of base pairs), often 
generated from EST mRNA and IMAGE clones [268, 269]. Arrays were often custom-made by 
researchers in their own labs [30, 270]. This type of DNA microarray design suffers from a 
number of limitations, including wide variations in melting cDNA probe melting temperatures 
(resulting in non-specific hybridization bias based on variable probe length and C/G content) and 
propensity for cross-hybridization artifact [271]. 
The first major commercial manufacturer of DNA microarrays was Affymetrix. To avoid 
the non-specific hybridization problems associated cDNA, Affymetrix introduced two novel 
features. One was to use ~25 base pair oligonucleotide probes instead of full-length cDNA. Also, 
to help distinguish between specific and non-specific hybridization, Affymetrix arrays use two 
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kinds of probes for every mRNA species measurement: perfect homology 25-mer probes 
(“perfect match” or PM) and a probe with a single nucleic acid mismatch (“mismatch” or MM). 
In principle, by subtracting probe intensity of the MM probe from the PM probe, one can 
subtract out any effect of non-specific probe hybridization. In practice, users and development 
engineers at Affymetrix found that this scheme did not work as well in the real world, and 
retreated to using solely the PM probe values . 
Most commercial microarray manufacturers now use oligonucleotide probes of a constant 
length or within a small defined range (e.g., 60-mer). Oligonucleotide probes are often carefully 
designed from curated genomic sequence databases to meet a number of criteria, such as 
minimal nucleotide repeats, similar G/C content, similar melting temperatures, minimal 
complementarity/self-annealing, etc [272]. The purpose of this is to reduce artifact and bias due 
to non-specific probe/target hybridization and probe cross-hybridization. 
6.2 OVERVIEW OF MICROARRAY WORKFLOW 
In principle, the concept behind DNA microarray measurements seems like it would be a 
very robust technology. In practice, however, the process is lengthy and the technology complex, 
resulting in numerous places for introduction of biases, errors, and outright mistakes. While 
microarray manufacturers have made great technological advancements in producing arrays with 
better reliability, accuracy, and reproducibility, it is instructive to understand their design 
features and workflow, and therefore some of their limitations.  
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6.2.1 RNA EXTRACTION 
The first step in doing microarray-based measurements is to extract and purify mRNA 
from the biological samples of interest. Among the number of RNA isolation methods, the most 
commonly used is based on the guanidinium isothiocyanate method of Chomczynski and Sacchi 
[273]. Guanidinium salts are powerful chaotropic agents that denature proteins and protect RNA 
against degradation. It is usually used as a mixture with phenol, which is sold under the trade 
name Trizol® (Invitrogen). Cells or tissues are placed in the guanidinium/phenol solution and 
agitated, lysing the cells and breaking up and solubilizing their constituent parts. The mixture is 
centrifuged and the mixture separates into an upper aqueous phase, an insoluble interphase, and a 
lower organic phase. RNA partitions in the upper aqueous phase, while lipids, proteins, and 
DNA partition into the interphase and lower organic phase. The aqueous phase is then recovered 
and the RNA concentrated and purified from it by isopropanolol or ethanol precipitation. 
An alternative RNA purification and concentration method is known as a spin column. 
The spin column is a small microcentrifuge tube containing a tiny silica disk that tightly binds 
nucleic acid at lower pH, and releases it at high pH. The tube has an upper chamber connected 
through the silica flow-through disk to a lower collection tube. The aqueous solution containing 
RNA to be purified is mixed with an acidic solution, loaded into the upper chamber, and 
centrifuged through the silica disk. Then a wash buffer containing ethanol is forced by 
centrifugation through the disk to remove impurities. Finally, a small volume of basic pH buffer 
is centrifuged through the disk into a new, clean microcentrifuge collection tube. RNA-
purification spin columns let short RNA strands (<200 bp) flow through, so they may not be 
suitable for experiments dealing with short RNA species such as microRNAs. 
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6.2.2 RNA AMPLIFICATION AND LABELING 
The amount of RNA from biological samples is usually not enough (on the order of 
nanograms) for the process of microarray hybridization (5-20 μg), especially when replicate 
microarrays are performed. The RNA sequence must therefore be amplified. Most microarray 
RNA amplification protocols are based on the original technique of Van Gelder and Eberwine 
which uses an oligo(dT) primer attached to a T7 RNA polymerase promoter [274]. The sample 
mRNA, which contains a 3’-end poly(A) tail, binds the complementary oligo(dT) primer. 
Moloney Murine Leukemia Virus (MMLV) reverse transcriptase and dNTPs are added to 
synthesize 1st and 2nd strands of complementary DNA sequence (cDNA). This cDNA, which 
contains the T7 promoter at the 3’ end of the original sample mRNA, is then used as a template 
for generating multiple copies of antisense cRNA with T7 RNA polymerase in an in vitro 
transcription reaction (IVT). For direct Cy3 or Cy5 labeling, Cy3 or Cy5 conjugated to CTP is 
added so that it will be incorporated into the cRNA strands as they are synthesized. Such a 
reaction will amplify input mRNA in excess of 100-fold [275]. As an alternative to direct 
labeling, indirect labeling incorporates amino allyl UTP into cRNA during the IVT. The amino 
molecule allyl UTP is then chemically coupled to an indicator such as a fluorescent dye. Since 
the T7 RNA polymerase incorporates allyl UTP at a higher rate than the much larger CTP-Cy3 
or CTP-Cy5 molecule, indirect labeling produces a much higher labeling density than direct 
labeling .  
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6.2.3 HYBRIDIZATION 
Once a sufficient amount of fluorescently-labeled cRNA (or cDNA) is obtained, the 
samples are placed on the microarray surfaces so that any sequences in the sample 
complementary to the probes on the microarray will anneal. The annealing process is an 
equilibrium process whose kinetics are governed by concentration of reactants and products as 
well as the applicable rate constants ka (association) and kd (dissociation) [276].  
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Further, the association and dissociation constants have a temperature dependence 
described by the Arrhenius equation (Eq. 6-2), where A is the Arrhenius constant, Ea is activation 
energy, R the gas constant, and T temperature (Kelvin) [276]. In the case of oligonucleotide 
annealing, the activation energy is influenced by the ionic properties of the solvent used in the 
hybridization solution. 
 Too low a hybridization temperature will promote association, meaning an increase in 
mismatch sequence annealing in addition to perfect match annealing. Too high a hybridization 
will promote dissociation, improving sequence annealing specificity but reducing total number of 
hybridizations and hence the fluorescent signal. There is therefore no perfect annealing 
temperature, only a tradeoff between signal strength and annealing specificity. Thus choosing an 
annealing temperature is an optimization involving how much loss of signal and how much non-
specificity one is willing to tolerate. The effects of temperature on annealing can also be 
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influenced by the ionic properties of the hybridization solution (i.e., salt concentration, pH), and 
therefore are also parameters to be optimized in relation to annealing temperature. 
Viscosity of the hybridization fluid also plays a role in the hybridization kinetics. Targets 
must come into close proximity to the probes. This can be achieved by diffusion, but is often 
encouraged by mechanical agitation or rotation of the array. The hybridization fluid under 
motion is then governed by principles of fluid dynamics. Higher fluid viscosity increases the 
static fluid layer at the boundary surface of the microarray which has two opposing effects. First, 
target velocity must be low enough to allow annealing to probes. Second, if target velocity is too 
low, then targets will not circulate extensively enough to find probes with a perfect 
complementarity match. Therefore, as in the case of temperature, an optimization balance must 
be struck between too high and too low a hybridization fluid viscosity. 
To reduce non-specific hybridization caused by repetitive nucleotide sequences inherent 
in the human genome, a hybridization solution often contains competitor sequences containing 
repeat DNA. Even though the probes are designed to not contain nucleotide repeats, the target 
RNA or DNA will likely contain some. Therefore, non-labeled competitor repetitive nucleotide 
DNA such as human Cot-1 DNA is often added to the mixture. 
The hybridization reaction will eventually reach equilibrium asymptotically, as all probe 
sequences have the chance on average to contact all complementary target sequences. The 
hybridization process is multifactorial and complex, and therefore in practice parameter 
optimization must be determined empirically (usually by the manufacturer) for a particular 
microarray platform. 
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6.2.4 MICROARRAY WASHING 
After microarrays are hybridized for a sufficient amount of time, remaining unbound 
targets must be washed off. Additionally, a proper wash or series of washes will help remove any 
non-specific binding to the array probes or intervening blank areas by fluorescently-labeled 
target (i.e., “background”). The wash steps can also be designed as a series of washes in 
incrementally lower ionic strength solutions to help encourage dissociation of partially mis-
matched targets from probes. As shown in Eq. 6-1, removal of reactants will shift equilibrium 
toward dissociation, so the duration of microarray washes plays a significant factor in the 
balance between probe/target specificity and signal strength. 
A typical microarray wash sequence is therefore: initial wash in a low stringency sodium 
chloride-sodium citrate buffer solution containing a small amount of ionic detergent. This is 
followed by one or more washes in higher-stringency diluted buffer of the same constituents. 
Often one or more finishing washes are done in an organic solvent to remove traces of water and 
any lipid-soluble residues. 
6.2.5 MICROARRAY SCANNING 
Microarrays need to be imaged in a way that measures the presence and intensity of 
signal from the probe/target complexes. Most commonly, the target label is a fluorophore such as 
Cy3 or Cy5. Imaging is accomplished through a laser-based excitation scan and emission 
measurement by a sensitive photomultiplier tube. Cy3 has its peak excitation at 550 nm and 
emits maximally at 570 nm, in the red part of the visible spectrum [277]. Cy5 has its peak 
excitation at 649 nm and emits maximally at 670 nm, in the far red part of the visible spectrum 
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[277]. Often, the laser scanning is done in a confocal manner, meaning the beam and 
photomultiplier tube imaging system are both focused at a particular point on the surface of the 
microarray slide. The system in tandem then scans the surface of the slide in a raster pattern. A 
false-color image of the slide is reconstructed from the raster pattern. This image shows a 
characteristic pattern of circular features or dots containing the probe/target/fluorophore 
complexes. Non-specific target/fluorophore binding will show up as artifact features or a 
widespread “haze” that constitutes the microarray background. Similarly, defects such as 
scratches or foreign body contaminants (e.g., lint) can be seen on the image as well. Background 
and artifacts are confounding intensity signals whose effects must be minimized with image 
analysis and statistical techniques. 
In early versions of microarray image analysis programs, individual target/probe spots 
had to be identified on a grid by a human operator. Most recent microarray platforms offer an 
integrated system of microarray, laser scanner, and image analysis program designed to work 
together. If the layout and dimensions of the probe grid is known and can be aligned through 
some kind of registration marking, then the image analysis program can automatically identify 
each probe feature. Automated scanning, feature recognition, and feature measurement greatly 
facilitates the high-throughput nature of microarray experiments. 
Since the probe features consist of (ideally) a circular, uniform deposit of a particular 
species of probe, the common algorithm for measuring overall feature intensity is to integrate 
individual signal intensity measurements over a series of 5 or 10 micron increments. 
Sophisticated image analysis programs can also evaluate the quality of the features (e.g.., loss of 
signal in the spot center, or “donuting”). Image analysis programs also measure signal 
background intensity adjacent to each probe feature, and subsequently subtract that value from 
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the feature signal intensity to yield a net signal. Once all the probe feature signal intensities are 
measured, the information is stored in a large flat-file database.  
 
 
Figure 6-2. Example of microarray artifacts (“donut” spotting, background spots). 
 
6.2.6 ARRAY NORMALIZATION 
Microarrays measure mRNA levels indirectly through a chain of biochemical steps 
culminating in a measure of fluorescence intensity. As such, they do not measure mRNA 
directly, but are surrogate measures of the mRNA levels in the originating biological samples. 
Therefore they are not usually calibrated to known biological standards. While the absolute value 
of array intensity values from an array may not immediately be interpreted for biological 
meaning, the relative relationship between intensity values may reflect the biological reality of 
the input sample. Individual intensity values in large microarray raw datasets therefore cannot be 
assumed to be comparable until suitable corrections have been made for systematic errors and 
biases [29]. We refer to this process as normalizing the data. Within and between arrays there 
may be many sources of systematic bias. For instance, there may be slight differences in starting 
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mRNA amounts, differences in efficiency of fluorophore incorporation, differences in array 
washes can make arrays differ in their absolute intensity values, etc. These sources, however 
seemingly slight, can end up having profound effects in the range and distribution of intensity 
values from a particular microarray.  
Microarray data therefore undergo a series of steps aimed at removing meaningless 
artifact and improving the ability to interpret the data in a biological context. In general these 
steps often include: 
• Image quality assessment, feature (spot) identification, and filtering—The microarray 
image is assessed for excessive background, image artifacts, and spot quality (i.e., 
circularity, evenness of spot intensity). Spots that do not meet pre-set criteria for quality 
are often removed from the analysis (i.e., filtering) as their intensity values represent 
artifact, not biological meaning. 
• Background subtraction—Background fluorescence intensity is measured adjacent to 
each probe spot and subtracted from the spot intensity to avoid misinterpreting 
background as biologically-relevant signal. 
• Log2 transform—As mentioned previously, absolute fluorescence values are essentially 
meaningless without reference to another value. Commonly, the reference value is 
provided within each spot by using two-dye arrays, with one dye corresponding to a 
reference (e.g., control) and the other a separate condition of interest (e.g., treated). In 
this case, the ratio between dyes (e.g., R/G), not either value separately, is the value to be 
interpreted. Similarly, in a single-dye array, the ratio between spots corresponding to the 
same gene (e.g., R1array1/R1array2) in two separate arrays conveys biological meaning 
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(assuming they are normalized). Thus, with microarrays, it is nearly always ratios 
between two numbers that are interpreted. 
Simple ratios, however, introduce a difficulty in interpreting data. A two-fold increase 
between two gene expression values would be 2, whereas a two-fold decrease would be 0.5. A 
decrease appears to be less of a difference to the human eye, even though the relative change is 
equal in magnitude albeit in opposite in direction. This is solved by transforming the data to a 
base 2 logarithm. Thus, log2 (2) = +1, while log2(0.5) = -1, giving up- and down-regulated gene 
expression values a pleasing symmetry that is easier to interpret visually. Log transformation 
offers other advantages as well, such as allowing faster and more efficient computation of large 
datasets: multiplying ratios simply becomes addition of their log values. 
• Normalization—a brief overview of normalization issues was presented in section 5.3.9 
in the previous chapter. 
• Analysis—see next section. 
6.3 STATISTICAL EVALUATION 
Normalized data are used in a variety of ways to gain biological knowledge. While gene 
expression microarrays are intended to measure mRNA levels, the values are relative to each 
other, not to a series of known biological reference standards. Therefore, microarray data is 
commonly used to derive differential expression values between the same gene transcript species 
under different conditions, disease states, or experimental treatments. 
Differential gene expression information can be used in a number of ways to try to glean 
biological insight. First, they can be evaluated through statistical hypothesis-testing procedures 
to find statistically-significant up- or down-regulation of particular genes. When replicate array 
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measurements are used, replicate data points for each gene can be used in parametric or non-
parametric statistical tests. Both statistical significance of change, as well as relative degree of 
change (i.e., fold-ratios) can be interpreted for biological meaning. Since thousands of statistical 
hypothesis tests are performed at once in this case, a large number of significant changes can be 
expected simply due to chance variation. Therefore, when performing thousands of simultaneous 
hypothesis tests on microarray data the p-values must be corrected for multiple hypothesis 
testing. The most stringent method is simply to divide the single-experiment p-value criterion for 
significance (e.g., 0.05) by the total number of tests (e.g., 10,000). In this example, called 
Bonferroni correction, only gene transcript changes whose test p-value are less than 0.05/10,000, 
or p < 0.000005, would meet the criterion for significance. Many statisticians feel this is an 
overly strict method of evaluating statistical significance, and so a number of less stringent 
alternative methods such as False Discovery Rate (FDR) have been developed [278]. FDR 
controls the expected proportion of false positives rather than setting a strict p-value cutoff such 
as 0.05. Therefore, if 100 genes are found to be significant, with an FDR of 0.3 we know that 
70% of the findings are likely to be true and 30% may be false positives. This may be beneficial 
when we are looking to discover new genes, where too strict a cutoff would force us to overlook 
potentially important findings. The FDR setting for analyzing microarray results can therefore be 
tailored to how many false positives we are willing to tolerate in the specific context of our 
experiment. 
Aside from hypothesis testing, one can also use computational methods for pure 
discovery, or in other words to mine data for biological meaning. This is normally accomplished 
through classifying gene expression measurements according to some property of the 
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measurements. The two categories of gene classification methods are class discovery, and class 
prediction [279-282]. 
Class discovery groups gene expression values by degree of similarity. This type of 
analysis is known as clustering. Clustering uses properties of the value to partition data points 
into subsets such that each subset of data shares some common trait. The key decisions in 
choosing a clustering analysis are what features or measures to use, what similarity measure to 
use, and what method for clustering values to use [279, 280].  
The features on which data may be clustered can be fluorescence intensity values only, or 
intensity values in relation to experimental treatment group, array replicates, etc. For a similarity 
measure, some metric is chosen as a way to establish the “distance” between numbers. One 
example of the choice of metric is simply Euclidean distance, which is a familiar direct distance 
measure. However, other non-Euclidean measures can also be used such as Manhattan distance 
measures or Mahalanobis distance [279, 280]. These other non-Euclidean distance measures 
have other desirable mathematical properties depending on the context, such being scale-
invariant [281, 282]. 
There are also numerous algorithms for choosing how to group similar items together. 
These often differ by whether one desires the data to segregate automatically according to certain 
criteria (hierarchical clustering, self-organizing maps), or segregate according to some pre-
established rules (k-means clustering, where the number of clusters k is pre-determined) [279, 
280].  
Class prediction is usually pursued for more practical purposes, such as for in clinical 
settings to help predict prognosis or response to therapies [283-286]. The idea behind class 
prediction is that automated methods of recognizing patterns in data are used to classify and 
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predict properties of new data sets based on previous data. Specifically, this is referred to as 
supervised learning, and requires one or more training sets of data where the input data and their 
correct classifications are both given as inputs. The algorithm then adapts or “learns” how to 
classify future data [281, 282].  
Differential gene expression values can also be inspected visually. In this case the 
microarray intensity values are converted to color intensities and plotted in a two-dimensional 
array known as a heat map. Typically, a heat map will list individual genes vertically, and 
individual arrays horizontally. The horizontal list will usually group the columns by replicates, 
and then by condition or treatment of the source biological sample. By using heat maps with 
clustering on one or more experimental or biological attributes, interesting trends or features  of 
biological significance may be discovered from microarray data. 
6.4 MAJOR LIMITATIONS OF ARRAYS 
Despite an impressive example of high-throughput technology, gene expression 
microarrays have a number of limitations that need to be acknowledged. First, by their very 
nature microarrays depend on hybridization of complementary sequences between targets and 
probes. As mentioned previously, this is a probabilistic process that inherently ensures some 
proportion of non-specific, i.e., mis-match, hybridizations. Further, the nature of probes and 
targets also makes it likely that there will be some number of species that will hybridize 
specifically to a small region of the correct sequence contained on another probe giving rise to 
cross-hybridization. 
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The miniaturization process that gives microarrays its ability to measure thousands of 
gene expression levels simultaneously also introduces limitations. With probe spots on the order 
of hundreds of microns, the effect of eneven backgrounds and handling artifacts are magnified. 
For instance, a stray piece of lint on a macroscopic dot blot has a negligible effect on signal 
intensity—the same lint on a microarray may completely obliterate the signal from dozens of 
probes. 
Unless done carefully, the spotting of probes on an array can introduce significant 
sources of error. The net number of probe molecular in each spot should ideally be equal, and the 
probes should each have equal physical access to interrogation by labeled targets in the 
hybridization mix. 
Similarly, dyes should ideally be incorporated equally in each target. Since the labeling 
methods incorporate a mix of dye-dUTP and dTTP in the polymerization process, there is 
inherently a stochastic component as to how many dye-UTP molecules are incorporated at a 
particular site. More significantly, since different targets have different sequences by definition, 
they also will each contain a different number of possible dye-UTP incorporation sites. Thus, 
different targets can each be expected to have different fluorescent intensities that is sequence-
dependent, not copy-dependent. In two-color arrays, probes containing Cy3 and Cy5 dyes 
compete for occupancy in the same probes—the size differential caused by different sizes of Cy3 
and Cy5 molecules introduces an inherent hybridization bias. 
Fluorescent dyes used in microarrays also are vulnerable to bleaching by room light as 
well as oxidation by atmospheric ozone, even at low levels. Any difference in handling or the 
amount of time arrays are exposed to light or room air can introduce array-to-array differences in 
fluorescence signal. When arrays are laser-scanned, slight differences in laser intensity or 
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photomultiplier tube sensitivity over time can also introduce signal biases over time—this 
highlights the importance of scanner manufacturers  usually recommending scanners be allowed 
sufficient warmup and stabilization time prior to use. 
Each of these technical issues with microarrays can introduce systematic and random 
errors into microarray data. Unfortunately, these errors are multiplicative, not merely additive. 
Many of these technical errors can be minimized through thoughtful design and precision 
manufacture of microarrays. Similarly, the effects of these sources of error can also be 
minimized during execution of microarray experimental protocols [287]. 
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7 DETAILED EXPERIMENTAL METHODS 
7.1 METHODS OVERVIEW 
The purpose of the study presented here was to globally identify the gene targets of the 
TGFβ/SMAD3 transcriptional regulatory pathway, and more specifically, how this gene 
regulatory pathway might be involved in the pathophysiology of pulmonary fibrosis. Therefore, 
this study used the combination of two discovery-based approaches rather than a purely (or 
single) hypothesis-driven approach. The strategy was to combine two high-throughput discovery 
methodologies, ChIP-on-chip and gene expression microarrays, to give a clearer, more 
comprehensive picture of global transcriptional regulation of TGFβ/SMAD3 gene targets in 
A549 alveolar epithelial cells. Since the information gained from high-throughput measurement 
techniques is ordinarily too vast and complex for proper interpretation solely by the human eye, 
the second part of the strategy was to integrate and analyze the data using systems biology 
computational tools. Thus, the main methods presented here describe the methods of chromatin 
immunoprecipitation, promoter microarrays, and gene expression microarrays. 
We ordinarily wish to spot-check the results of high-throughput measurements, as well as 
pursue new hypotheses generated from interpretation of the data using traditional molecular 
biology techniques. To verify ChIP pulldown, gene-specific PCR on single promoter targets is 
commonly used. The concept behind this is that PCR primers are designed for the promoter 
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regions of specific genes expected or known to be targets of the transcription factor under study 
(in this case, SMAD3). Ideally, the PCR primers will straddle a known or predicted transcription 
factor binding sequence. The presence of a PCR amplification product in comparison to a 
mock/no-antibody IP control on an agarose gel indicates specific pulldown of a portion of the 
expected promoter sequence. Thus, gene-specific PCR serves as a supporting validation of the 
quality of a ChIP experiment. 
Similarly, information derived from a ChIP-on-chip experiment provides indirect 
evidence that the transcription factor under study binds to the promoter region of identified target 
genes. To provide an independent confirmation that the transcription factor protein under study 
indeed binds specifically to the identified target DNA sequence, an electromobility shift assay 
(EMSA, or sometimes called “gel shift”) is used. The concept behind EMSA is that a short 
labeled DNA sequence (20-100 bp) containing the putative transcription factor binding site is 
added to the transcription factor protein (either purified recombinant protein or nuclear lysate 
which contains the native protein, or both), run on a resolving electrophoretic gel, and the 
protein-DNA interaction is indicated by retardation of the bound complex in the gel as compared 
to a lane containing the DNA alone. Specificity of protein-DNA binding is further confirmed by 
adding incremental amounts of non-labeled target DNA of the identical sequence in a series of 
other gel lanes. Specific protein-DNA interaction is indicated by a “competing out” of labeled 
DNA binding as evidence by a reduction in band intensity proportional to the amount of non-
labeled competitor added. Further verification of specificity of protein-DNA binding is gained by 
(in yet another gel lane) also adding an antibody specific to the transcription factor protein. The 
motility of the resultant heavy complex of target DNA/transcription factor protein/antibody is 
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significantly reduced in the electrophoretic gel, producing a very highly retarded band. This is 
known as a “supershift” assay. 
Finally, to confirm the results of gene expression microarrays, individually selected gene 
expression activity is measured using standard real-time quantitative PCR. Thus, the methods 
described here consist of the techniques associated with chromatin immunoprecipitation, 
promoter microarrays, gene expression microarrays, gene-specific PCR, EMSA, and quantitative 
real-time PCR. Additionally, the methods involved in data analysis and visualization are also 
described. 
7.2 CELL CULTURES 
Cryopreserved A549 lung alveolar epithelial carcinoma cells (CCL-185) were obtained 
from the American Type Cell Culture collection (ATCC; Manassas, VA). Cells were grown in 
F12-K culture medium (ATCC; 30-2004) supplemented with 10% fetal bovine serium (ATCC; 
30-2020) and subcultured at 80-90% confluency. Prior to all experiments, cells were serum-
starved for 18-24 hours. Cryopreserved primary Small Airway Epithelial Cells (Clonetics SAEC; 
CC-2547) were obtained from Lonza, Inc. (Walkersville, MD). Cells were grown in serum-free 
Small Airway Medium with supplied supplements (Clonetics BulletKit®, CC-3118). 
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7.3 CHROMATIN IMMUNOPRECIPITATION 
The ChIP procedure was performed according to the protocol originally described by 
Weinmann et al., with the following modifications: 1 x 107 A549 cells were treated with TGFβ1 
(2 ng/ml) for up to 2 h. Cells were cross-linked with 1% formaldehyde for 12 min at room 
temperature (RT), after which glycine (125 mM) was added to quench the formaldehyde. The 
cells were washed twice with ice-cold PBS and lysed in 500 μl cell lysis buffer [50 mM Tris-
HCl, pH 8.0; 1% Triton X-100; 10 mM KCl; supplemented with Complete protease inhibitor 
cocktail (Roche Diagnostics, Basel, Switzerland)]. Nuclei were pelleted at 5000 rpm for 5 min at 
4°C, and resuspended in 400 μl of nuclear lysis buffer (50 mM Tris- HCl, pH 8.0; 10 mM 
EDTA; 0.1% SDS; supplemented with Complete). The samples were sonicated 3 x 10 s to yield 
sheared DNA fragments between 200 and 700 bp, and lysates were clarified by centrifugation 
(13,000 rpm, 10 min, 4°C). Samples were then incubated with 25 μg of anti-Smad3 antibody or 
control IgG (both from Upstate/Millipore) for 1 h at 4°C. To reduce nonspecific association, 30 
μg of sonicated salmon sperm competitor DNA and 50 μg of BSA (both from Promega, 
Madison, WI, USA) were added to each sample. Immunoprecipitation was carried out using 50 
μl of 50% (v/v) Protein A/G PLUS-Agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA) 
at 4°C overnight. The immune complexes were washed as follows:  three times with low-salt 
wash buffer (10 mM Tris-HCl, pH 8.0; 0.1% SDS; 0.1% sodium deoxycholate; 1% Triton X-
100; 1 mM EDTA; 140 mM NaCl), 3 times with high-salt buffer (same as low-salt wash buffer, 
but with 500 mM NaCl), 2 times with LiCl wash buffer (10 mM Tris-HCl, pH 8.0; 250 mM 
LiCl; 1% Nonidet P-40; 1% sodium deoxycholate; 1 mM EDTA), and 2 times with TE buffer 
(20 mM Tris-HCl, pH 8.0; 1 mM EDTA). Elution was performed twice at 65°C for 15 min, first 
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with 200 μl of 1.5% SDS solution, and then with 250 μl of 0.5% SDS solution. 
Immunoprecipitated DNA-protein complexes were then reverse cross-linked at 65°C overnight 
and purified by phenol-chloroform extraction and ethanol precipitation with 30 μg glycogen 
(Roche Diagnostics). The resultant purified DNA was dissolved in 20 μl of water. 
7.4 PROMOTER MICROARRAYS 
Purified nucleic acid for array hybridization was blunt-ended using T4 DNA polymerase 
and ligated to linkers (sense strand: oJW102: 5’-GCGGTGACCCGGGAGATCTGAATTC ; 
anti-sense strand: oJW103: 5’-GAATTCAGATC ) using T4 DNA ligase. Ligation products were 
amplified using a two-stage (15 cycle followed by dilution and input to a 25 cycle reaction) Taq 
polymerase-based PCR and purified using Qiagen PCR reaction purification columns. Amplified 
DNA was labeled through a random-primed, Klenow-based extension protocol derived from 
Invitrogen’s BioPrime® Array CGH Genomic Labeling kit. Immunoprecipitated nucleic acid 
was labeled with Cy5 and mock IP (anti-flag) was labeled with Cy3 (Cy-5 and Cy-3 dyes; 
PerkinElmer Life and Analytical Sciences, Boston, MA). Dye incorporation was verified by 
Nanodrop spectrophotomer measurement (Nanodrop Technologies, Wilmington, DE). Labeled 
amplified DNA (Cy5 and Cy3) was combined and hybridized to Agilent 44K two-array whole 
genome promoter sets (G4112F; Agilent Technologies, Inc., Santa Clara, CA) for 40 hours at 
65°C. Arrays were then washed in a series of sodium chloride-sodium citrate (SSC) buffers and 
acetonitrile, and treated with Agilent stabilization and drying solution for 30 seconds. Arrays 
were then immediately scanned on a GenePix 4000B scanner in two-color array mode (Cy5/Cy3) 
yielding an intensity ratio of Cy5 (IP) to Cy3 (mock IP) for each probe. 
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7.5 CHIP-ON-CHIP PROMOTER MICROARRAY ANALYSIS  
Agilent 44K whole genome promoter arrays contain probes that cover 2000 base pair 
upstream to 800 base pair downstream of the transcriptional start site for 44,000 published 
RefSeq genes. The probed areas contain on average four to six separate 60-mer sequences spaced 
at approximately 300 base pair intervals. 
For Agilent promoter microarray analysis, we used a model-based algorithm developed 
by Kaplan and Friedman [288]. The algorithm uses the length distribution of input sonicated 
target DNA fragments to predict the shape of the frequency distribution of overlapping targets 
over the series of 60-mer probes in each promoter sequence on the array. The method then uses 
this predicted shape to discriminate actual binding events from random binding events (i.e., 
noise), as well as estimate the location of the true binding event.  
The estimated shape of the binding curve is modeled by the following equation, 
Equation 7-1
   ∫
∞
Δ=
Δ−∝Δ
xl
xx dllclF )()()(  
where x is the location of the probe on the promoter sequence and l is the length of the 
target DNA fragment. The probability of a probe located Δx bases away from the binding 
location is proportional to the integral over all fragment lengths (of length larger than Δx) of the 
number of possible alignments of the target DNA fragment bound to the reporting probe, 
multiplied by the relative abundance of DNA fragments of such length, denoted by c(l). 
Once the shape of a binding event is estimated, relative enrichment is estimated by 
measuring relative peak height. For this, Kaplan and Friedman have developed an iterative 
algorithm to identify all significant binding events that appear in the ChIP-chip data. Briefly, this 
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is done by using a “sliding window” approach that identifies stretches of enriched probes and 
attempts to explain (at least part of) their values using the shape of a peak. For each peak, the 
algorithm enumerates and selects the most probable values for center position and peak height 
(enrichment), and then computes the statistical significance of this peak. 
The statistical significance of a binding event is estimating by computing an empirical 
log-likelihood ratio (LLR) p-value. They compute the likelihood of the set of probes S given the 
null model L0 that assumes the values are normally distributed around the median enrichment 
ratio of the array. They then compute the likelihood of the same probes given a peak model with 
center x and height alpha, denoted by Lpeak. They use the log-likelihood-ratio (LLR) Lpeak/L0 to 
score the significance value of the peak by computing 1000 shuffling-based LLR scores as 
follows: they replaced the measured enrichment values for each probe in S with a randomly 
chosen probe from the array, find the optimal peak height as described above, and then calculate 
the log likelihood ratio for this set. Finally, they calculated the empirical LLR-based p-value of 
the original peak by computing the percentile of the rank of the true LLR score among the 1000 
shuffling-based scores. If the p-value was significant (i.e. falls below 0.01), and the peak’s height 
exceeded 1.5, they call it a “binding event.” This model-based approach also allows us to 
integrate data from different replicates, calculating the likelihood of the peak based on all 
intensity values of its probes.  
Kaplan and Friedman analyzed the SMAD3 ChIP-on-chip data for peaks with and 
without TGFβ1 stimulation. Each peak was assigned an enrichment value and a p-value (the 
statistical significance of seeing such a peak at random). To differentiate the true target genes of 
SMAD3 with and without TGFβ1 stimulation, we analyzed the ChIP-chip data, and identified 
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genes whose promoter was bound by SMAD3 in at least two of the three array replicates. For 
this, we used a p-value threshold of 0.01 in each of the two replicates. 
7.6 GENE-SPECIFIC PCR VERIFICATION 
A portion of LM-PCR amplified immunoprecipitation product was used as input for a 
separate gene-specific PCR reactions (25 cycles) to verify enrichment of promoter regions of the 
known TGFβ1-responsive genes PAI-1 and SMAD7 as well as the FOXA2 promoter sequence. 
PCR was performed using Taq polymerase (Invitrogen Corporation, Carlsbad, CA) in 15 µl 
reactions according to the manufacturer’s protocol.  
7.7 GENE EXPRESSION MICROARRAYS 
For gene expression measurements we used Agilent 4 x 44K whole human genome 
microarray kits (G4112F; Agilent Technologies, Inc., Santa Clara, CA) according to the 
manufacturer’s protocol. Briefly, 500 ng of total RNA was amplified using an Agilent Low Input 
Linear Amplification and Labeling kit and resultant cRNA was labeled with cyanine-3 (cy-3, 10 
mM; PerkinElmer Life and Analytical Sciences, Boston, MA). Cy-3 labeled probes were purified 
using Qiagen RNeasy Mini kit (Qiagen, Hilden, Germany) per the manufacturer’s protocol. 
Sufficient yield and dye incorporation were confirmed using a Nanodrop spectrophotometer 
(Nanodrop Technologies, Wilmington, DE). Arrays were hybridized for 17 hours at 60°C under 
continuous rotation at ~ 20 RPM. The gasket slide coverslips were removed and the slides 
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washed for one minute in Agilent Wash Buffer 1 (6x sodium chloride/sodium phosphate/EDTA 
(SSPE) + 0.005% N-laurylsarcosine). The slides were then washed in Agilent Wash Buffer 2 
(0.06x SSPE + 0.005% N-laurylsarcosine) for 1 minute followed by 1 minute in acetonitrile and 
then 30 seconds Agilent Stabilization and Drying solution. Arrays were scanned using the 
Agilent DNA microarray scanner. 
7.8 EXPRESSION MICROARRAY DATA ANALYSIS AND STATISTICS 
DNA microarray feature intensities were measured using Agilent Feature Extraction 
software version 9.5.2. There were three replicates each of four time points (0, 2 hour, 12 hour, 
24 hour) of TGFβ1 stimulation, each for vehicle-only control (DMSO) and for SIS3 treatment. 
This yielded 24 microarrays total. The three replicates of the 2 hour time point in the SIS3 
treatment came out completely blank due to some unknown technical or manufacturing error and 
were therefore excluded from normalization or further analysis. 
Background-subtracted signal intensities of the remaining arrays were log-base 2 
transformed and then normalized across arrays by cyclic lowess in the R statistical package (see 
Appendix B). Since array data often contains multiple (and variable numbers of) probes per 
gene, the probe intensities were averaged and combined into individual gene intensity values. 
Individual gene intensities across arrays (i.e., row) were geometric mean normalized to the first 
time point (0 hr control). 
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Figure 7-1. Gene expression microarray images. 
 
To assess data quality, a boxplot of signal intensities was created. From visual inspection 
arrays Control, 12 hour, replicate 1 (C12.1) and control, SIS3, 12 hour, replicate 1 (S12.1) 
showed significant variability due to unknown technical problems and were excluded from 
further analysis. The raw data from the remaining good microarrays were again normalized as 
described and this data were used for all subsequent analysis. 
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Figure 7-2. Boxplot of 21 microarrays after lowess normalization. 
 
The data were analyzed using three separate software packages: first, by permutation test 
between separate time points in the R statistical programming environment (www.r-project.org/); 
next by the Significance Analysis of Microarrays package from Stanford (www-
stat.stanford.edu/~tibs/SAM/) [289]; and finally in the Short Time-series Expression Miner 
(STEM) program developed by Jason Ernst and Ziv Bar-Joseph at Carnegie Mellon University 
(www.cs.cmu.edu/~jernst/stem/ ) [290, 291]. Since the features of STEM are ideally suited to the 
time series nature of the gene expression microarray data, and also minimizes the effect of the 
missing time point of the SIS3 microarray data. Therefore it was the main program used for 
further analysis. 
STEM is a Java program developed for clustering, comparing, and visualizing time-series 
microarray data having eight or fewer individual time points. STEM first compares expression 
behavior of genes against all possible behaviors. It then clusters the gene expression behaviors it 
sees into groups of similarly behaving genes. Next, it performs hypothesis testing on genes in 
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each cluster to identify significantly regulated genes. The null hypothesis is that the probability 
of observing any value at a point in time is independent of its future and past values, i.e., gene  
expression values fluctuate randomly. The program uses a permutation test to quantify the 
expected number of genes that would have been assigned to each model if the data were random. 
Thus, a gene expression profile deemed as significant would generate an established pattern 
similar to other genes in its group and distinctly different from random deviation. The resultant 
p-values are then Bonferroni corrected [290, 291].  
 
7.9 ELECTROMOBILITY SHIFT ASSAY 
Cultured A549 lung alveolar epithelial carcinoma cells (ATCC; CCL-185) at 60-70% 
confluence were treated with 2 ng/ml recombinant human TGFβ1 (catalog number 240 B/CF; 
R&D Systems, Minneapolis, MN) for 60 minutes. Nuclear proteins were isolated using a 
micropreparation technique published previously [292]. Briefly, A549 cells at ~80% confluence 
were scraped into 1.5 ml of cold phosphate-buffered saline and pelleted for 10 seconds. The cell 
pellet was resuspended in 400 μl cold Buffer A (10 mM HEPES-KOH pH 7.9 at 4°C, 1.5 mm 
MgCl2, 10 mM KCl, 0.5 mM dithiothreitol, 0.2 mM PMSF). The cells were then allowed to 
swell on ice for 10 minutes, vortexed for 10 seconds, centrifuged for 10 seconds, and the 
supernatant fraction discarded. The pellet was resuspended in 100 μl of cold Buffer C (20 mM 
HEPES-KOH pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM 
dithiothreitol, 0.2 mM PMSF) and incubated on ice for 20 minutes. Cellular debris was removed 
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by centrifugation for 2 minutes at 4°C and the supernatant containing nuclear proteins was flash-
frozen in liquid nitrogen and stored at -80°C. 
Nuclear extracts at 1:10 dilution and recombinant full length SMAD3 protein (catalog 
number sc-4709; Santa Cruz Biotechnology, Santa Cruz, CA) were incubated with 5’-end 
Cyanine-5 labeled probe and/or non-labeled competitor oligonucleotide for 20 minutes at room 
temperature in a binding buffer consisting of 20% glycerol, 5 mM MgCl2, 2.5 mM EDTA, 25 
mM DTT, 200 mM NaCl, 50 mM Tris HCl pH 7.6, and 0.25 mg/mL poly(dI-dC). The 
oligonucleotides (5'- Cy5-GATTGCTGGTCGTTTGTTGTGGCT - 3', 5' - 
AGCCACAACAAACGACCAGCAATC - 3') were synthesized by Integrated DNA 
Technologies (Coralville, IA), and consisted of a sequence obtained from the HNF3β/FOXA2 
promoter sequence (chr20:22,512,934-22,512,958). Supershift assay was performed by 
additionally incubating nuclear extract with 0.4 μg rabbit polyclonal antibody to SMAD3 
(Catalog Number ab28379; Abcam, Cambridge, MA) prior to incubating with oligonucleotide. 
The protein/DNA complexes were run on a 6% native polyacrylamide gel and visualized on a 
Typhoon 9400 imaging and documentation system using Cyanine-5 dye excitation and 
fluorescence settings. 
7.10 SIS3 INHIBITION OF SMAD3 ACTIVITY 
Specific Inhibitor of SMAD3 (SIS3, Catalog Number 566405; EMD Chemicals, Inc., San 
Diego, CA) is a potent, specific inhibitor of TGFβ1/ALK-5 phosphorylation of SMAD3 while 
having no effect on SMAD2, p38 MAPK, ERK, or phosphoinositide 3-kinase (PI3K) signaling 
[293]. Cultured A549 cells at 30-50% confluence were treated with 10 uM SIS3 in dimethyl 
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sulfoxide (DMSO), or DMSO (vehicle-only) 30 minutes prior to TGFβ1 treatment. Cells were 
treated with 2 ng/mL recombinant TGFβ1 (Catalog Number 240 B/CF; R&D Systems, 
Minneapolis, MN) for 0, 2, 12, and 24 hours. Total mRNA was extracted using Trizol 
(Invitrogen Corporation, Carlsbad, CA) according to the supplier’s protocol for adherent cultured 
cells. 
7.11 QUANTITATIVE REAL-TIME PCR 
A549 cells (Catalog Number CCL-185; ATCC) and Small Airway Epithelial Cells 
(Catalog Number CC-2547, Lonza, Inc.) were grown to 80-90% confluence. Cells were treated 
with 2 ng/mL recombinant TGFβ1 (Catalog Number 240 B/CF; R&D Systems, Minneapolis, 
MN) for 0 (control), 2, 12, and 24 hours. Total mRNA was extracted using Trizol (Invitrogen 
Corporation, Carlsbad, CA) according to the supplier’s protocol for adherent cultured cells. 
Singly-purified total mRNA was normalized to 600 ng and reverse-transcribed using random 
hexamer priming with a SuperScript kit (Invitrogen Corporation, Carlsbad, CA). Quantitative 
PCR was performed using FAM/MGB TaqMan Gene Expression Assays (Applied Biosystems) 
on an ABI Prism 7900HT thermocycler/measurement instrument. Cycling parameters were Taq 
activation 95°C for 12 minutes, then 40 cycles cycling between denaturing at 95°C for 15 
seconds and annealing at 60°C for 1 minute. The ABI Taqman primers used are listed in Table 1  
To evaluate relative mRNA expression of FOXA2 and PAI-1 (Serpine1), we used GAPDH as a 
reference gene. Relative changes in transcript levels of FOXA2 and PAI-1 (serpine1) as 
compared to controls are expressed as ΔΔCt values (ΔΔCt = ΔCttreated – ΔCtcontrol) using ABI 
Sequence Detection Software v2.2.2. 
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7.12 INGENUITY PATHWAYS FUNCTIONAL ANALYSIS 
7.12.1 NETWORK GENERATION 
A data set of signficantly bound (ChIP) or up/down-regulated (expression) genes 
containing gene identifiers and corresponding binding/expression values was uploaded into in 
the application. Each gene identifier was mapped to its corresponding gene object in the 
Ingenuity Pathways Knowledge Base. These genes, called focus genes, were overlaid onto a 
global molecular network developed from information contained in the Ingenuity Pathways 
Knowledge Base. Networks of these focus genes were then algorithmically generated by 
Ingenuity Pathways Analysis based on their connectivity. 
Genes or gene products are represented as nodes, and the biological relationship between 
two nodes is represented as an edge (line). All edges are supported by at least one reference from 
the literature, from a textbook, or from canonical information stored in the Ingenuity Pathways 
Knowledge Base. The intensity of the node color indicates the degree of up- (red) or down- 
(green) regulation. Nodes are displayed using various shapes that represent the functional class 
of the gene product. 
7.12.2 FUNCTIONAL ANALYSIS OF A NETWORK 
The Functional Analysis of a network identified the biological functions that were most 
significant to the genes in the network. The network genes associated with biological functions 
and/or diseases in the Ingenuity Pathways Knowledge Base were considered for the analysis. 
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Fischer’s exact test was used to calculate a p-value determining the probability that each 
biological function assigned to that network is due to chance alone. 
7.12.3 CANONICAL PATHWAY ANALYSIS 
Canonical pathway analysis identified the pathways from the Ingenuity Pathways 
Analysis library of canonical pathways that were most significant to the data set. A data set of 
signficantly bound (ChIP) or up/down-regulated (expression) genes containing gene identifiers 
and corresponding binding/expression values was uploaded into in the application and associated 
with a canonical pathway in the Ingenuity Pathways Knowledge Base. The significance of the 
association between the data set and the canonical pathway was measured in two ways: 1) A 
ratio of the number of genes from the data set that map to the pathway divided by the total 
number of genes that map to the canonical pathway is displayed. 2) Fischer’s exact test was used 
to calculate a p-value determining the probability that the association between the genes in the 
dataset and the canonical pathway is explained by chance alone. 
  
 111 
8 EXPERIMENTAL RESULTS 
This chapter will present detailed experimental results from ChIP-on-chip and gene 
expression microarrays, followed by a systems-level integrated analysis of this data. From this 
systems-level analysis arise three novel findings that may provides clues to transcriptional 
regulatory mechanisms involved in the pathogenesis of IPF. The following descriptions of ChIP-
on-chip and gene expression results, respectively and in combination, serve to confirm activation 
of the TGFβ1/SMAD3 signal transduction and gene transcriptional regulatory pathways in the 
experimental system. The first discussion is of the three specific findings, transgelin, FOXA2, 
and PINX1. 
8.1 SPECIFIC FINDINGS FROM SYSTEMS-LEVEL ANALYSIS OF THE 
TGFβ1/SMAD3 PATHWAY 
Three previously unknown SMAD3 target genes were identified from the ChIP-on-chip 
experiments. Each is discussed in this section, along with their respective supporting 
experimental results. 
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8.1.1 TRANSGELIN (TAGLN) 
From analysis of ChIP and gene expression data were derived three findings relative to 
the pathogenesis of IPF. First, transgelin (TAGLN), a marker of EMT and cell mobility, was 
found and confirmed to be strongly up-regulated in alveolar epithelial cells in response to direct 
activation from the TGFβ1/SMAD3 pathway. In the follow up experiments, TGFβ1 was 
confirmed to induce upregulation of both transgelin mRNA and protein in alveolar epithelial 
cells. In bleomycin-treated mice and IPF patients alike, transgelin was also shown to be 
increased in type II alveolar epithelial cells by qRT-PCR and immunohistochemistry. SiRNA 
inhibition of transgelin suppressed TGFβ1-induced migration of A549 and primary type II 
alveolar epithelial cells. This gene identification and detailed follow up work was performed by 
the lab of our collaborator, Oliver Eickelberg, MD of Geissen University and published 
separately in a recent article in FASEB (Yu, H., Konigshoff, M., Jayachandran, A., Handley, D., 
Seeger, W., Kaminski, N., Eickelberg, O.) [35]. 
 
 
Figure 8-1. ChIP promoter binding profile of transgelin, baseline (left) and after 30 
minutes 2ng/ml TGFβ1 stimulation (right). Each bar height indicates respective array 
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signal intensity for that probe. Values from the three promoter array replicates are 
shown (green, blue, purple, respectively). If the binding was statistically significant, 
the binding curve (red) is also included and shows the fitted peak shape. The region 
shown maps to Chromosome 11q23.2 
8.1.2 FORKHEAD BOX A2 (FOXA2) 
We identified a novel transcription factor, Forkhead Box A2 (FOXA2, also known as 
HNF3β), as one of the key genes that is transcriptionally regulated directly through the c. 
FOXA2 is a highly conserved member of the winged helix nuclear factor gene family and plays a 
major role in embryonic development as well as proper function of the mature lung [38], [294]. 
Its role in alveolar epithelial cell function, in particular surfactant production, established 
FOXA2 as key gene that may be involved in the pathogenesis of IPF. 
The following experimental results help establish the TGFβ1/SMAD3 as a transcriptional 
regulator of FOXA2. These include (1) the binding graph of the FOXA2 promoter with and 
without TGFβ1 stimulation, (2) electromobility shift assay (EMSA) demonstrating direct and 
specific binding of SMAD3 to the promoter of FOXA2, (3) quantitative real-time PCR of 
FOXA2 after TGFβ1 stimulation with and without specific SIS3 inhibition of the 
TGFβ1/SMAD3 pathway, and (4) gene expression data showing down-regulation of FOXA2 by 
the TGFβ1/SMAD3 pathway that is largely abrogated by SIS3 treatment. Further, the gene 
expression data shows a TGFβ1/SMAD3 pathway specific effect on surfactant proteins A,B,C, 
and D. Since surfactant proteins in alveolar epithelial cells are known to be mediated through the 
FOXA2 transcription factor, we believe this provide strong evidence for the direct role of 
TGFβ1/SMAD3/FOXA2/surfactants in the pathogenesis of IPF. This will be discussed in greater 
detail in the following chapter.  
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8.1.3 FOXA2 CHIP SMAD3 BINDING 
ChIP-on-chip analysis identified the FOXA2 promoter as significantly bound after TGF 
TGFβ1 stimulation, but not at baseline (Figure 8-35). The maximum peak height before TGFβ1 
stimulation is 1.41 and after TGFβ1 stimulation is 2.62.  
8.1.3.1 FOXA2 
 
Figure 8-2. ChIP promoter binding profile of FOXA2, baseline (left) and after 30 
minutes 2ng/ml TGFβ1 stimulation (right). Each bar height indicates respective array 
signal intensity for that probe. Values from the three promoter array replicates are shown 
(green, blue, purple, respectively). If the binding was statistically significant, the binding 
curve (red) is also included and shows the fitted peak shape. The region shown maps to 
Chromsome 20p11. 
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8.1.3.2 EMSA 
Electromobility shift assay (EMSA) using both recombinant SMAD3 protein and nuclear 
extract from A549 cells stimulated with TGFβ1 shows specific binding of the protein to the 
promoter region of the FOXA2 gene (Figure 8-36 below).  
 
 
 
Figure 8-3. Electromobility shift assay shows specific binding of the SMAD3 
protein (lanes 2-4) and nuclear extract from TGFβ1-stimulated A549 cells (lanes 5-
7). Lanes 3/6 and 4/7 contain non-labeled competitor FOXA2 promoter sequence 
DNA, 40 ng and 200 ng, respectively. Lane 8 contains a PAb against SMAD3 and 
has a supershift band (3). 
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8.1.3.3 FOXA2 QRT-PCR 
Quantitative real-time PCR (qRT-PCR) was also performed to assess levels of  FOXA2 
mRNA after 2, 12, and 24 hours of stimulation with 2 ng/ml exogenous TGFβ1, respectively. 
This was performed in A549 cells receiving 2 μl of DMSO containing a potent and specific 
SMAD3 inhibitor, SIS3, or a vehicle-only control (DMSO). The results show that FOXA2 is 
significantly repressed (approximately 70% decrease in mRNA levels) at 2 hours. This effect is 
largely abrogated by SIS3 treatment, suggesting the effect is mediated specifically and directly 
through the TGFβ1/SMAD3 pathway. 
 
 
Figure 8-4. Quantitative real-time PCR of FOXA2 levels in A549 cells with and without 
SIS3 treatment. 
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To assess whether this effect was specific to the A549 cell line, FOXA2 mRNA levels 
were also measured in primary human small airway epithelial cells (SAEC). FOXA2 mRNA 
levels were measured in relation to the known TGFβ1-responsive gene, Serpine1 as a verification 
of TGFβ1/SMAD3 pathway induction. The results show that in relation to no TGFβ1treatment, 
FOXA2 levels are repressed by about 70-80% at 2, 12, and 24 hours. Conversely, Serpine1 
levels increase steadily and monotonically by over 2-fold during the same time series (Figure 8-
34). The qRT-PCR results in both A549 alveolar epithelial cells and primary SAECs suggests 
that TGFβ1 represses mRNA expression of FOXA2 in pulmonary epithelial cells. 
 
Figure 8-5. Quantitative real-time PCR of FOXA2 and Serpine1 levels in Small Airway 
Epithelial Cells (SAEC) at 2, 12, and 24 hours TGFβ1 treatment in relation to control (no 
TGFβ1). 
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8.1.3.4 CHIP AND GENE EXPRESSION MICROARRAY DATA ON FOXA2 
The specific results from both ChIP-on-chip and gene expression microarray data are 
consistent with each other, as shown in Figure 8-35 below. On the left top portion of the figure 
we see evidence of significant, strong binding of SMAD3 to the promoter of FOXA2. Similarly, 
FOXA2 gene expression microarray levels are strongly decreased after TGFβ1treatment (top, 
right). This effect is largely abolished by SIS3 treatment, which is in complete agreement with 
the qRT-PCR results shown above. This suggests regulation of FOXA2 directly by SMAD3. 
 
 
Figure 8-6. Combined ChIP binding values (left, top) with gene expression microarray 
values (right, top). The microarray expression values are plotted in a bar graph (bottom) 
and show significant repression (white bars) of FOXA2 during a time course of TGFβ1 
treatment that is largely abolished by SIS3 treatment (black bars). 
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8.1.3.5 SURFACTANT GENE EXPRESSION HEAT MAP 
The effect of TGFβ1treatment on expression of various surfactant genes (A1, B, C, D) are 
seen in the gene expression microarray results. The following heat map summarizes the findings. 
The microarray contains probes for three transcript variants of Surfactant A1. The first one is 
strongly upregulated after TGFβ1 treatment; SIS3  largely reverses this upregulation. The second 
variant is also strongly upregulated by TGFβ1 treatment and is only slightly affected by SIS3. 
The third variant shows a variable time course of up- and down-regulation, whose pattern 
appears completely inverted with SIS3 treatment. TGFβ1 treatment appears to strongly down-
regulate Surfactant B (SFTPB); this effect appears reversed (SFTPB is up-regulated) with SIS3 
treatment. Finally, Surfactant D is first down-regulated at 2 hours, then up-regulated at 24 hours. 
With SIS3 treatment, gene expression appears to be up-regulation at 12 and 24 hours. FOXA2 is 
a known transcriptional regulator of surfactants in alveolar Type II epithelial cells []. 
 
 
Figure 8-7. Heat map illustration of gene expression microarray results for Surfactant A1, B, C, 
and D, in a time course treatment of TGFβ1 at 2, 12, and 24 hours (left; vehicle-only control) and 
12 and 24 hours (right; SIS3 treatment). 
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8.1.4 PIN2-INTERACTING PROTEIN 1 (PINX1) 
Finally, SMAD3 was identified as binding to the promoter of the gene for PIN2-
interacting protein 1 (PINX1). PINX1, a potent inhibitor of telomerase reverse transcriptase 
(hTERT), was also found by ChIP/gene expression network analysis to be involved in the 
protein-interaction network of hTERT (Sections 8.2.4.2-8.2.4.5) [46, 47, 49]. 
8.1.4.1 PINX1 CHIP BINDING CURVE 
 
Figure 8-8. ChIP SMAD3 promoter binding curves showing baseline (no TGFβ1; left) 
and after TGFβ1 treatment (right). This suggests specific and strong binding of SMAD3 
to the promoter of PINX1 both at baseline and after SMAD3 phosphorylation/nuclear 
translocation. Each bar height indicates respective array signal intensity for that probe. 
Values from the three promoter array replicates are shown (green, blue, purple, 
respectively). If the binding was statistically significant, the binding curve (red) is also 
included and shows the fitted peak shape. The region shown maps to Chromosome 8p23. 
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8.1.4.2 CHIP SMAD3-BOUND GENES IN TERT NETWORK 
 
 
Figure 8-9. ChIP SMAD3-bound target genes illustrated in the TERT interaction 
network. Red denotes bound target gene; Color intensity depicts binding peak height. 
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8.1.4.3 GENE EXPRESSION IN TERT NETWORK AFTER TGFβ1 TREATMENT 
 
 
Figure 8-10. Gene expression values illustrated in the ChIP SMAD3-bound target genes 
illustrated in the TERT interaction network. Significant gene expression profiles after 
TGFβ1 stimulation; red denotes up-regulation, green denotes down-regulation. Color 
intensity depicts relative gene expression levels. 
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8.1.4.4 COMBINED CHIP BINDING AND GENE EXPRESSION IN TERT NETWORK 
AFTER TGFβ1 TREATMENT 
 
 
 
Figure 8-11. Combined ChIP target genes and gene expression data in the same TERT 
interaction network illustration, showing that a majority of network members are either 
bound by SMAD3 or significantly up- or down-regulated by TGFβ1. 
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8.1.4.5 GENE EXPRESSION IN TERT NETWORK AFTER TGFβ1 AND SIS3 
TREATMENT 
 
 
Figure 8-12. Gene expression data in the same TERT interaction network illustration 
with SIS3 treatment and TGFβ1. Demonstrates that the gene expression profiles seen in 
the previous network illustrations are likely specifically SMAD3-mediated. 
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8.2 CHIP-ON-CHIP RESULTS 
As described in detail in the methods section, ChIP was performed using an antibody 
against SMAD3 on A549 cells in two conditions: treated with 2 ng/mL TGFβ1  and non-treated 
(control). ChIP-enriched DNA fragments were amplified, labeled, and hybridized to promoter 
microarrays in triplicate for each condition. Binding peaks were identified by the model-based 
method of Kaplan and Friedman [288]. The complete lists of found gene whose promoters were 
identified as bound to SMAD3 (significant binding, peak height of at least 1.5) are listed in 
Appendix C. Since some of the promoter regions listed on the array gene list were sometimes 
common to more than one gene, they were hand-curated to ensure the list correctly listed binding 
for individual, distinct genes. After curation, 350 genes met the binding criteria before TGFβ1 
stimulation, and 474 after 30 minutes TGFβ1. 
8.3 EXPERIMENTAL VERIFICATION OF KNOWN TARGET BINDING 
 
Figure 8-13. Gene-specific PCR of SMAD7 and Serpine-1 promoters. (1) Mock IP (anti-
flag Ab); (2) anti-SMAD3 Ab (Upstate Biosciences); (3) anti-SMAD2,3 Ab (BD 
Biosciences). Data from Oliver Eickelberg, M.D., University of Geissen. 
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8.4 CHIP PROBE BINDING CURVES OF SELECTED BOUND GENES 
The following figures show the intensities of the labeled targets bound to probe clusters 
in the promoters of their respective genes. Each bar height indicates respective array signal 
intensity for that probe. Values from the three promoter array replicates are shown (green, blue, 
purple, respectively). If the binding was statistically significant, the binding curve (red) is also 
included and shows the fitted peak shape. The bound promoter regions in the following figures 
show many expected species (serpine1, collagen 7A1, etc.) which serves as a validation of the 
method. 
 
8.4.1.1 SERPINE1 
 
 
Figure 8-14. Serpine1 (PAI-1) is a well-recognized highly-responsive TGFβ1-induced 
gene. The left panel shows baseline promoter binding of SMAD3 in the absence of 
exogenous TGFβ1 stimulation. The right panel shows highly increased Serpine1 promoter 
binding after 30 minutes 2 ng/mL TGFβ1 stimulation. 
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8.4.1.2 COLLAGEN 7A1 
 
Figure 8-15. Collagen 7A1 is a component of extracellular matrix and a known TGFβ1-
induced gene. The left panel shows baseline promoter binding of SMAD3 to the collagen 
7A1 promoter in the absence of exogenous TGFβ1 stimulation. The right panel shows 
highly increased collagen 7A1 promoter binding after 30 minutes 2 ng/mL TGFβ1 
stimulation. 
8.4.1.3 SMAD6 
 
Figure 8-16. SMAD6 is an inhibitory SMAD protein involved in terminating TGFβ 
activation and is also a known TGFβ-induced gene. The left panel shows baseline 
promoter binding of SMAD3 to the SMAD6 promoter in the absence of exogenous 
 128 
TGFβ1 stimulation. The right panel shows highly increased SMAD6 promoter binding 
after 30 minutes 2 ng/mL TGFβ1 stimulation. 
8.4.1.4 SMAD7 
 
 
Figure 8-17. SMAD7 is another inhibitory SMAD protein involved in terminating 
TGFβ1 activation and a known TGFβ1-induced gene. The left panel shows baseline 
promoter binding of SMAD3 in the absence of exogenous TGFβ1  stimulation. The right 
panel shows highly increased Serpine1 promoter binding after 30 minutes 2 ng/mL 
TGFβ1  stimulation. 
8.4.1.5 TGFβ1 
 
Figure 8-18. TGFβ1 is known to auto-induce. The left panel shows baseline promoter 
binding of SMAD3 to the TGFβ1 promoter in the absence of exogenous TGFβ1  
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stimulation. The right panel shows highly increased TGFβ1  promoter binding after 30 
minutes 2 ng/mL TGFβ1  stimulation. 
 
8.4.1.6 LATENT TRANSFORMING GROWTH FACTOR BINDING PROTEIN 3 
(LTBP3) 
 
Figure 8-19. Latent Transforming Growth Factor Binding Protein 3 (LTBP3) is a protein 
responsible for binding TGFβ1 in the extracellular space in inactivated form (see Chapter 
3). The left panel shows baseline promoter binding of SMAD3 to the LTBP3 promoter in 
the absence of exogenous TGFβ1 stimulation. The right panel shows highly increased 
LTBP3 promoter binding after 30 minutes 2 ng/mL TGFβ1 stimulation. 
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8.4.2 INGENUITY PATHWAYS FUNCTIONAL GENE GROUPING, CHIP-ON-CHIP: 
BIOLOGICAL FUNCTION 
 
Figure 8-20. Functional grouping of biological functions of ChIP SMAD3-bound target 
genes, ranked by statistical significance. Cell-to-Cell Signaling and Interaction and 
Cellular Movement are consistent with epithelial cells undergoing epithelial-to-
mesenchymal transition (EMT). Connective Tissue Development and Function is 
consistent with cells producing and depositing extracellular matrix proteins. Organismal 
Development, Cell Death, Cellular Growth and Proliferation, and Cell Cycle are all 
functions consistent with the known functions of the growth factor/cytokine, TGFβ1. 
From Ingenuity Pathways Analysis [32]. 
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8.4.3 INGENUITY PATHWAYS FUNCTIONAL GENE GROUPING, CHIP-ON-CHIP: 
PHYSIOLOGICAL FUNCTION 
 
Figure 8-21. Functional grouping of ChIP SMAD3-bound target by physiological 
function, ranked by statistical significance. Connective Tissue Development and Function 
is consistent with cells producing and depositing extracelullar matrix proteins. From 
Ingenuity Pathways Analysis [32]. 
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8.4.4 INGENUITY PATHWAYS FUNCTIONAL GENE GROUPING, CHIP-ON-CHIP: 
SIGNALING PATHWAYS 
 
Figure 8-22. ChIP SMAD3-bound target genes grouped by signaling pathway and ranked in 
order of statistical significance. The ratio of genes (orange line) refers to number of genes 
involved in pathway divided by total genes; approximately 10% of bound genes are identified as 
belonging to the known TGFβ1 signaling pathway. Other prominent signaling pathways include 
ERK/MAPK and Integrin Signaling, which is consistent with known interactions of TGFβ1. 
From Ingenuity Pathways Analysis. 
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8.5 GENE EXPRESSION MICROARRAY RESULTS 
Short Time Series Expression Mining (STEM) identified ten highly significant 
expression time course profiles (Figure 8-1). Expression profiles 41, 14, 23, 43, and 39 exhibit 
up-regulation activity while profiles 9, 44, 37, 24, and 19 exhibit down-regulation activity. 
 
 
Figure 8-23. Screen output of STEM program showing identification of statistically 
signifant gene expression time course profiles. 
 
Specific gene expression microarray results are consistent with many of the known 
TGFβ1/SMAD3-responsive elements as discussed previously in Chapter 3; specific instances and 
functional clusters of genes will be illustrated below. Further, gene expression profiles of 
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TGFβ1-simulated cells previously treated with SIS3, a specific and potent SMAD3/ALK5 
phosphorylation inhibitor, suggests that the changes we see in gene expression are indeed 
mediated specifically through the TGFβ1/SMAD3 regulatory pathway. In the following figure 
we see Serpine1 (PAI-1), SMAD6, SMAD7, TGFβ1, SMURF1, and Connective Tissue Growth 
Factor (CTGF) are highly upregulated after TGFβ1 simulation. Further, Jun, JunB, and the 
ERK/MAPK pathways are also affected by TGFβ1/SMAD3 as expected. These gene expression 
profiles were all identified as significantly up- or down-regulated (p<0.00001) by STEM [290, 
291]. As added confirmation of the microarray results, Serpine1 (PAI-1) mRNA levels were 
measured by quantitative real-time PCR (qRT-PCR) in both the TGFβ1 stimulation time-series 
with and without SIS3 inhibition. The qRT-PCR results are statistically highly significant and are 
consistent with both the expected behavior of Serpine1 after TGFβ1 stimulation as well as the 
gene expression micorarray results (see Figure 8-11) below. 
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Figure 8-24. Heat map of average expression values for genes known to be affected by 
the TGFβ1/SMAD3 pathway. Color intensity values correspond to log2 of absolute 
intensity and reach saturation on the heat map at value 4 to preserve dynamic range at 
lower values. The time series is in hours after TGFβ1 stimulation and vehicle only 
(DMSO; left) and with TGFβ1 stimulation and also inhibition of SMAD3/ALK5 
phosphorylation by Specific Inhibitor of SMAD3 (SIS3) (right)[293]. The gene 
expression profiles on the left (non-SIS3-treated) were all identified as significantly up- 
or down-regulated (p<0.00001) by STEM [290, 291]. 
 
Similarly, in the following heat map we see significant up- and down-regulation of 
known key mediators of epithelial-mesenchymal transition (EMT). Again, most of the 
stimulatory effects of exogenous TGFβ1 administration are largely abrogated by SIS3, 
suggesting specific transcriptional regulation of these genes is mediated through the SMAD3/ 
TGFβ1 pathway.  
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Figure 8-25. Heat map of average expression values for genes associated with epithelial-
mesenchymal transition (EMT). Time series in hours after TGFβ1 stimulation (left) and 
with TGFβ1 stimulation and inhibition of SMAD3/ALK5 phosphorylation by Specific 
Inhibitor of SMAD3 (SIS3) (right) [293]. With the exception of α-smooth muscle actin 
on the first row (ACTA2) and collagen type I on the fourth row, the gene expression 
profiles on the left (non-SIS3-treated) were all identified as significantly up- or down-
regulated (p<0.00001) by STEM [290, 291]. 
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Figure 8-26. Quantitative real-time PCR results confirming induction of Serpine1 (PAI-
1) in A549 cells after 2 ng/ml TGFβ1 simulation at 2, 12, and 24 hours respectively. The 
up-regulation of Serpine1 was clearly suppressed by treatment with SIS3. The asterisk 
denotes a highly statistically significant (p<0.001; n=3) difference at each time point 
between SIS3-treated and vehicle-only controls after TGFβ1 treatment. 
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Figure 8-27. Heat map of TGFβ1 time series expression profiles of highest up-regulated 
genes. 
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Figure 8-28. Heat map of TGFβ1 time series expression profiles of highest down-
regulated genes. 
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8.6 FUNCTIONAL ANALYSIS OF COMBINED CHIP-CHIP AND GENE 
EXPRESSION DATA 
The following diagrams illustrate the overlap between significant gene expression values 
and ChIP SMAD3 binding data: 
 
(a)  (b) 
 
(c)  (d) 
 
(e)  (f) 
 
Figure 8-29. Venn diagrams of combined ChIP (yellow) and gene expression (blue) data. 
Numbers denote significant genes total (a,b) and both up- (c,d) and down-regulated (e,f) 
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in comparison to ChIP. The left column is TGFβ1 simulated A549 cells. The right column 
is TGFβ1 simulated A549 cells treated with SIS3 SMAD3-inhibitor. 
8.6.1 COMBINED CHIP-ON-CHIP AND GENE EXPRESSION HEAT MAP 
 
Figure 8-30. Heat map of SMAD3-target genes from ChIP sorted by peak height 
intensity for TGFβ1-stimulated A549 cells, alongside respective gene expression 
microarray intensities for the same gene (vehicle, middle series) and SIS3-treated (right 
series). 
 142 
 
Extensive functional analysis was performed on ChIP data, gene expression data, and 
combined data using several systems biology software tools. These include Ingenuity Pathways 
Analysis (IPA) [32], and Metacore GeneGo [33]. First, the list of significantly bound targets 
from ChIP was submitted for analysis through Ingenuity Pathways Analysis and MetaCore 
GeneGo and matched to their participation in known biological functions, physiological 
functions, and signal transduction pathways. 
8.6.2 METACORE GENEGO FUNCTIONAL GROUPING 
ChIP SMAD3-binding and gene expression data were also analyzed in combination with 
MetaCore GeneGo systems biology tools [33]. The results were consistent with TGFβ1 signaling 
epithelial-mesenchymal transition (e.g., cytoskeletin remodeling, changes to cellular adhesion), 
and collagen deposition.. 
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Figure 8-31. Combined ChIP SMAD3 and TGFβ1-induced gene expression data grouped 
according to membership in known signaling pathways.   
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8.6.3 METACORE FUNCTIONAL GROUPING 
 
 
Figure 8-32. Combined ChIP SMAD3 and TGFβ1-induced gene expression data grouped 
according to membership in known cellular processes.   
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8.6.4 METACORE FUNCTIONAL GROUPING 
 
 
Figure 8-33. Combined ChIP SMAD3 and TGFβ1-induced gene expression data grouped 
according to membership in known physiological responses.   
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8.6.5 TGFβ1,/SMAD3 SIGNALING PATHWAY—CHIP 
The following figures illustrate a systems-level visual integration of data from ChIP and 
gene expression data individually, and then combined in several canonical signaling pathways. 
The figures show involvement of SMAD3 binding and TGFβ1-induced gene expression 
respectively and combined in TGFβ1, ERK/MAPK, p38 MAPK, and NFκB signaling. It is 
known that the TGFβ1/SMAD3 signaling pathways interact with ERK/MAPK, p38 MAPK, and 
NFκB. However, these visualization tools show the specific relationships between promoter 
binding and gene expression in the signaling pathway elements. 
 
 
Figure 8-34. ChIP SMAD3-bound target genes illustrated in the TGFβ1 signaling 
pathway. Red denotes bound target gene; Color intensity depicts ChIP SMAD3 binding 
peak height. 
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8.6.6 TGFβ1,/SMAD3 SIGNALING PATHWAY—GENE EXPRESSION 
 
 
 
 
Figure 8-35. Gene expression values illustrated in the TGFβ1 signaling pathway. 
Significant gene expression profiles after TGFβ1 stimulation; red denotes up-regulation, 
green denotes down-regulation. Color intensity depicts relative gene expression levels. 
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8.6.7 TGFβ1,/SMAD3 SIGNALING PATHWAY—COMBINED 
 
 
 
 
Figure 8-36. Combined ChIP target genes and gene expression data in the same TGFβ1 
signaling pathway illustration. 
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8.6.8 ERK/MAPK SIGNALING PATHWAY—CHIP 
 
 
Figure 8-37. ChIP SMAD3-bound target genes illustrated in the ERK/MAPK signaling 
pathway. Red denotes bound target gene; Color intensity depicts ChIP SMAD3 binding 
peak height. 
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8.6.9 ERK/MAPK SIGNALING PATHWAY—GENE EXPRESSION 
 
 
 
Figure 8-38. Gene expression values illustrated in the ERK/MAPK signaling pathway. 
Significant gene expression profiles after TGFβ1 stimulation; red denotes up-regulation, 
green denotes down-regulation. Color intensity depicts relative gene expression levels. 
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8.6.10 ERK/MAPK SIGNALING PATHWAY—COMBINED 
 
Figure 8-39. ERK/MAPK Signaling Pathway; Combined ChIP target genes and gene 
expression data in the same ERK/MAPK signaling pathway illustration. 
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8.6.11 P38/MAPK SIGNALING PATHWAY—CHIP 
 
 
Figure 8-40. ChIP SMAD3-bound target genes illustrated in the p38 MAPK signaling 
pathway. Red denotes bound target gene; Color intensity depicts ChIP SMAD3 binding 
peak height. 
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8.6.12 P38/MAPK SIGNALING PATHWAY—GENE EXPRESSION 
 
 
Figure 8-41. Gene expression values illustrated in the p38 MAPK signaling pathway. 
Significant gene expression profiles after TGFβ1 stimulation; red denotes up-regulation, 
green denotes down-regulation. Color intensity depicts relative gene expression levels. 
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8.6.13 P38/MAPK SIGNALING PATHWAY—COMBINED 
 
 
 
Figure 8-42. Combined ChIP target genes and gene expression data in the same p38 
MAPK signaling pathway illustration. 
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8.6.14 NFκB SIGNALING PATHWAY—CHIP 
 
 
Figure 8-43. ChIP SMAD3-bound target genes illustrated in the NFκB signaling 
pathway. Red denotes bound target gene; Color intensity depicts ChIP SMAD3 binding 
peak height. 
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8.6.15 NFκB SIGNALING PATHWAY—GENE EXPRESSION 
 
 
Figure 8-44. Gene expression values illustrated in the ChIP SMAD3-bound target genes 
illustrated in the NFκB signaling pathway. Significant gene expression profiles after 
TGFβ1 stimulation; red denotes up-regulation, green denotes down-regulation. Color 
intensity depicts relative gene expression levels. 
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8.6.16 NFκB SIGNALING PATHWAY—COMBINED 
 
 
Figure 8-45. Combined ChIP target genes and gene expression data in the same NFκB 
signaling pathway illustration. 
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9 DISCUSSION AND CONCLUSIONS 
The data presented here suggest three novel different transcriptional regulatory 
mechanisms by which the TGFβ1/SMAD3 pathway may directly contribute to the pathogenesis 
of IPF. As discussed in the introductory chapters, TGFβ1-induced transition of epithelial cells 
into myofibroblasts seems to play a major role in fibrotic deposition in the lung. ChIP-on-chip, a 
high-throughput method for simultaneous identification of transcription factor/promoter binding, 
led to the specific identification of transgelin (TAGLN) as a mediator of EMT in alveolar Type II 
epithelial cells. Similarly, ChIP-on-chip identified a novel connection between the TGF 
TGFβ1/SMAD3 transcriptional regulatory pathway and FOXA2, a transcription factor vitally 
necessary to proper lung development and function. Finally, a systems-level analysis of ChIP-on-
chip and gene expression data led to the identification of a possible suppressor of telomerase 
(TERT) in pulmonary epithelial cells, which may be a third mechanism directly connecting the 
TGFβ1 cytokine with the pathogenesis of IPF.  
9.1 FOXA2 AND SUPPRESSION OF PULMONARY SURFACTANTS 
Pulmonary surfactants are vital lipoprotein complexes produced by type II alveolar 
epithelial cells [295]. Among their functions is to reduce liquid surface tension in the alveolar 
sacs. This allows the lung to expand fully for maximal gas exchange as well as prevent it from 
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collapsing at the end of expiration. In addition to these functions, surfactant protein A (Sp-A) 
and protein D (Sp-D) are involved in host defense again pathogens in the lung . Surfactant 
proteins B and C (Sp-B, Sp-C) are hydrophobic membrane proteins that enable the other 
surfactants to more easily spread over the alveolar surface [45, 295]. 
Sp-A, Sp-B, and Sp-C are each implicated separately in the pathogenesis of IPF through 
animal models and/or human studies. Genetic variants of Sp-A have been found to strongly 
increase risk of IPF [85]. Sp-A levels also are found to be increased in newly diagnosed IPF 
patients [84]. Administration of exogenous Sp-A in cell culture of fibroblasts doubled their 
collagen expression [86]. Sp-B (SFTPB -/-) null animals, and humans born with a congenital 
absence of Sp-B due to mutations, die shortly after birth from respiratory failure [45, 296-298]. 
As discussed previously, mutations in SFTPC and consequent defective Sp-C proteins have been 
clearly identified in clusters of familial IPF [41, 42, 44]. Further, in a bleomycin animal model of 
IPF, Sp-C null mice (SFTPC -/-) exhibited a much more severe and longer time course of 
pulmonary fibrosis than wild type controls (SFTPC +/+) [299].  
TGFβ1 is a known regulator of all these surfactant levels and is known to suppress levels 
of Sp-B and Sp-C specifically through Thyroid Transcription Factor (TTF-1), which is in turn 
regulated by FOXA2 [300-303]. Previously it was argued that FOXA2 regulates TTF-1 levels 
and Sp-B/C through protein-protein interactions [300, 301]. However, the current data strongly 
suggests that SMAD3 binds the promoter of FOXA2 and directly regulates it at the 
transcriptional level. No statistically significant changes in TTF-1 levels were seen in the current 
data; however, probes for only one of the two transcript variants are present on the array, and the 
differences in levels of TTF-1 may not have been significant enough to be detected by the array 
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measurements. The exact nature of the transcriptional regulatory mechanisms of surfactants 
through FOXA2 remain to be elucidated and warrant further study. 
9.2 PINX1 AND SUPPRESSION OF HTERT 
As discussed previously, telomere reverse transcriptase (hTERT) is another gene which 
has a strong association with IPF. Linkage analysis of 46 families with two or more individuals 
affected with IIPs identified hTERT as a candidate gene [51]. Mutation analysis revealed a 
missense mutation and a frameshift mutation in hTERT that co-segregated with IIP in two 
families [50]. Sequence comparisons of hTERT between 44 sporadic IPF cases and probands 
from 44 unrelated families revealed five other mutations. One family had a mutation in hTERT as 
well. Those individuals with heterozygous mutations in hTERT or hTERC had shorter telomere 
lengths compared to controls [50, 51]. Thus, telomerase is another gene with a distinct 
association with IPF. Since telomeres overall shorten with age, this connection may also provide 
a clue to the profoundly increased risk of IPF with age [56, 304, 305]. Finally, dyskeratosis 
congenita is a rare disorder caused mutations in dyskerin (DSK1) that results in loss of 
telomerase activity. Although not the primary effect of the genetic disease, approximately twenty 
percent of patients develop a form of pulmonary fibrosis that radiographically and clinically 
resembles that seen in IPF [306, 307]. 
In bleomycin-induced animal models of pulmonary fibrosis, the activities of TERT are 
restricted to cell type. In a bleomycin rat model, telomerase activity increased specifically in 
fibroblasts and not α-smooth muscle positive cells, indicating the effect is restricted to 
proliferating fibroblasts and does not occur in myofibroblasts [308, 309]. In a bleomycin mouse 
model, mTERT mRNA was upregulated after bleomycin-induced injury, and at 72 hours dropped 
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below controls. Decreased telomerase activity, either as result of bleomycin injury or directly 
induced, produced increased epithelial cell apoptosis [310].  In most normal cells, significant 
telomerase activity appears to be present only in injured cells, stem cells, and neoplastic cells 
[311-313]. Since the bleomycin animal models involve an injury phase followed by a repair 
phase during which the induced pulmonary fibrosis resolves, it is unclear how well these results 
can be generalized to human IPF (in which case pulmonary fibrosis is irreversible). However the 
information does suggest that there is a delicate balance of cell proliferation and cell apoptosis in 
the various pulmonary cell populations, and this balance in part depends on the activities of 
TERT and its various regulators. 
In the present study, network analysis using IPA identified numerous members of the 
hTERT regulatory pathway populated by ChIP-identified promoters and significantly up- or 
down-regulated genes (see Figures 8-41 through 8-43). Most prominently, SMAD3 ChIP-on-
chip identified the promoter for the protein PIN2-interacting protein 1, or PINX1. The binding of 
SMAD3 to the promoter of PINX1 was still significant without exogenous TGFβ1 stimulation, 
but reduced. The expression of genes in the hTERT regulatory was all but abolished with SIS3 
treatment, strongly suggesting activation of that network is mediated through the TGFβ1/SMAD3 
pathway (see Figure 8-44).  
PINX1 is well-established as a potent inhibitor of hTERT activity, and this inhibition is a 
result of direct interaction with the PINX1 protein with the hTERT enzyme [46-49]. Further, 
PINX1 upregulation and hTERT inactivation shortened telomeres and promoted apoptosis in an 
HT1080 fibrosarcoma cell line [49]. This suggests the possibility that the TGFβ1/SMAD3 
pathway may directly inhibit hTERT activity in epithelial cells, contributing to their apoptosis as 
well as reducing their ability to proliferate in response to injury. Thus, this may be one 
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mechanism that chronic lung exposure to TGFβ1 may promote fibroblast proliferation while 
reducing epithelial cell populations. This is another pathway connection that warrants further 
research. 
9.3 FUTURE DIRECTIONS 
The systems biology methods used here demonstrated the utility of the approach in 
discovering new mechanistic connections, overall patterns, and suggesting new hypotheses. The 
results presented here are not an endpoint, but rather a starting point for follow-up by traditional 
reductionist techniques. In particular, the transcriptional regulatory targets of FOXA2 should be 
explored, particularly in the context of surfactant regulation. The transcriptional regulation of 
hTERT and PINX1, and their activities in normal alveolar epithelial cells and fibroblasts, with 
and with out TGFβ1 stimulation, is another promising area that warrants a more detailed 
investigation.  
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APPENDIX A: MICROARRAY NORMALIZATION R CODE 
This code was written by Thomas Richards, Ph.D. 
 
############################################################################# 
require(tcltk) 
require(Hmisc) 
require(affy) 
assign("DIR",".",.GlobalEnv) 
assign("ANNOTfn","./Agilent_HumanGenome.RData",.GlobalEnv) 
setwd(DIR) 
DIR <- getwd() 
source("./MAfns.r") 
CTRLlist <- NULL 
############################################################################# 
DATESTART <- Sys.time() 
cDATESTART <- format(DATESTART,"%d%b%YAT%H%M%S") 
LISTfn <- paste("List_",cDATESTART,".RData",sep="") 
DFfn <- paste("gPS_",cDATESTART,".RData",sep="") 
RDfn <- paste("RData","_",cDATESTART,sep="") 
ROUT <- file(description=paste("Rout","_",cDATESTART,".log",sep=""),open="w") 
sink(ROUT,split=TRUE) 
############################################################################# 
  ##  Read in data as list: 
cat("\n\n") 
print("ReadAgilent.r:  Reading Agilent data files...") 
.LIST <- AgilentDataFolder2List(FOLDER=DIR) 
############################################################################# 
  ##  Make data frame from this list: 
cat("\n\n") 
print("ReadAgilent.r:  Making data frame from list of Agilent data...") 
AgilentDF <- AgilentDataList2DF(.LIST) 
#############################################################################  
##  Load annotation file, from Agilent: 
cat("\n\n") 
print("ReadAgilent.r:  Loading Agilent annotation file...") 
load(ANNOTfn) 
############################################################################# 
  ##  Merge data and annotations: 
AgilentDF <- 
merge(x=Agilent_HumanGenome,y=AgilentDF,by.x="Probe_ID",by.y="ProbeName",all.
x=FALSE,all.y=FALSE) 
#############################################################################
################################################################# 
  ##  Save list and data frame data, in RDfn, if possible. 
  ##  RECALL:  DIR was made earlier. 
setwd(DIR) 
..TRY <- try(system(paste("MKDIR ",RDfn,sep=""))) 
if (!inherits(..TRY,"try-error")) setwd(RDfn) 
save(list=".LIST",file=LISTfn) 
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rm(.LIST);gc() 
save(list="AgilentDF",file=DFfn) 
############################################################################# 
  ##  Crucial variable names follow: 
nms <- names(AgilentDF) 
ANNOTnms <- 
c("Probe_ID","Clone_Name","Genbank_Acc","UniGene_ID","EntrezGene_ID","Gene_Sy
mbol___Name","Symbol_", 
  
"Gene_Synonyms","Human_TC","Human_GC","RefSeq_Acc","TC_PubMed_Ref","GO","TGI_
Annotation","Phy_Map", 
  
"Genetic_Marker","Mouse_ortholog","Rat_ortholog","Zebrafish_ortholog","Xenopu
s_ortholog","Cattle_ortholog", 
  
"Elegans_ortholog","Yeast_ortholog","Dog_ortholog","Chicken_ortholog","Featur
eNum","ProbeUID","ControlType", 
  "GeneName","SystematicName","Description") 
nmsDATA <- setdiff(nms,ANNOTnms) 
WHCHcols <- which(nms %in% nmsDATA) 
WHCHann <- which(nms %nin% nmsDATA) 
############################################################################# 
  ##  Limit to probes with Entrez Gene IDs: 
AgilentDF <- AgilentDF[which(!is.na(AgilentDF$EntrezGene_ID)),] 
############################################################################# 
  ##  Convert to log2: 
..MTX <- log2(as.matrix(AgilentDF[,WHCHcols])) 
############################################################################# 
  ##  Normalize by cyclic loess: 
cat("\n\n") 
print("ReadAgilent.r:  Running cyclic loess...") 
####..MTXc <- normalize.loess(mat=..MTX, maxit = 4, epsilon=0.01,log.it = 
FALSE, verbose = TRUE, span = 0.4, family.loess = "symmetric") 
..MTXc <- myNL(mat=..MTX, maxit = 10, epsilon=0.01,log.it = FALSE, verbose = 
TRUE, span = 0.4, family.loess = "symmetric") 
AgilentDF[,WHCHcols] <- ..MTXc 
rm(..MTX,..MTXc);gc() 
############################################################################# 
  ##  Combine probes for each ProbeName, one obs per ProbeName: 
cat("\n\n") 
print("ReadAgilent.r:  Combining probes...") 
nms <- sub("Probe_ID","ProbeName",names(AgilentDF)) 
names(AgilentDF) <- nms 
AgilentDF <- 
CombineProbes(DF=AgilentDF,VAR="ProbeName",AnnotColumns=WHCHann,method="mean"
) 
save(list="AgilentDF",file=paste("gPSntrz2clmnPN_",cDATESTART,".RData",sep=""
)) 
write.table(x=AgilentDF[,c("ProbeName","Description",nmsDATA)], 
  
file=paste("gPSntrz2clmnPN_",cDATESTART,".tab",sep=""),sep="\t",row=FALSE,col
=TRUE,na="",quote=FALSE) 
AgilentDFntrz2clmnPN <- AgilentDF 
############################################################################# 
  ##  Geometric mean normalize, over rows: 
cat("\n\n") 
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print("ReadAgilent.r:  Applying Geometric Mean normalization, over all 
samples in experiment...") 
.MN <- apply(as.matrix(AgilentDF[,WHCHcols]),1,function(W) 
mean(W,na.rm=TRUE)) 
for(J in WHCHcols) AgilentDF[,J] <- AgilentDF[,J] - .MN 
.MN <- apply(as.matrix(AgilentDF[,WHCHcols]),1,function(W) 
mean(W,na.rm=TRUE)) 
cat("\n\n") 
print("ReadAgilent.r:  Summary, after Geometric mean normalization, over all 
samples in experiment:") 
print(summary(.MN)) 
############################################################################# 
save(list="AgilentDF",file=paste("gPSntrz2clmnPNGM_",cDATESTART,".RData",sep=
"")) 
write.table(x=AgilentDF[,c("ProbeName","Description",nmsDATA)], 
  
file=paste("gPSntrz2clmnPNGM_",cDATESTART,".tab",sep=""),sep="\t",row=FALSE,c
ol=TRUE,na="",quote=FALSE) 
############################################################################# 
setwd(DIR) 
CTRLin <- try(file("Controls.tab","r")) 
if (!inherits(CTRLin,"try-error")) CTRLlist <- 
gsub("\\.txt","",gsub('\"',"",readLines(CTRLin))) 
if (!is.null(CTRLlist)){ 
  cat("\n\n") 
  print("ReadAgilent.r:  Applying Geometric mean normalization, over 
controls...") 
  WHCHctrl <- which(names(AgilentDFntrz2clmnPN) %in% CTRLlist) 
  .MN <- apply(as.matrix(AgilentDFntrz2clmnPN[,WHCHctrl]),1,function(W) 
mean(W,na.rm=TRUE)) 
  for(J in WHCHcols) AgilentDFntrz2clmnPN[,J] <- AgilentDFntrz2clmnPN[,J] - 
.MN 
  .MN <- apply(as.matrix(AgilentDFntrz2clmnPN[,WHCHctrl]),1,function(W) 
mean(W,na.rm=TRUE)) 
  cat("\n\n") 
  print("ReadAgilent.r:  Summary, after Geometric mean normalization, over 
controls listed in Controls.tab:") 
  print(summary(.MN)) 
  if (!inherits(..TRY,"try-error")) setwd(RDfn) 
  
save(list="AgilentDFntrz2clmnPN",file=paste("gPSntrz2clmnPNGMctrl_",cDATESTAR
T,".RData",sep="")) 
  write.table(x=AgilentDFntrz2clmnPN[,c("ProbeName","Description",nmsDATA)], 
    
file=paste("gPSntrz2clmnPNGMCtrl_",cDATESTART,".tab",sep=""),sep="\t",row=FAL
SE,col=TRUE,na="",quote=FALSE) 
  setwd(DIR) 
} 
############################################################################# 
sink() 
rm(AgilentDF,AgilentDFntrz2clmnPN,.MN,nms,ANNOTnms,nmsDATA,DIR,ANNOTfn,DATEST
ART,cDATESTART, 
  RDfn,DFfn,ROUT,CTRLin,J,LISTfn,WHCHann,WHCHcols,WHCHctrl);gc() 
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APPENDIX B: CHIP-ON-CHIP RESULTS 
ChIP-on-chip Significant Bound Genes, TGFβ-stimulated cells 
 
GENE ID 
PEAK 
HEIGHT UNIGENE ID ENTREZ ID GENE DESCRIPTION 
SERPINE1 10.40 Hs.414795  5054 Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 
FLJ45248 7.67 Hs.224506  401472 FLJ45248 protein 
CCDC129 7.50 Hs.224269  223075 Coiled-coil domain containing 129 
CLC 6.62 Hs.889  1178 Charcot-Leyden crystal protein 
PPP1R13L 6.08 Hs.466937  10848 Protein phosphatase 1, regulatory (inhibitor) subunit 13 like 
COL7A1 4.63 Hs.476218  1294 Collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive) 
SMAD6 4.63 Hs.153863  4091 SMAD family member 6 
STXBP1 4.20 Hs.288229  6812 Syntaxin binding protein 1 
FAM129B 4.20 Hs.522401  64855 Family with sequence similarity 129, member B 
FGB 4.10 Hs.300774  2244 Fibrinogen beta chain 
TINAGL1 4.00 Hs.199368  64129 Tubulointerstitial nephritis antigen-like 1 
POLD4 3.98 Hs.523829  57804 Polymerase (DNA-directed), delta 4 
SMAD7 3.91 Hs.465087  4092 SMAD family member 7 
BCL9L 3.84 Hs.414740  283149 B-cell CLL/lymphoma 9-like 
GRIN2D 3.76 Hs.445015  2906 Glutamate receptor, ionotropic, N-methyl D-aspartate 2D 
KDELR1 3.76 Hs.515515  10945 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 1 
TAGLN2 3.72 Hs.517168  8407 Transgelin 2 
MRC2 3.72 Hs.7835  9902 Mannose receptor, C type 2 
RUSC2 3.70 Hs.493796  9853 RUN and SH3 domain containing 2 
MUC1 3.68 Hs.89603  4582 Mucin 1, cell surface associated 
DOCK7 3.60 Hs.538059  85440 Dedicator of cytokinesis 7 
SRXN1 3.51 Hs.355284  140809 Sulfiredoxin 1 homolog (S. cerevisiae) 
SNX12 3.34 Hs.260750  29934 Sorting nexin 12 
S100A2 3.31 Hs.516484  6273 S100 calcium binding protein A2 
RRAS 3.30 Hs.515536  6237 Related RAS viral (r-ras) oncogene homolog 
SNCG 3.30 Hs.349470  6623 Synuclein, gamma (breast cancer-specific protein 1) 
BLOC1S2 3.30 Hs.702055  282991 Biogenesis of lysosome-related organelles complex-1, subunit 2 
PINX1 3.27 Hs.490991  54984 PIN2-interacting protein 1 
MYO1D 3.23 Hs.658000  4642 Myosin ID 
FLJ10357 3.20 Hs.35125  55701 Hypothetical protein FLJ10357 
TRIB1 3.17 Hs.444947  10221 Tribbles homolog 1 (Drosophila) 
C21orf84 3.04 Hs.592161  114038 Chromosome 21 open reading frame 84 
GIPC1  3.03 Hs.655012  10755 GIPC PDZ domain containing family, member 1 
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ACLY 3.01 Hs.387567  47 ATP citrate lyase 
ENO3 2.99 Hs.224171  2027 Enolase 3 (beta, muscle) 
PFN1 2.99 Hs.494691  5216 Profilin 1 
IFI44 2.97 Hs.82316  10561 Interferon-induced protein 44 
VASP 2.95 Hs.702197  7408 Vasodilator-stimulated phosphoprotein 
DC2 2.95 Hs.445803  58505 DC2 protein 
ITGA3 2.93 Hs.265829  3675 Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor) 
PALLD 2.92 Hs.151220  23022 Palladin, cytoskeletal associated protein 
UPP1 2.90 Hs.488240  7378 Uridine phosphorylase 1 
HNRPUL1 2.90 Hs.699274  11100 Heterogeneous nuclear ribonucleoprotein U-like 1 
ACYP2 2.89 Hs.516173  98 Acylphosphatase 2, muscle type 
NXNL2 2.83 Hs.668937  158046 Nucleoredoxin-like 2 
EPS8 2.78 Hs.591160  2059 Epidermal growth factor receptor pathway substrate 8 
RCOR3 2.77 Hs.696152  55758 REST corepressor 3 
CS 2.75 Hs.430606  1431 Citrate synthase 
C11orf1 2.74 Hs.17546  64776 Chromosome 11 open reading frame 1 
ALG9 2.74 Hs.503850  79796 Asparagine-linked glycosylation 9 homolog (S. cerevisiae, alpha- 1,2-mannosyltransferase) 
ZYX 2.71 Hs.490415  7791 Zyxin 
HERPUD2 2.70 Hs.599851  64224 HERPUD family member 2 
IL31RA 2.70 Hs.55378  133396 Interleukin 31 receptor A 
TGFB1 2.69 Hs.645227  7040 Transforming growth factor, beta 1 
SLC20A1 2.68 Hs.187946  6574 Solute carrier family 20 (phosphate transporter), member 1 
QPCT 2.67 Hs.79033  25797 Glutaminyl-peptide cyclotransferase (glutaminyl cyclase) 
PRKAB2 2.66 Hs.50732  5565 Protein kinase, AMP-activated, beta 2 non-catalytic subunit 
C14orf79 2.66 Hs.27183  122616 Chromosome 14 open reading frame 79 
CALM2 2.62 Hs.643483  805 Calmodulin 2 (phosphorylase kinase, delta) 
FOXA2 2.62 Hs.155651  3170 Forkhead box A2 
TAGLN 2.62 Hs.632099  6876 Transgelin 
C14orf4 2.62 Hs.179260  64207 Chromosome 14 open reading frame 4 
NAB2 2.60 Hs.159223  4665 NGFI-A binding protein 2 (EGR1 binding protein 2) 
TMEM194 2.60 Hs.591040  23306 Transmembrane protein 194 
ATAD2 2.60 Hs.370834  29028 ATPase family, AAA domain containing 2 
C14orf43 2.60 Hs.656506  91748 Chromosome 14 open reading frame 43 
IL11 2.59 Hs.467304  3589 Interleukin 11 
TMEM190 2.59 Hs.590943  147744 Transmembrane protein 190 
SMAD3 2.58 Hs.618504  4088 SMAD family member 3 
USP3 2.56 Hs.458499  9960 Ubiquitin specific peptidase 3 
WDR55 2.55 Hs.286261  54853 WD repeat domain 55 
SH2D4A 2.54 Hs.303208  63898 SH2 domain containing 4A 
KIF21A 2.53 Hs.374201  55605 Kinesin family member 21A 
ARF6 2.52 Hs.525330  382 ADP-ribosylation factor 6 
BAIAP2L1 2.52 Hs.656063  55971 BAI1-associated protein 2-like 1 
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PDE7B 2.51 Hs.652367  27115 Phosphodiesterase 7B 
GTF2B 2.50 Hs.481852  2959 General transcription factor IIB 
ITGB1 2.50 Hs.695946  3688 Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) 
GCC2 2.48 Hs.705434  9648 GRIP and coiled-coil domain containing 2 
ZCCHC11 2.48 Hs.655407  23318 Zinc finger, CCHC domain containing 11 
SPRED1 2.48 Hs.525781  161742 Sprouty-related, EVH1 domain containing 1 
ANXA2 2.47 Hs.511605  302 Annexin A2 
PLAUR 2.47 Hs.466871  5329 Plasminogen activator, urokinase receptor 
PLS3 2.47 Hs.496622  5358 Plastin 3 (T isoform) 
SEMA4B 2.47 Hs.474935  10509 Sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4B 
ZNF219 2.46 Hs.250493  51222 Zinc finger protein 219 
C14orf104 2.44 Hs.231761  55172 Chromosome 14 open reading frame 104 
C14orf24 2.44 Hs.446357  283635 Chromosome 14 open reading frame 24 
KPNA1 2.41 Hs.161008  3836 Karyopherin alpha 1 (importin alpha 5) 
SOX1 2.40 Hs.202526  6656 SRY (sex determining region Y)-box 1 
SULT2B1 2.40 Hs.369331  6820 Sulfotransferase family, cytosolic, 2B, member 1 
TRIM16 2.36 Hs.123534  10626 Tripartite motif-containing 16 
CA3 2.35 Hs.82129  761 Carbonic anhydrase III, muscle specific 
CSN2 2.35 Hs.2242  1447 Casein beta 
DDX5 2.35 Hs.279806  1655 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 
CCDC45 2.35 Hs.569713  90799 Coiled-coil domain containing 45 
PVR 2.33 Hs.171844  5817 Poliovirus receptor 
XRCC2 2.33 Hs.647093  7516 X-ray repair complementing defective repair in Chinese hamster cells 2 
MEX3B 2.33 Hs.104744  84206 Mex-3 homolog B (C. elegans) 
UTRN 2.32 Hs.133135  7402 Utrophin 
DHRS12 2.32 Hs.266728  79758 Dehydrogenase/reductase (SDR family) member 12 
JMJD2A 2.31 Hs.155983  9682 Jumonji domain containing 2A 
ZBTB45  2.31 Hs.515662  84878 Zinc finger and BTB domain containing 45 
ART1 2.29 Hs.382188  417 ADP-ribosyltransferase 1 
PC 2.29 Hs.89890  5091 Pyruvate carboxylase 
LRCH1 2.29 Hs.656722  23143 Leucine-rich repeats and calponin homology (CH) domain containing 1 
ART5 2.29 Hs.125680  116969 ADP-ribosyltransferase 5 
ACTN1 2.28 Hs.509765  87 Actinin, alpha 1 
DHRS7B 2.28 Hs.386989  25979 Dehydrogenase/reductase (SDR family) member 7B 
CBX8 2.28 Hs.387258  57332 Chromobox homolog 8 (Pc class homolog, Drosophila) 
ATF3 2.26 Hs.460  467 Activating transcription factor 3 
DUSP1 2.26 Hs.171695  1843 Dual specificity phosphatase 1 
SOCS5 2.26 Hs.468426  9655 Suppressor of cytokine signaling 5 
POLE3 2.26 Hs.108112  54107 Polymerase (DNA directed), epsilon 3 (p17 subunit) 
KCTD15 2.26 Hs.221873  79047 Potassium channel tetramerisation domain containing 15 
C9orf43 2.26 Hs.632691  257169 Chromosome 9 open reading frame 43 
PRCC 2.25 Hs.516948  5546 Papillary renal cell carcinoma (translocation-associated) 
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DYNLT1 2.25 Hs.445999  6993 Dynein, light chain, Tctex-type 1 
ANKRD25 2.25 Hs.284208  25959 Ankyrin repeat domain 25 
CSDC2  2.25 Hs.310893  27254 Cold shock domain containing C2, RNA binding 
RHPN2 2.25 Hs.466435  85415 Rhophilin, Rho GTPase binding protein 2 
SYTL3 2.25 Hs.436977  94120 Synaptotagmin-like 3 
LDHA 2.24 Hs.2795  3939 Lactate dehydrogenase A 
R3HDML 2.24 Hs.580807  140902 R3H domain containing-like 
RTP3 2.23 Hs.196584  83597 Receptor (chemosensory) transporter protein 3 
NANP 2.23 Hs.666255  140838 N-acetylneuraminic acid phosphatase 
PRPS1 2.22 Hs.56  5631 Phosphoribosyl pyrophosphate synthetase 1 
DNAJB2 2.21 Hs.77768  3300 DnaJ (Hsp40) homolog, subfamily B, member 2 
RGS13 2.21 Hs.497220  6003 Regulator of G-protein signaling 13 
FILIP1 2.21 Hs.696158  27145 Filamin A interacting protein 1 
RBM25 2.21 Hs.531106  58517 RNA binding motif protein 25 
BEST3 2.21 Hs.280782  144453 Bestrophin 3 
PLK3 2.20 Hs.632415  1263 Polo-like kinase 3 (Drosophila) 
UVRAG 2.20 Hs.202470  7405 UV radiation resistance associated gene 
FADS2 2.20 Hs.502745  9415 Fatty acid desaturase 2 
NUTF2 2.20 Hs.696342  10204 Nuclear transport factor 2 
GTF3C2 2.19 Hs.75782  2976 General transcription factor IIIC, polypeptide 2, beta 110kDa 
METTL2A 2.19 Hs.381204  339175 Methyltransferase like 2A 
ZBTB25 2.18 Hs.654571  7597 Zinc finger and BTB domain containing 25 
ZBTB1 2.18 Hs.655536  22890 Zinc finger and BTB domain containing 1 
DNAJB11 2.18 Hs.317192  51726 DnaJ (Hsp40) homolog, subfamily B, member 11 
DNAJB11 2.18 Hs.317192  51726 DnaJ (Hsp40) homolog, subfamily B, member 11 
TBCCD1 2.18 Hs.518469  55171 TBCC domain containing 1 
JMJD1A 2.18 Hs.557425  55818 Jumonji domain containing 1A 
CD63 2.17 Hs.445570  967 CD63 molecule 
TSKU 2.17 Hs.8361  25987 Tsukushin 
CYHR1 2.17 Hs.459379  50626 Cysteine/histidine-rich 1 
KIFC2 2.17 Hs.528713  90990 Kinesin family member C2 
LENG8 2.17 Hs.502378  114823 Leukocyte receptor cluster (LRC) member 8 
GPR92 2.16 Hs.155538  57121 G protein-coupled receptor 92 
HTR1F 2.15 Hs.248136  3355 5-hydroxytryptamine (serotonin) receptor 1F 
PHEX 2.15 Hs.495834  5251 Phosphate regulating endopeptidase homolog, X-linked (hypophosphatemia, vitamin D resistant rickets) 
ODZ1 2.15 Hs.23796  10178 Odz, odd Oz/ten-m homolog 1(Drosophila) 
KLF13 2.15 Hs.525752  51621 Kruppel-like factor 13 
LTBP3 2.14 Hs.289019  4054 Latent transforming growth factor beta binding protein 3 
P2RY2 2.14 Hs.339  5029 Purinergic receptor P2Y, G-protein coupled, 2 
RDH13 2.14 Hs.327631  112724 Retinol dehydrogenase 13 (all-trans/9-cis) 
CCND1 2.13 Hs.523852  595 Cyclin D1 
NQO1 2.12 Hs.406515  1728 NAD(P)H dehydrogenase, quinone 1 
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LIF 2.12 Hs.2250  3976 Leukemia inhibitory factor (cholinergic differentiation factor) 
NOTCH2 2.12 Hs.487360  4853 Notch homolog 2 (Drosophila) 
MEP1A 2.11 Hs.179704  4224 Meprin A, alpha (PABA peptide hydrolase) 
RSF1 2.11 Hs.420229  51773 Remodeling and spacing factor 1 
FLJ45256 2.11 Hs.592028  400511 Hypothetical LOC400511 
GSS 2.10 Hs.82327  2937 Glutathione synthetase 
NME1 2.09 Hs.463456  4830 Non-metastatic cells 1, protein (NM23A) expressed in 
NPY1R 2.09 Hs.519057  4886 Neuropeptide Y receptor Y1 
ZNF384 2.09 Hs.103315  171017 Zinc finger protein 384 
ALDH3A2 2.08 Hs.499886  224 Aldehyde dehydrogenase 3 family, member A2 
CER1 2.08 Hs.248204  9350 Cerberus 1, cysteine knot superfamily, homolog (Xenopus laevis) 
NUBP2 2.08 Hs.256549  10101 Nucleotide binding protein 2 (MinD homolog, E. coli) 
SPSB3 2.08 Hs.592080  90864 SplA/ryanodine receptor domain and SOCS box containing 3 
SSX6 2.08 Hs.511998  280657 Synovial sarcoma, X breakpoint 6 
CXADR 2.07 Hs.705503  1525 Coxsackie virus and adenovirus receptor 
EDG6 2.07 Hs.662006  8698 Endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 6 
SPECC1 2.07 Hs.431045  92521 Sperm antigen with calponin homology and coiled-coil domains 1 
TIPARP 2.06 Hs.12813  25976 TCDD-inducible poly(ADP-ribose) polymerase 
CCDC123 2.06 Hs.599703  84902 Coiled-coil domain containing 123 
ITGB6 2.05 Hs.470399  3694 Integrin, beta 6 
RNPS1 2.05 Hs.355643  10921 RNA binding protein S1, serine-rich domain 
USP32 2.05 Hs.132868  84669 Ubiquitin specific peptidase 32 
LOC338799 2.05 Hs.654994  338799 Hypothetical locus LOC338799 
SEPT7 2.04 Hs.191346  989 Septin 7 
ITGAV 2.04 Hs.436873  3685 Integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51) 
PYGL 2.03 Hs.282417  5836 Phosphorylase, glycogen; liver (Hers disease, glycogen storage disease type VI) 
SSR3 2.03 Hs.518346  6747 Signal sequence receptor, gamma (translocon-associated protein gamma) 
DYNLL1 2.03 Hs.5120  8655 Dynein, light chain, LC8-type 1 
SPINT2 2.03 Hs.31439  10653 Serine peptidase inhibitor, Kunitz type, 2 
C19orf33 2.03 Hs.631544  64073 Chromosome 19 open reading frame 33 
PPP1R14A 2.03 Hs.631569  94274 Protein phosphatase 1, regulatory (inhibitor) subunit 14A 
AVPI1 2.02 Hs.23918  60370 Arginine vasopressin-induced 1 
TNMD 2.02 Hs.132957  64102 Tenomodulin 
ADM2 2.02 Hs.449099  79924 Adrenomedullin 2 
SHOC2 2.01 Hs.104315  8036 Soc-2 suppressor of clear homolog (C. elegans) 
BRWD1 2.01 Hs.654740  54014 Bromodomain and WD repeat domain containing 1 
BICD1 2.00 Hs.505202  636 Bicaudal D homolog 1 (Drosophila) 
DBT 2.00 Hs.633217  1629 Dihydrolipoamide branched chain transacylase E2 
DLX4 2.00 Hs.591167  1748 Distal-less homeobox 4 
KLF10 2.00 Hs.435001  7071 Kruppel-like factor 10 
ETHE1 2.00 Hs.7486  23474 Ethylmalonic encephalopathy 1 
RNF19A 2.00 Hs.292882  25897 Ring finger protein 19A 
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GEMIN8  2.00 Hs.592237  54960 Gem (nuclear organelle) associated protein 8 
B4GALNT2 2.00 Hs.374679  124872 Beta-1,4-N-acetyl-galactosaminyl transferase 2 
ZNF575 2.00 Hs.213534  284346 Zinc finger protein 575 
NOTCH2NL 2.00 Hs.655156  388677 Notch homolog 2 (Drosophila) N-terminal like 
NR3C2 1.99 Hs.163924  4306 Nuclear receptor subfamily 3, group C, member 2 
SLC16A1 1.99 Hs.75231  6566 Solute carrier family 16, member 1 (monocarboxylic acid transporter 1) 
JPH2 1.99 Hs.441737  57158 Junctophilin 2 
CDK7 1.98 Hs.184298  1022 Cyclin-dependent kinase 7 
RARA 1.98 Hs.654583  5914 Retinoic acid receptor, alpha 
GNL2 1.98 Hs.75528  29889 Guanine nucleotide binding protein-like 2 (nucleolar) 
MLL5 1.98 Hs.592262  55904 Myeloid/lymphoid or mixed-lineage leukemia 5 (trithorax homolog, Drosophila)
DAND5 1.98 Hs.331981  199699 DAN domain family, member 5 
DAB2 1.97 Hs.481980  1601 Disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila) 
PHKA2 1.97 Hs.54941  5256 Phosphorylase kinase, alpha 2 (liver) 
PNMA1 1.97 Hs.194709  9240 Paraneoplastic antigen MA1 
LDOC1 1.97 Hs.45231  23641 Leucine zipper, down-regulated in cancer 1 
BRF2 1.97 Hs.705411  55290 BRF2, subunit of RNA polymerase III transcription initiation factor, BRF1-like 
KLC1 1.96 Hs.20107  3831 Kinesin light chain 1 
RPH3AL 1.96 Hs.651925  9501 Rabphilin 3A-like (without C2 domains) 
MTP18 1.96 Hs.656909  51537 Mitochondrial protein 18 kDa 
MPP5 1.96 Hs.652312  64398 Membrane protein, palmitoylated 5 (MAGUK p55 subfamily member 5) 
E2F4 1.95 Hs.108371  1874 E2F transcription factor 4, p107/p130-binding 
IL6R 1.95 Hs.695954  3570 Interleukin 6 receptor 
PFTK1 1.95 Hs.430742  5218 PFTAIRE protein kinase 1 
HLTF 1.95 Hs.3068  6596 Helicase-like transcription factor 
MAP3K7IP2 1.95 Hs.269775  23118 Mitogen-activated protein kinase kinase kinase 7 interacting protein 2 
TPTE2 1.95 Hs.377488  93492 Transmembrane phosphoinositide 3-phosphatase and tensin homolog 2 
FAM33A 1.95 Hs.463607  348235 Family with sequence similarity 33, member A 
HIBCH 1.94 Hs.656685  26275 3-hydroxyisobutyryl-Coenzyme A hydrolase 
AXL 1.93 Hs.590970  558 AXL receptor tyrosine kinase 
ARL4C 1.93 Hs.699342  10123 ADP-ribosylation factor-like 4C 
KIAA1161 1.93 Hs.522083  57462 KIAA1161 
SLC25A28 1.93 Hs.403790  81894 Solute carrier family 25, member 28 
KIAA1737 1.93 Hs.22452  85457 KIAA1737 
CTPS 1.92 Hs.473087  1503 CTP synthase 
DBP 1.92 Hs.414480  1628 D site of albumin promoter (albumin D-box) binding protein 
C20orf29 1.92 Hs.104806  55317 Chromosome 20 open reading frame 29 
KIAA1609 1.92 Hs.288274  57707 KIAA1609 
EPB41L1 1.91 Hs.437422  2036 Erythrocyte membrane protein band 4.1-like 1 
LBR 1.91 Hs.435166  3930 Lamin B receptor 
MDFI 1.91 Hs.520119  4188 MyoD family inhibitor 
SPIN1 1.91 Hs.146804  10927 Spindlin 1 
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TRIM31 1.91 Hs.493275  11074 Tripartite motif-containing 31 
DDT 1.90 Hs.656723  1652 D-dopachrome tautomerase 
GSTT2 1.90 Hs.654462  2953 Glutathione S-transferase theta 2 
JARID1A 1.90 Hs.654806  5927 Jumonji, AT rich interactive domain 1A 
PLA2G7 1.90 Hs.584823  7941 Phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) 
SLC7A5 1.90 Hs.513797  8140 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 5
PGS1 1.90 Hs.654671  9489 Phosphatidylglycerophosphate synthase 1 
ARHGAP11A 1.90 Hs.591130  9824 Rho GTPase activating protein 11A 
SH3TC1 1.90 Hs.479116  54436 SH3 domain and tetratricopeptide repeats 1 
MKI67IP 1.90 Hs.367842  84365 MKI67 (FHA domain) interacting nucleolar phosphoprotein 
JUB 1.89 Hs.655832  84962 Jub, ajuba homolog (Xenopus laevis) 
ARHGAP5 1.88 Hs.592313  394 Rho GTPase activating protein 5 
CHRNB2 1.88 Hs.2306  1141 Cholinergic receptor, nicotinic, beta 2 (neuronal) 
HNRPK 1.88 Hs.695973  3190 Heterogeneous nuclear ribonucleoprotein K 
CCDC9 1.88 Hs.227782  26093 Coiled-coil domain containing 9 
TMEM132A 1.88 Hs.118552  54972 Transmembrane protein 132A 
UBE2Q1 1.88 Hs.607928  55585 Ubiquitin-conjugating enzyme E2Q (putative) 1 
MUS81 1.88 Hs.288798  80198 MUS81 endonuclease homolog (S. cerevisiae) 
MGC34761 1.88 Hs.556045  283971 Hypothetical protein MGC34761 
SH3BGR 1.87 Hs.473847  6450 SH3 domain binding glutamic acid-rich protein 
KIAA0174 1.87 Hs.232194  9798 KIAA0174 
DSTN 1.87 Hs.304192  11034 Destrin (actin depolymerizing factor) 
THAP8 1.87 Hs.350209  199745 THAP domain containing 8 
WDR62 1.87 Hs.116244  284403 WD repeat domain 62 
PNRC1 1.86 Hs.75969  10957 Proline-rich nuclear receptor coactivator 1 
NHS 1.85 Hs.201623  4810 Nance-Horan syndrome (congenital cataracts and dental anomalies) 
STAT3 1.85 Hs.463059  6774 Signal transducer and activator of transcription 3 (acute-phase response factor) 
TXN 1.85 Hs.435136  7295 Thioredoxin 
CATSPER2 1.85 Hs.662284  117155 Cation channel, sperm associated 2 
HSPA2 1.84 Hs.432648  3306 Heat shock 70kDa protein 2 
PHLDA2 1.84 Hs.154036  7262 Pleckstrin homology-like domain, family A, member 2 
KIAA1576 1.84 Hs.461405  57687 KIAA1576 protein 
KLC4 1.84 Hs.655123  89953 Kinesin light chain 4 
ADPRHL1 1.84 Hs.98669  113622 ADP-ribosylhydrolase like 1 
HTRA4 1.84 Hs.661014  203100 HtrA serine peptidase 4 
SLC1A4 1.83 Hs.654352  6509 Solute carrier family 1 (glutamate/neutral amino acid transporter), member 4 
RABGAP1 1.83 Hs.271341  23637 RAB GTPase activating protein 1 
PGM2L1 1.83 Hs.26612  283209 Phosphoglucomutase 2-like 1 
OR8H3 1.83 Hs.553745  390152 Olfactory receptor, family 8, subfamily H, member 3 
NR6A1 1.82 Hs.586460  2649 Nuclear receptor subfamily 6, group A, member 1 
TPSG1 1.81 Hs.592076  25823 Tryptase gamma 1 
ZNF34 1.81 Hs.631854  80778 Zinc finger protein 34 
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C19orf36 1.81 Hs.424049  113177 Chromosome 19 open reading frame 36 
MOBKL2A 1.81 Hs.86912  126308 MOB1, Mps One Binder kinase activator-like 2A (yeast) 
RAB3IL1 1.80 Hs.13759  5866 RAB3A interacting protein (rabin3)-like 1 
DMTF1 1.80 Hs.654981  9988 Cyclin D binding myb-like transcription factor 1 
ACAA2 1.80 Hs.200136  10449 Acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme A thiolase) 
ANKRD10 1.80 Hs.525163  55608 Ankyrin repeat domain 10 
MTUS1 1.80 Hs.7946  57509 Mitochondrial tumor suppressor 1 
C14orf80 1.80 Hs.72363  283643 Chromosome 14 open reading frame 80 
MAP3K8 1.79 Hs.432453  1326 Mitogen-activated protein kinase kinase kinase 8 
MEF2A 1.79 Hs.268675  4205 Myocyte enhancer factor 2A 
PDE3A 1.79 Hs.591150  5139 Phosphodiesterase 3A, cGMP-inhibited 
SIRT1 1.79 Hs.369779  23411 Sirtuin (silent mating type information regulation 2 homolog) 1 (S. cerevisiae) 
WDR34 1.79 Hs.495240  89891 WD repeat domain 34 
SELM 1.79 Hs.55940  140606 Selenoprotein M 
VWA2  1.79 Hs.197741  340706 Von Willebrand factor A domain containing 2 
LOC388272 1.79 Hs.705603  388272 Similar to RIKEN cDNA 4921524J17 
ACACA 1.78 Hs.160556  31 Acetyl-Coenzyme A carboxylase alpha 
PRKAR1A 1.78 Hs.280342  5573 Protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1) 
PPP1R11 1.78 Hs.82887  6992 Protein phosphatase 1, regulatory (inhibitor) subunit 11 
C2orf25 1.78 Hs.5324  27249 Chromosome 2 open reading frame 25 
SLC25A23 1.78 Hs.356231  79085 Solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 23
CRB3 1.78 Hs.150319  92359 Crumbs homolog 3 (Drosophila) 
GPR39 1.77 Hs.432395  2863 G protein-coupled receptor 39 
PPM1B 1.77 Hs.416769  5495 Protein phosphatase 1B (formerly 2C), magnesium-dependent, beta isoform 
TXK 1.77 Hs.479669  7294 TXK tyrosine kinase 
CIB1 1.77 Hs.135471  10519 Calcium and integrin binding 1 (calmyrin) 
OR6C2 1.77 Hs.524483  341416 Olfactory receptor, family 6, subfamily C, member 2 
DLX3 1.76 Hs.134194  1747 Distal-less homeobox 3 
EWSR1 1.76 Hs.374477  2130 Ewing sarcoma breakpoint region 1 
H3F3B 1.76 Hs.180877  3021 H3 histone, family 3B (H3.3B) 
PFKFB3 1.76 Hs.195471  5209 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 
STYX 1.76 Hs.364980  6815 Serine/threonine/tyrosine interacting protein 
TRDN 1.76 Hs.654601  10345 Triadin 
KIAA0182 1.76 Hs.461647  23199 KIAA0182 
RHBDD3 1.76 Hs.106730  25807 Rhomboid domain containing 3 
PLEKHG3 1.76 Hs.509637  26030 Pleckstrin homology domain containing, family G (with RhoGef domain) member 3 
AXUD1 1.76 Hs.370950  64651 AXIN1 up-regulated 1 
GSTP1 1.75 Hs.523836  2950 Glutathione S-transferase pi 
MAP2K1 1.75 Hs.145442  5604 Mitogen-activated protein kinase kinase 1 
CTDSP2 1.75 Hs.524530  10106 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase 2 
DDX39 1.75 Hs.311609  10212 DEAD (Asp-Glu-Ala-Asp) box polypeptide 39 
RAB40C 1.75 Hs.459630  57799 RAB40C, member RAS oncogene family 
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INTS4 1.75 Hs.533723  92105 Integrator complex subunit 4 
PDHX 1.74 Hs.502315  8050 Pyruvate dehydrogenase complex, component X 
APIP 1.74 Hs.447794  51074 APAF1 interacting protein 
LENG9 1.74 Hs.590976  94059 Leukocyte receptor cluster (LRC) member 9 
KCNN4 1.73 Hs.10082  3783 Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 
RFX1 1.73 Hs.655215  5989 Regulatory factor X, 1 (influences HLA class II expression) 
TNIP1 1.73 Hs.543850  10318 TNFAIP3 interacting protein 1 
ANK2 1.72 Hs.620557  287 Ankyrin 2, neuronal 
DIAPH2 1.72 Hs.696382  1730 Diaphanous homolog 2 (Drosophila) 
TSC22D3 1.72 Hs.522074  1831 TSC22 domain family, member 3 
ZNF155 1.72 Hs.502127  7711 Zinc finger protein 155 
PAK6 1.72 Hs.513645  56924 P21(CDKN1A)-activated kinase 6 
RFT1 1.72 Hs.631910  91869 RFT1 homolog (S. cerevisiae) 
ME1 1.71 Hs.21160  4199 Malic enzyme 1, NADP(+)-dependent, cytosolic 
PSMD13 1.71 Hs.134688  5719 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 13 
VAPB 1.71 Hs.182625  9217 VAMP (vesicle-associated membrane protein)-associated protein B and C 
COTL1 1.71 Hs.289092  23406 Coactosin-like 1 (Dictyostelium) 
SIRT3 1.71 Hs.592292  23410 Sirtuin (silent mating type information regulation 2 homolog) 3 (S. cerevisiae) 
TRPM7 1.71 Hs.512894  54822 Transient receptor potential cation channel, subfamily M, member 7 
PPP2R2D 1.71 Hs.380372  55844 Protein phosphatase 2, regulatory subunit B, delta isoform 
CARD14 1.71 Hs.675480  79092 Caspase recruitment domain family, member 14 
HAVCR2 1.71 Hs.616365  84868 Hepatitis A virus cellular receptor 2 
REEP3 1.71 Hs.499833  221035 Receptor accessory protein 3 
GPLD1 1.70 Hs.591810  2822 Glycosylphosphatidylinositol specific phospholipase D1 
MAP3K3 1.70 Hs.29282  4215 Mitogen-activated protein kinase kinase kinase 3 
OR5I1 1.70 Hs.533706  10798 Olfactory receptor, family 5, subfamily I, member 1 
PLEK2 1.70 Hs.170473  26499 Pleckstrin 2 
EEF2K 1.70 Hs.498892  29904 Eukaryotic elongation factor-2 kinase 
COX18 1.70 Hs.356697  285521 COX18 cytochrome c oxidase assembly homolog (S. cerevisiae) 
ELA2 1.69 Hs.99863  1991 Elastase 2, neutrophil 
SFTPD 1.69 Hs.253495  6441 Surfactant, pulmonary-associated protein D 
DGCR6 1.69 Hs.474185  8214 DiGeorge syndrome critical region gene 6 
DENR 1.69 Hs.22393  8562 Density-regulated protein 
WDR53 1.69 Hs.385865  348793 WD repeat domain 53 
FSHB 1.68 Hs.36975  2488 Follicle stimulating hormone, beta polypeptide 
MMP12 1.68 Hs.1695  4321 Matrix metallopeptidase 12 (macrophage elastase) 
NRL 1.68 Hs.652297  4901 Neural retina leucine zipper 
PON2 1.68 Hs.530077  5445 Paraoxonase 2 
RBMS2 1.68 Hs.645521  5939 RNA binding motif, single stranded interacting protein 2 
WDR19 1.68 Hs.438482  57728 WD repeat domain 19 
MET 1.67 Hs.132966  4233 Met proto-oncogene (hepatocyte growth factor receptor) 
VDAC1 1.67 Hs.519320  7416 Voltage-dependent anion channel 1 
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PPP2R3C 1.67 Hs.530712  55012 Protein phosphatase 2 (formerly 2A), regulatory subunit B'', gamma 
H2AFV 1.67 Hs.488189  94239 H2A histone family, member V 
CTGF 1.66 Hs.591346  1490 Connective tissue growth factor 
GIPR 1.66 Hs.658534  2696 Gastric inhibitory polypeptide receptor 
MCM6 1.66 Hs.444118  4175 Minichromosome maintenance complex component 6 
FZD1 1.66 Hs.94234  8321 Frizzled homolog 1 (Drosophila) 
MAN1B1 1.66 Hs.591887  11253 Mannosidase, alpha, class 1B, member 1 
MAF1 1.66 Hs.19673  84232 MAF1 homolog (S. cerevisiae) 
FCHO2 1.66 Hs.165762  115548 FCH domain only 2 
ANXA5 1.65 Hs.480653  308 Annexin A5 
SF3B2 1.65 Hs.406423  10992 Splicing factor 3b, subunit 2, 145kDa 
ATF7 1.65 Hs.12286  11016 Activating transcription factor 7 
OSBPL1A 1.65 Hs.370725  114876 Oxysterol binding protein-like 1A 
CYP2C19 1.64 Hs.282409  1557 Cytochrome P450, family 2, subfamily C, polypeptide 19 
MAP3K4 1.64 Hs.390428  4216 Mitogen-activated protein kinase kinase kinase 4 
MYOG 1.64 Hs.2830  4656 Myogenin (myogenic factor 4) 
PCBP2 1.64 Hs.546271  5094 Poly(rC) binding protein 2 
PIN4 1.64 Hs.655623  5303 Protein (peptidylprolyl cis/trans isomerase) NIMA-interacting, 4 (parvulin) 
WNT9A 1.64 Hs.149504  7483 Wingless-type MMTV integration site family, member 9A 
OR10W1 1.64 Hs.531507  81341 Olfactory receptor, family 10, subfamily W, member 1 
GAS2L3 1.64 Hs.20575  283431 Growth arrest-specific 2 like 3 
C5orf13 1.63 Hs.36053  9315 Chromosome 5 open reading frame 13 
ARL4A 1.63 Hs.245540  10124 ADP-ribosylation factor-like 4A 
MESDC1 1.63 Hs.513071  59274 Mesoderm development candidate 1 
P4HA3 1.63 Hs.660541  283208 Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide III 
PTGS2 1.62 Hs.196384  5743 Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) 
TEC 1.62 Hs.479670  7006 Tec protein tyrosine kinase 
SLCO1B3 1.62 Hs.504966  28234 Solute carrier organic anion transporter family, member 1B3 
VCPIP1 1.62 Hs.632066  80124 Valosin containing protein (p97)/p47 complex interacting protein 1 
FAH 1.61 Hs.73875  2184 Fumarylacetoacetate hydrolase (fumarylacetoacetase) 
PICALM 1.61 Hs.163893  8301 Phosphatidylinositol binding clathrin assembly protein 
CIT 1.61 Hs.119594  11113 Citron (rho-interacting, serine/threonine kinase 21) 
ANKRD2 1.61 Hs.73708  26287 Ankyrin repeat domain 2 (stretch responsive muscle) 
LUC7L2 1.61 Hs.370475  51631 LUC7-like 2 (S. cerevisiae) 
C21orf29 1.61 Hs.660703  54084 Chromosome 21 open reading frame 29 
FBXO17 1.61 Hs.531770  115290 F-box protein 17 
NEBL 1.60 Hs.5025  10529 Nebulette 
FASTKD2  1.60 Hs.84429  22868 FAST kinase domains 2 
TPCN1 1.60 Hs.524763  53373 Two pore segment channel 1 
MDH1B 1.60 Hs.147816  130752 Malate dehydrogenase 1B, NAD (soluble) 
GATA6 1.59 Hs.514746  2627 GATA binding protein 6 
CCPG1 1.59 Hs.612814  9236 Cell cycle progression 1 
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RBM7 1.59 Hs.533736  10179 RNA binding motif protein 7 
PPIL2 1.59 Hs.438587  23759 Peptidylprolyl isomerase (cyclophilin)-like 2 
MTERFD3 1.59 Hs.5009  80298 MTERF domain containing 3 
RTN3 1.58 Hs.473761  10313 Reticulon 3 
DKFZP564J0863 1.58 Hs.356719  25923 DKFZP564J0863 protein 
CTDSPL2 1.58 Hs.646495  51496 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase like 2 
GALNT10 1.58 Hs.651323  55568 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 10 (GalNAc-T10) 
ADCK4 1.58 Hs.130712  79934 AarF domain containing kinase 4 
ITPKC 1.58 Hs.515415  80271 Inositol 1,4,5-trisphosphate 3-kinase C 
OR4K17 1.58 Hs.553765  390436 Olfactory receptor, family 4, subfamily K, member 17 
PIM3 1.58 Hs.530381  415116 Pim-3 oncogene 
GALNAC4S 1.58 Hs.287537 51363 B cell RAG associated protein 
BCL3 1.57 Hs.31210  602 B-cell CLL/lymphoma 3 
CALR 1.57 Hs.515162  811 Calreticulin 
FARSA 1.57 Hs.23111  2193 Phenylalanyl-tRNA synthetase, alpha subunit 
GCLM 1.57 Hs.315562  2730 Glutamate-cysteine ligase, modifier subunit 
KPNA4 1.57 Hs.288193  3840 Karyopherin alpha 4 (importin alpha 3) 
PSMA1 1.57 Hs.102798  5682 Proteasome (prosome, macropain) subunit, alpha type, 1 
HIP1R 1.57 Hs.524815  9026 Huntingtin interacting protein 1 related 
GALNT7 1.57 Hs.548088  51809 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7 (GalNAc-T7) 
DAP3 1.56 Hs.516746  7818 Death associated protein 3 
RGS20 1.56 Hs.368733  8601 Regulator of G-protein signaling 20 
CAMTA1 1.56 Hs.397705  23261 Calmodulin binding transcription activator 1 
MYEF2 1.56 Hs.6638  50804 Myelin expression factor 2 
YY1AP1 1.56 Hs.584927  55249 YY1 associated protein 1 
CENPN 1.56 Hs.55028  55839 Centromere protein N 
ZNF223 1.55 Hs.279840  7766 Zinc finger protein 223 
CCNK 1.55 Hs.705475  8812 Cyclin K 
NPC2 1.55 Hs.433222  10577 Niemann-Pick disease, type C2 
SNX5 1.55 Hs.316890  27131 Sorting nexin 5 
SETD3 1.55 Hs.510407  84193 SET domain containing 3 
ISCA2 1.55 Hs.702169  122961 Iron-sulfur cluster assembly 2 homolog (S. cerevisiae) 
ADH1B 1.54 Hs.4  125 Alcohol dehydrogenase 1B (class I), beta polypeptide 
PTK2B 1.54 Hs.491322  2185 PTK2B protein tyrosine kinase 2 beta 
PAFAH1B2 1.54 Hs.696131  5049 Platelet-activating factor acetylhydrolase, isoform Ib, beta subunit 30kDa 
PRCP 1.54 Hs.523936  5547 Prolylcarboxypeptidase (angiotensinase C) 
SEPP1 1.54 Hs.275775  6414 Selenoprotein P, plasma, 1 
SLC12A4 1.54 Hs.10094  6560 Solute carrier family 12 (potassium/chloride transporters), member 4 
IQCE 1.54 Hs.520627  23288 IQ motif containing E 
RTDR1 1.54 Hs.526920  27156 Rhabdoid tumor deletion region gene 1 
C12orf5 1.54 Hs.504545  57103 Chromosome 12 open reading frame 5 
TFB2M 1.54 Hs.7395  64216 Transcription factor B2, mitochondrial 
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C7orf27 1.54 Hs.520623  221927 Chromosome 7 open reading frame 27 
CTNNA1 1.53 Hs.534797  1495 Catenin (cadherin-associated protein), alpha 1, 102kDa 
EIF6 1.53 Hs.654848  3692 Eukaryotic translation initiation factor 6 
POLG 1.53 Hs.702153  5428 Polymerase (DNA directed), gamma 
CSAD 1.53 Hs.279815  51380 Cysteine sulfinic acid decarboxylase 
SMPD4 1.53 Hs.516450  55627 Sphingomyelin phosphodiesterase 4, neutral membrane (neutral sphingomyelinase-3) 
POLR3B 1.53 Hs.62696  55703 Polymerase (RNA) III (DNA directed) polypeptide B 
FAM128B 1.53 Hs.469925  80097 Family with sequence similarity 128, member B 
ZNF740 1.53 Hs.524458  283337 Zinc finger protein 740 
RAB11FIP3 1.52 Hs.531642  9727 RAB11 family interacting protein 3 (class II) 
SMURF2 1.52 Hs.705442  64750 SMAD specific E3 ubiquitin protein ligase 2 
DHRS4L2 1.52 Hs.647569  317749 Dehydrogenase/reductase (SDR family) member 4 like 2 
CTCF 1.51 Hs.368367  10664 CCCTC-binding factor (zinc finger protein) 
MRPL39 1.51 Hs.420696  54148 Mitochondrial ribosomal protein L39 
PARP16 1.51 Hs.30634  54956 Poly (ADP-ribose) polymerase family, member 16 
ARPC5L 1.51 Hs.132499  81873 Actin related protein 2/3 complex, subunit 5-like 
RELA 1.50 Hs.502875  5970 V-rel reticuloendotheliosis viral oncogene homolog A, nuclear factor of kappa light polypeptide gene enhancer in B-cells 3, p65 (avian) 
DHX38 1.50 Hs.570079  9785 DEAH (Asp-Glu-Ala-His) box polypeptide 38 
POLR1D 1.50 Hs.507584  51082 Polymerase (RNA) I polypeptide D, 16kDa 
PEX26 1.50 Hs.517400  55670 Peroxisome biogenesis factor 26 
LNX2 1.50 Hs.132359  222484 Ligand of numb-protein X 2 
 
ChIP-chip Significant Bound Genes, Non-Stimulated Cells 
GENE ID PEAK HEIGHT UNIGENE ID ENTREZ ID GENE DESCRIPTION 
NDUFA3 4.77 Hs.198269  4696 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3, 9kDa 
OSCAR 4.77 Hs.347655  126014 Osteoclast associated, immunoglobulin-like receptor 
SLC16A9 3.52 Hs.499709  220963 Solute carrier family 16, member 9 (monocarboxylic acid transporter 9) 
SERPINE1 3.47 Hs.414795  5054 Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
SRPX2 3.31 Hs.306339  27286 Sushi-repeat-containing protein, X-linked 2 
COL7A1 3.08 Hs.476218  1294 Collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)
C1orf43 2.96 Hs.287471  25912 Chromosome 1 open reading frame 43 
UBAP2L 2.96 Hs.490551  9898 Ubiquitin associated protein 2-like 
C14orf104 2.79 Hs.231761  55172 Chromosome 14 open reading frame 104 
TAAR1 2.75 Hs.375030  134864 Trace amine associated receptor 1 
TAP2 2.73 Hs.502  6891 Transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) 
MTMR7 2.73 Hs.625674  9108 Myotubularin related protein 7 
UGCGL1 2.69 Hs.34180  56886 UDP-glucose ceramide glucosyltransferase-like 1 
SLITRK2 2.6 Hs.320368  84631 SLIT and NTRK-like family, member 2 
CLC 2.57 Hs.889  1178 Charcot-Leyden crystal protein 
CD44 2.5 Hs.502328  960 CD44 molecule (Indian blood group) 
DDX53 2.46 Hs.434416  168400 DEAD (Asp-Glu-Ala-Asp) box polypeptide 53 
FLJ45248 2.45 Hs.224506  401472 FLJ45248 protein 
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HOXB3 2.45 Hs.654560  3213 Homeobox B3 
LOXHD1 2.44 Hs.345877  125336 Lipoxygenase homology domains 1 
KIAA1576 2.44 Hs.461405  57687 KIAA1576 protein 
PSPC1 2.43 Hs.213198  55269 Paraspeckle component 1 
SMPX 2.42 Hs.86492  23676 Small muscle protein, X-linked 
HEXB 2.4 Hs.69293  3074 Hexosaminidase B (beta polypeptide) 
CYP7A1 2.38 Hs.1644  1581 Cytochrome P450, family 7, subfamily A, polypeptide 1 
ZNF45 2.38 Hs.381285  7596 Zinc finger protein 45 
TEX15 2.34 Hs.458316  56154 Testis expressed 15 
CYP2C8 2.32 Hs.282871  1558 Cytochrome P450, family 2, subfamily C, polypeptide 8 
OR1L3 2.32 Hs.626839  26735 Olfactory receptor, family 1, subfamily L, member 3 
SMAD6 2.31 Hs.153863  4091 SMAD family member 6 
UBAP2 2.3 Hs.493739  55833 Ubiquitin associated protein 2 
OR6S1 2.25 Hs.513132  341799 Olfactory receptor, family 6, subfamily S, member 1 
KIAA1377 2.24 Hs.156352  57562 KIAA1377 
ANKRD32 2.24 Hs.657315  84250 Ankyrin repeat domain 32 
DOCK7 2.23 Hs.538059  85440 Dedicator of cytokinesis 7 
IPO11 2.21 Hs.482269  51194 Importin 11 
C21orf84 2.21 Hs.592161  114038 Chromosome 21 open reading frame 84 
MRC1 2.21 Hs.75182  4360 Mannose receptor, C type 1 
NR0B1 2.2 Hs.268490  190 Nuclear receptor subfamily 0, group B, member 1 
TCF20 2.2 Hs.475018  6942 Transcription factor 20 (AR1) 
CHD1 2.2 Hs.643465  1105 Chromodomain helicase DNA binding protein 1 
FAM12B 2.19 Hs.525202  64184 Family with sequence similarity 12, member B (epididymal) 
SNX12 2.17 Hs.260750  29934 Sorting nexin 12 
ZNF384 2.16 Hs.103315  171017 Zinc finger protein 384 
MITF 2.14 Hs.166017  4286 Microphthalmia-associated transcription factor 
KPTN 2.13 Hs.25441  11133 Kaptin (actin binding protein) 
ITIH1 2.13 Hs.420257  3697 Inter-alpha (globulin) inhibitor H1 
NEK4 2.13 Hs.631921  6787 NIMA (never in mitosis gene a)-related kinase 4 
MAGEH1 2.12 Hs.279819  28986 Melanoma antigen family H, 1 
ADPRHL1 2.12 Hs.98669  113622 ADP-ribosylhydrolase like 1 
C14orf119 2.1 Hs.525238  55017 Chromosome 14 open reading frame 119 
PTH 2.09 Hs.37045  5741 Parathyroid hormone 
POU1F1 2.09 Hs.591654  5449 POU class 1 homeobox 1 
MNDA 2.08 Hs.153837  4332 Myeloid cell nuclear differentiation antigen 
ATAD2 2.07 Hs.370834  29028 ATPase family, AAA domain containing 2 
USP9X 2.07 Hs.77578  8239 Ubiquitin specific peptidase 9, X-linked 
DHX33 2.06 Hs.250456  56919 DEAH (Asp-Glu-Ala-His) box polypeptide 33 
WDR47 2.06 Hs.654760  22911 WD repeat domain 47 
IFNA8 2.06 Hs.73890  3445 Interferon, alpha 8 
PLSCR2 2.05 Hs.147305  57047 Phospholipid scramblase 2 
RANBP2 2.05 Hs.199561  5903 RAN binding protein 2 
C8B 2.05 Hs.391835  732 Complement component 8, beta polypeptide 
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OR4D10 2.04 Hs.553756  390197 Olfactory receptor, family 4, subfamily D, member 10 
VNN1 2.03 Hs.12114  8876 Vanin 1 
PRDM2 2.02 Hs.371823  7799 PR domain containing 2, with ZNF domain 
TMPO 2.01 Hs.11355  7112 Thymopoietin 
WNT16 2.01 Hs.272375  51384 Wingless-type MMTV integration site family, member 16 
KERA 2 Hs.125750  11081 Keratocan 
CDC2 2 Hs.334562  983 Cell division cycle 2, G1 to S and G2 to M 
ZNF615 1.99 Hs.368355  284370 Zinc finger protein 615 
ZNF519 1.97 Hs.352635  162655 Zinc finger protein 519 
C6orf1 1.97 Hs.381300  221491 Chromosome 6 open reading frame 1 
IVD 1.97 Hs.449599  3712 Isovaleryl Coenzyme A dehydrogenase 
GPHN 1.95 Hs.208765  10243 Gephyrin 
IL20 1.95 Hs.272373  50604 Interleukin 20 
CYP39A1 1.94 Hs.387367  51302 Cytochrome P450, family 39, subfamily A, polypeptide 1 
PLCB4 1.94 Hs.472101  5332 Phospholipase C, beta 4 
CCDC7 1.93 Hs.585464  221016 Coiled-coil domain containing 7 
OR7A5 1.92 Hs.137573  26659 Olfactory receptor, family 7, subfamily A, member 5 
FBXL19 1.92 Hs.152149  54620 F-box and leucine-rich repeat protein 19 
PPM1E 1.92 Hs.245044  22843 Protein phosphatase 1E (PP2C domain containing) 
NOX3 1.92 Hs.247776  50508 NADPH oxidase 3 
NQO1 1.92 Hs.406515  1728 NAD(P)H dehydrogenase, quinone 1 
WDR22 1.92 Hs.509780  8816 WD repeat domain 22 
SCN10A 1.91 Hs.250443  6336 Sodium channel, voltage-gated, type X, alpha subunit 
ZNF146 1.91 Hs.643436  7705 Zinc finger protein 146 
C10orf120 1.9 Hs.363649  399814 Chromosome 10 open reading frame 120 
KDELR2 1.9 Hs.654552  11014 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 2
SGCG 1.89 Hs.37167  6445 Sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein) 
ABCG2 1.89 Hs.480218  9429 ATP-binding cassette, sub-family G (WHITE), member 2 
OR4A16 1.89 Hs.554530  81327 Olfactory receptor, family 4, subfamily A, member 16 
CNGB3 1.88 Hs.154433  54714 Cyclic nucleotide gated channel beta 3 
SUPT6H 1.87 Hs.250429  6830 Suppressor of Ty 6 homolog (S. cerevisiae) 
RECK 1.87 Hs.388918  8434 Reversion-inducing-cysteine-rich protein with kazal motifs 
RCOR3 1.87 Hs.696152  55758 REST corepressor 3 
GJA1 1.87 Hs.74471  2697 Gap junction protein, alpha 1, 43kDa 
DLAT 1.86 Hs.335551  1737 Dihydrolipoamide S-acetyltransferase (E2 component of pyruvate dehydrogenase complex)
DBP 1.86 Hs.414480  1628 D site of albumin promoter (albumin D-box) binding protein 
OCM 1.86 Hs.571315  654231 Oncomodulin 
SUMF2 1.85 Hs.279696  25870 Sulfatase modifying factor 2 
CCT6A 1.85 Hs.82916  908 Chaperonin containing TCP1, subunit 6A (zeta 1) 
NME1 1.84 Hs.463456  4830 Non-metastatic cells 1, protein (NM23A) expressed in 
MGAT5 1.84 Hs.651869  4249 Mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase
ARHGAP1 1.83 Hs.138860  392 Rho GTPase activating protein 1 
GPNMB 1.83 Hs.190495  10457 Glycoprotein (transmembrane) nmb 
PDZRN4 1.83 Hs.380044  29951 PDZ domain containing RING finger 4 
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ZNF408 1.83 Hs.656931  79797 Zinc finger protein 408 
SLC31A2 1.82 Hs.24030  1318 Solute carrier family 31 (copper transporters), member 2 
WFDC3 1.82 Hs.419126  140686 WAP four-disulfide core domain 3 
SCEL 1.81 Hs.534699  8796 Sciellin 
DMTF1 1.81 Hs.654981  9988 Cyclin D binding myb-like transcription factor 1 
ADH4 1.8 Hs.1219  127 Alcohol dehydrogenase 4 (class II), pi polypeptide 
DDX5 1.8 Hs.279806  1655 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 
P4HA2 1.8 Hs.519568  8974 Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide II
OR4D9 1.8 Hs.553757  390199 Olfactory receptor, family 4, subfamily D, member 9 
TMEM20 1.8 Hs.632085  159371 Transmembrane protein 20 
CDC14A 1.79 Hs.127411  8556 CDC14 cell division cycle 14 homolog A (S. cerevisiae) 
COTL1 1.79 Hs.289092  23406 Coactosin-like 1 (Dictyostelium) 
RAB11A 1.79 Hs.321541  8766 RAB11A, member RAS oncogene family 
S100A8 1.79 Hs.416073  6279 S100 calcium binding protein A8 
MRPL39 1.79 Hs.420696  54148 Mitochondrial ribosomal protein L39 
MCM7 1.79 Hs.438720  4176 Minichromosome maintenance complex component 7 
ULK1 1.79 Hs.47061  8408 Unc-51-like kinase 1 (C. elegans) 
MORF4L2 1.78 Hs.326387  9643 Mortality factor 4 like 2 
SMAD7 1.78 Hs.465087  4092 SMAD family member 7 
CSNK1E 1.78 Hs.474833  1454 Casein kinase 1, epsilon 
C6orf170 1.77 Hs.121396  221322 Chromosome 6 open reading frame 170 
FOXA3 1.77 Hs.36137  3171 Forkhead box A3 
LCP1 1.77 Hs.381099  3936 Lymphocyte cytosolic protein 1 (L-plastin) 
TRIB1 1.77 Hs.444947  10221 Tribbles homolog 1 (Drosophila) 
GRM8 1.77 Hs.449625  2918 Glutamate receptor, metabotropic 8 
FILIP1 1.77 Hs.696158  27145 Filamin A interacting protein 1 
RAB2B 1.76 Hs.22399  84932 RAB2B, member RAS oncogene family 
SLC19A2 1.76 Hs.30246  10560 Solute carrier family 19 (thiamine transporter), member 2 
LECT2 1.76 Hs.512580  3950 Leukocyte cell-derived chemotaxin 2 
KCNJ5 1.76 Hs.632109  3762 Potassium inwardly-rectifying channel, subfamily J, member 5 
SCN2B 1.75 Hs.129783  6327 Sodium channel, voltage-gated, type II, beta 
MBIP 1.75 Hs.368647  51562 MAP3K12 binding inhibitory protein 1 
C14orf124 1.75 Hs.643552  56948 Chromosome 14 open reading frame 124 
RPH3AL 1.75 Hs.651925  9501 Rabphilin 3A-like (without C2 domains) 
NDUFB2 1.75 Hs.655788  4708 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2, 8kDa 
TRIM16 1.74 Hs.123534  10626 Tripartite motif-containing 16 
XDH 1.74 Hs.250  7498 Xanthine dehydrogenase 
PSMC3 1.74 Hs.250758  5702 Proteasome (prosome, macropain) 26S subunit, ATPase, 3 
SFTPD 1.74 Hs.253495  6441 Surfactant, pulmonary-associated protein D 
RAB1A 1.74 Hs.310645  5861 RAB1A, member RAS oncogene family 
CLDN11 1.74 Hs.31595  5010 Claudin 11 (oligodendrocyte transmembrane protein) 
HDHD2 1.74 Hs.465041  84064 Haloacid dehalogenase-like hydrolase domain containing 2 
OR8H3 1.74 Hs.553745  390152 Olfactory receptor, family 8, subfamily H, member 3 
MLL5 1.74 Hs.592262  55904 Myeloid/lymphoid or mixed-lineage leukemia 5 (trithorax homolog, Drosophila)
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TBL1X 1.74 Hs.699315  6907 Transducin (beta)-like 1X-linked 
UMPS 1.73 Hs.2057  7372 Uridine monophosphate synthetase (orotate phosphoribosyl transferase and orotidine-5'-decarboxylase)
USP52 1.73 Hs.273397  9924 Ubiquitin specific peptidase 52 
RPS4Y1 1.73 Hs.282376  6192 Ribosomal protein S4, Y-linked 1 
ENTPD1 1.73 Hs.576612  953 Ectonucleoside triphosphate diphosphohydrolase 1 
CALM2 1.73 Hs.643483  805 Calmodulin 2 (phosphorylase kinase, delta) 
GNRHR 1.72 Hs.407587  2798 Gonadotropin-releasing hormone receptor 
POLI 1.72 Hs.438533  11201 Polymerase (DNA directed) iota 
OPA3 1.72 Hs.466945  80207 Optic atrophy 3 (autosomal recessive, with chorea and spastic paraplegia) 
FBXL2 1.72 Hs.475872  25827 F-box and leucine-rich repeat protein 2 
MAGEA9 1.72 Hs.512582  4108 Melanoma antigen family A, 9 
PJA1 1.72 Hs.522679  64219 Praja 1 
SUMF1 1.72 Hs.588682  285362 Sulfatase modifying factor 1 
ZDHHC7 1.72 Hs.592065  55625 Zinc finger, DHHC-type containing 7 
TMEM41A 1.72 Hs.634586  90407 Transmembrane protein 41A 
AKR1C3 1.72 Hs.78183  8644 Aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II)
ARID4A 1.71 Hs.161000  5926 AT rich interactive domain 4A (RBP1-like) 
NAP1L3 1.71 Hs.21365  4675 Nucleosome assembly protein 1-like 3 
WWP2 1.71 Hs.408458  11060 WW domain containing E3 ubiquitin protein ligase 2 
IPO4 1.71 Hs.411865  79711 Importin 4 
RRAS 1.71 Hs.515536  6237 Related RAS viral (r-ras) oncogene homolog 
HFE2 1.71 Hs.632436  148738 Hemochromatosis type 2 (juvenile) 
POM121 1.71 Hs.655217  9883 POM121 membrane glycoprotein (rat) 
VASP 1.71 Hs.702197  7408 Vasodilator-stimulated phosphoprotein 
PSMB7 1.7 Hs.213470  5695 Proteasome (prosome, macropain) subunit, beta type, 7 
ART3 1.7 Hs.24976  419 ADP-ribosyltransferase 3 
IL13RA2 1.7 Hs.336046  3598 Interleukin 13 receptor, alpha 2 
SLC22A9 1.7 Hs.502772  114571 Solute carrier family 22 (organic anion/cation transporter), member 9 
ZNF410 1.69 Hs.270869  57862 Zinc finger protein 410 
PIAS3 1.69 Hs.435761  10401 Protein inhibitor of activated STAT, 3 
TPSG1 1.69 Hs.592076  25823 Tryptase gamma 1 
PPM1A 1.69 Hs.592298  5494 Protein phosphatase 1A (formerly 2C), magnesium-dependent, alpha isoform
ZBTB1 1.69 Hs.655536  22890 Zinc finger and BTB domain containing 1 
HNRPUL1 1.69 Hs.699274  11100 Heterogeneous nuclear ribonucleoprotein U-like 1 
SLITRK4 1.68 Hs.272284  139065 SLIT and NTRK-like family, member 4 
USP3 1.68 Hs.458499  9960 Ubiquitin specific peptidase 3 
HSPA5 1.68 Hs.605502  3309 Heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) 
GABRA3 1.67 Hs.123024  2556 Gamma-aminobutyric acid (GABA) A receptor, alpha 3 
USP32 1.67 Hs.132868  84669 Ubiquitin specific peptidase 32 
MRCL3 1.67 Hs.190086  10627 Myosin regulatory light chain MRCL3 
IL22 1.67 Hs.287369  50616 Interleukin 22 
C5orf15 1.67 Hs.355177  56951 Chromosome 5 open reading frame 15 
SSX6 1.67 Hs.511998  280657 Synovial sarcoma, X breakpoint 6 
PON2 1.67 Hs.530077  5445 Paraoxonase 2 
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TOB1 1.67 Hs.531550  10140 Transducer of ERBB2, 1 
CCDC9 1.66 Hs.227782  26093 Coiled-coil domain containing 9 
WDR34 1.66 Hs.495240  89891 WD repeat domain 34 
BRMS1L 1.66 Hs.525299  84312 Breast cancer metastasis-suppressor 1-like 
PTPN22 1.66 Hs.535276  26191 Protein tyrosine phosphatase, non-receptor type 22 (lymphoid) 
NCOA5 1.66 Hs.654991  57727 Nuclear receptor coactivator 5 
PIN4 1.66 Hs.655623  5303 Protein (peptidylprolyl cis/trans isomerase) NIMA-interacting, 4 (parvulin) 
SMYD2 1.66 Hs.66170  56950 SET and MYND domain containing 2 
EDG6 1.66 Hs.662006  8698 Endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 6
CSN1S1 1.65 Hs.3155  1446 Casein alpha s1 
CPA2 1.65 Hs.490038  1358 Carboxypeptidase A2 (pancreatic) 
SEMA3E 1.65 Hs.528721  9723 Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3E
OR1S2 1.65 Hs.553644  219958 Olfactory receptor, family 1, subfamily S, member 2 
OR1S1 1.65 Hs.553645  219959 Olfactory receptor, family 1, subfamily S, member 1 
PRKAB1 1.65 Hs.6061  5564 Protein kinase, AMP-activated, beta 1 non-catalytic subunit 
DHX34 1.64 Hs.151706  9704 DEAH (Asp-Glu-Ala-His) box polypeptide 34 
DMC1 1.64 Hs.339396  11144 DMC1 dosage suppressor of mck1 homolog, meiosis-specific homologous recombination (yeast)
EXTL2 1.64 Hs.357637  2135 Exostoses (multiple)-like 2 
ITGB6 1.64 Hs.470399  3694 Integrin, beta 6 
SLC30A7 1.64 Hs.533903  148867 Solute carrier family 30 (zinc transporter), member 7 
C5orf5 1.64 Hs.657919  51306 Chromosome 5 open reading frame 5 
USP51 1.63 Hs.134289  158880 Ubiquitin specific peptidase 51 
FMO2 1.63 Hs.144912  2327 Flavin containing monooxygenase 2 (non-functional) 
HDC 1.63 Hs.1481  3067 Histidine decarboxylase 
C14orf4 1.63 Hs.179260  64207 Chromosome 14 open reading frame 4 
GSR 1.63 Hs.271510  2936 Glutathione reductase 
PDGFD 1.63 Hs.352298  80310 Platelet derived growth factor D 
BEX2 1.63 Hs.398989  84707 Brain expressed X-linked 2 
CDC14B 1.63 Hs.40582  8555 CDC14 cell division cycle 14 homolog B (S. cerevisiae) 
KIAA0831 1.63 Hs.414809  22863 KIAA0831 
CHM 1.63 Hs.496449  1121 Choroideremia (Rab escort protein 1) 
KCTD7 1.63 Hs.546627  154881 Potassium channel tetramerisation domain containing 7 
OR2T12 1.63 Hs.553582  127064 Olfactory receptor, family 2, subfamily T, member 12 
SLC23A1 1.63 Hs.643467  9963 Solute carrier family 23 (nucleobase transporters), member 1 
GNAS 1.62 Hs.125898  2778 GNAS complex locus 
MAN2C1 1.62 Hs.26232  4123 Mannosidase, alpha, class 2C, member 1 
PRRG2 1.62 Hs.35101  5639 Proline rich Gla (G-carboxyglutamic acid) 2 
PRKAB2 1.62 Hs.50732  5565 Protein kinase, AMP-activated, beta 2 non-catalytic subunit 
OCIAD1 1.62 Hs.518750  54940 OCIA domain containing 1 
FH 1.62 Hs.592490  2271 Fumarate hydratase 
DNAH10 1.62 Hs.622654  196385 Dynein, axonemal, heavy chain 10 
PDC 1.62 Hs.654381  5132 Phosducin 
NOSIP 1.62 Hs.7236  51070 Nitric oxide synthase interacting protein 
CHRNA6 1.61 Hs.103128  8973 Cholinergic receptor, nicotinic, alpha 6 
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UVRAG 1.61 Hs.202470  7405 UV radiation resistance associated gene 
CCL14 1.61 Hs.272493  6358 Chemokine (C-C motif) ligand 14 
NPHP1 1.61 Hs.280388  4867 Nephronophthisis 1 (juvenile) 
LBR 1.61 Hs.435166  3930 Lamin B receptor 
SUV39H1 1.61 Hs.522639  6839 Suppressor of variegation 3-9 homolog 1 (Drosophila) 
OR4M1 1.61 Hs.553829  441670 Olfactory receptor, family 4, subfamily M, member 1 
MYEF2 1.61 Hs.6638  50804 Myelin expression factor 2 
NDUFS2 1.6 Hs.173611  4720 NADH dehydrogenase (ubiquinone) Fe-S protein 2, 49kDa (NADH-coenzyme Q reductase)
PARP2 1.6 Hs.409412  10038 Poly (ADP-ribose) polymerase family, member 2 
LOC51057 1.6 Hs.414952  51057 Hypothetical protein LOC51057 
CYHR1 1.6 Hs.459379  50626 Cysteine/histidine-rich 1 
MDH1 1.6 Hs.526521  4190 Malate dehydrogenase 1, NAD (soluble) 
OR4K13 1.6 Hs.553573  390433 Olfactory receptor, family 4, subfamily K, member 13 
FUCA2 1.6 Hs.591332  2519 Fucosidase, alpha-L- 2, plasma 
SERPINA12 1.6 Hs.99476  145264 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 12
SMAD2 1.59 Hs.12253  4087 SMAD family member 2 
NEGR1 1.59 Hs.146542  257194 Neuronal growth regulator 1 
H3F3B 1.59 Hs.180877  3021 H3 histone, family 3B (H3.3B) 
ZNF302 1.59 Hs.436350  55900 Zinc finger protein 302 
TWSG1 1.59 Hs.514685  57045 Twisted gastrulation homolog 1 (Drosophila) 
SERPINA1 1.59 Hs.525557  5265 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1
CASP10 1.59 Hs.5353  843 Caspase 10, apoptosis-related cysteine peptidase 
ASB5 1.59 Hs.591712  140458 Ankyrin repeat and SOCS box-containing 5 
B2M 1.59 Hs.626605  567 Beta-2-microglobulin 
KIF23 1.58 Hs.270845  9493 Kinesin family member 23 
DCTN4 1.58 Hs.328865  51164 Dynactin 4 (p62) 
PPIG 1.58 Hs.470544  9360 Peptidylprolyl isomerase G (cyclophilin G) 
AQR 1.58 Hs.510958  9716 Aquarius homolog (mouse) 
AP2B1 1.58 Hs.514819  163 Adaptor-related protein complex 2, beta 1 subunit 
PEX12 1.58 Hs.591190  5193 Peroxisomal biogenesis factor 12 
LRRC6 1.58 Hs.591865  23639 Leucine rich repeat containing 6 
LPPR2 1.58 Hs.6846  64748 Lipid phosphate phosphatase-related protein type 2 
FAH 1.58 Hs.73875  2184 Fumarylacetoacetate hydrolase (fumarylacetoacetase) 
ZBTB3 1.57 Hs.147554  79842 Zinc finger and BTB domain containing 3 
RHOBTB2 1.57 Hs.372688  23221 Rho-related BTB domain containing 2 
PEBP4 1.57 Hs.491242  157310 Phosphatidylethanolamine-binding protein 4 
GJB2 1.57 Hs.524894  2706 Gap junction protein, beta 2, 26kDa 
JMJD1A 1.57 Hs.557425  55818 Jumonji domain containing 1A 
NCOA1 1.57 Hs.699183  8648 Nuclear receptor coactivator 1 
SLC39A6 1.57 Hs.79136  25800 Solute carrier family 39 (zinc transporter), member 6 
HTR1E 1.56 Hs.1611  3354 5-hydroxytryptamine (serotonin) receptor 1E 
PPP1CA 1.56 Hs.183994  5499 Protein phosphatase 1, catalytic subunit, alpha isoform 
KIAA0528 1.56 Hs.271014  9847 KIAA0528 
TSGA14 1.56 Hs.368315  95681 Testis specific, 14 
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FLJ34503 1.56 Hs.376634  285759 Hypothetical FLJ34503 
EFHA1 1.56 Hs.412103  221154 EF-hand domain family, member A1 
NUDCD3 1.56 Hs.488171  23386 NudC domain containing 3 
OR2T29 1.56 Hs.553707  343563 Olfactory receptor, family 2, subfamily T, member 29 
PCDH9 1.56 Hs.654709  5101 Protocadherin 9 
BNC2 1.56 Hs.656581  54796 Basonuclin 2 
AKAP10 1.56 Hs.694769  11216 A kinase (PRKA) anchor protein 10 
FOXP4 1.55 Hs.131436  116113 Forkhead box P4 
SENP1 1.55 Hs.371957  29843 SUMO1/sentrin specific peptidase 1 
MAP2K6 1.55 Hs.463978  5608 Mitogen-activated protein kinase kinase 6 
SLC9A11 1.55 Hs.494981  284525 Solute carrier family 9, member 11 
ZNF41 1.55 Hs.496074  7592 Zinc finger protein 41 
SPRED1 1.55 Hs.525781  161742 Sprouty-related, EVH1 domain containing 1 
GSPT1 1.55 Hs.528780  2935 G1 to S phase transition 1 
COPS7A 1.55 Hs.530823  50813 COP9 constitutive photomorphogenic homolog subunit 7A (Arabidopsis) 
SCAP 1.55 Hs.531789  22937 SREBF chaperone 
RIN1 1.54 Hs.1030  9610 Ras and Rab interactor 1 
C14orf126 1.54 Hs.116014  112487 Chromosome 14 open reading frame 126 
EPHX2 1.54 Hs.212088  2053 Epoxide hydrolase 2, cytoplasmic 
NFYC 1.54 Hs.233458  4802 Nuclear transcription factor Y, gamma 
C21orf81 1.54 Hs.364456  114035 Chromosome 21 open reading frame 81 
RBJ 1.54 Hs.434993  51277 Rab and DnaJ domain containing 
FAM33A 1.54 Hs.463607  348235 Family with sequence similarity 33, member A 
MTF1 1.54 Hs.471991  4520 Metal-regulatory transcription factor 1 
GNL3L 1.54 Hs.654677  54552 Guanine nucleotide binding protein-like 3 (nucleolar)-like 
SNX11 1.53 Hs.15827  29916 Sorting nexin 11 
PRPF18 1.53 Hs.161181  8559 PRP18 pre-mRNA processing factor 18 homolog (S. cerevisiae) 
ARIH1 1.53 Hs.268787  25820 Ariadne homolog, ubiquitin-conjugating enzyme E2 binding protein, 1 (Drosophila)
TXN 1.53 Hs.435136  7295 Thioredoxin 
NEUROD1 1.53 Hs.440955  4760 Neurogenic differentiation 1 
GLT6D1 1.53 Hs.522491  360203 Glycosyltransferase 6 domain containing 1 
NOTCH2NL 1.53 Hs.655156  388677 Notch homolog 2 (Drosophila) N-terminal like 
C14orf43 1.53 Hs.656506  91748 Chromosome 14 open reading frame 43 
CBX1 1.53 Hs.77254  10951 Chromobox homolog 1 (HP1 beta homolog Drosophila ) 
HSPE1 1.52 Hs.1197  3336 Heat shock 10kDa protein 1 (chaperonin 10) 
PARP15 1.52 Hs.120250  165631 Poly (ADP-ribose) polymerase family, member 15 
HAP1 1.52 Hs.158300  9001 Huntingtin-associated protein 1 (neuroan 1) 
TAF1 1.52 Hs.158560  6872 TAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 250kDa
CASP9 1.52 Hs.329502  842 Caspase 9, apoptosis-related cysteine peptidase 
HIST4H4 1.52 Hs.352191  121504 Histone cluster 4, H4 
RPS17 1.52 Hs.433427  6218 Ribosomal protein S17 
DAB2 1.52 Hs.481980  1601 Disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila) 
RUSC2 1.52 Hs.493796  9853 RUN and SH3 domain containing 2 
TAGLN2 1.52 Hs.517168  8407 Transgelin 2 
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EPS8 1.52 Hs.591160  2059 Epidermal growth factor receptor pathway substrate 8 
HSPD1 1.52 Hs.595053  3329 Heat shock 60kDa protein 1 (chaperonin) 
LOX 1.51 Hs.102267  4015 Lysyl oxidase 
UQCRB 1.51 Hs.131255  7381 Ubiquinol-cytochrome c reductase binding protein 
ACAA2 1.51 Hs.200136  10449 Acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme A thiolase)
STMN4 1.51 Hs.201058  81551 Stathmin-like 4 
FLJ11184 1.51 Hs.267446  55319 Hypothetical protein FLJ11184 
MAP3K3 1.51 Hs.29282  4215 Mitogen-activated protein kinase kinase kinase 3 
FEN1 1.51 Hs.409065  2237 Flap structure-specific endonuclease 1 
TARS 1.51 Hs.481860  6897 Threonyl-tRNA synthetase 
ATXN3 1.51 Hs.532632  4287 Ataxin 3 
DLG7 1.51 Hs.77695  9787 Discs, large homolog 7 (Drosophila) 
SHOC2 1.5 Hs.104315  8036 Soc-2 suppressor of clear homolog (C. elegans) 
PTDSS2 1.5 Hs.12851  81490 Phosphatidylserine synthase 2 
AQP2 1.5 Hs.130730  359 Aquaporin 2 (collecting duct) 
SNAP25 1.5 Hs.167317  6616 Synaptosomal-associated protein, 25kDa 
EHBP1 1.5 Hs.271667  23301 EH domain binding protein 1 
RBBP8 1.5 Hs.546282  5932 Retinoblastoma binding protein 8 
SREBF1 1.5 Hs.592123  6720 Sterol regulatory element binding transcription factor 1 
HEXA 1.5 Hs.604479  3073 Hexosaminidase A (alpha polypeptide) 
MANBAL 1.5 Hs.6126  63905 Mannosidase, beta A, lysosomal-like 
ZBTB20 1.5 Hs.655108  26137 Zinc finger and BTB domain containing 20 
NEK11 1.5 Hs.657336  79858 NIMA (never in mitosis gene a)- related kinase 11 
PPP1R11 1.5 Hs.82887  6992 Protein phosphatase 1, regulatory (inhibitor) subunit 11 
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